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ix Zusammenfassung 
Zusammenfassung 
Die fortschreitende Verbesserung von Sequenziertechnologien ermöglicht den Zugang zu einer 
stetig wachsenden Zahl von mikrobiellen Genomsequenzen. Gleichzeitig liefern bioinformatische 
Methoden ein immer besseres Bild des genetischen Potentials der Mikroorganismen für die Produktion 
von Sekundärmetaboliten. Die vorliegende Arbeit befasst sich mit der Entwicklung von 
bioinformatischen Werkzeugen um die Entdeckung, die Dereplikation und letztendlich  die 
Charakterisierung von multimodularen Biosynthesewegen in mikrobiellen Genomen zu unterstützen. 
Kernstück des Ansatzes ist der „konzept-basierte“ Vergleich der Architekturen von komplexen PKS-, 
NRPS- und hybriden Genclustern, der sich auf Anordnung und Eigenschaften biosynthetischer Domänen 
stützt anstelle von Sequenzähnlichkeit. Das neu entwickelte Softwarewerkzeug, genannt BiosynML, 
wurde mit antiSMASH (dem de-facto Standard für die automatische Annotation von Biosynthesewegen) 
verknüpft und in eine bestehende Forschungsdatenbank (Mxbase) integriert. BiosynML Methoden 
wurden anhand der Biosynthesewege für 42 bekannte Naturstoffe in 71 myxobakteriellen 
Genomsequenzen getestet und auf öffentlich zugängliche Genome relevanter Mikroorganismen 
angewendet. Die Analyse von 1347 Biosyntheswegen aus den Genomen der Myxobakterien, darunter ein 
derepliziertes Set von 783 Typen, ergab eine nur minimale Überlappung zwischen Unterordnungen und 
ermöglichte die Abschätzung der Diversität an myxobakteriellen Sekundärmetaboliten-Genclustern. 
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xi Abstract 
Abstract  
Recent advances in sequencing technology have set the stage for a steadily growing number of 
microbial whole-genome sequences. At the same time, bioinformatic analysis increasingly sheds light on 
the genome-encoded capacity of certain microorganisms for the production of secondary metabolites. 
This work describes the development of a bioinformatic toolkit to underpin discovery and dereplication 
efforts in a genomics-based workflow aimed at the characterization of multimodular biosynthetic gene 
clusters from bacterial genomes. Key to the “conceptual genome mining” approach implemented here is 
the comparison of pathways architectures represented by arrangement and properties of domains in 
complex PKS-, NRPS- and hybrid pathways rather than resorting to DNA- or protein-level sequence 
similarity. The new analysis framework named BiosynML toolkit was interfaced to antiSMASH, the de-
facto standard for automatic annotation of biosynthetic pathways, and integrated with an existing in-
house research database system (Mxbase). BiosynML methods were tested using 42 characterized 
pathways from 71 myxobacterial genomes and also applied to publicly accessible genomes from relevant 
microbial taxa. BiosynML tools were ultimately used to create an overview of 1347 pathways of which 
783 distinct models were identified. This analysis revealed minimal overlap between suborders and 
enabled the tentative estimation of myxobacterial secondary metabolite gene cluster richness. 
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1 Introduction 
1 Introduction 
1.1 Natural products for drug discovery 
For thousands of years, natural products proved to be a rich source of drugs and drug leads, playing 
a vital role for prevention and cure of various diseases (1). During the last century, the discovery of 
natural products is filled with stories of numerous lifesaving drugs produced by microorganisms. For 
example, Sir Alexander Fleming in 1928 discovered penicillin from Penicillium notatum, which became  
world's first industrially produced antibiotic and was widely used to combat infections (2).  
 
Figure 1.1: Drugs derived from natural products. (a) Erythromycin (macrolide antibiotic drug used to treat 
different types of infections caused by bacteria, (b) Daptomycin (antibiotic drug used to treat bacterial infections 
of the skin and underlying tissues) (c) Epothilone (the semisynthetic derivative Ixabepilone is on the market for 
anticancer treatment) (d) Mitoxantrone (antineoplastic agent). 
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The majority of the drugs available in the market are derived from natural products obtained from 
various sources such as plants and microorganisms (3, 4).  For example, drugs like penicillin, 
erythromycin (Figure 1.1 a), daptomycin (Figure 1.1 b) are used clinically against bacterial infections (5–
8); drugs like epothilone (Figure 1.1 c), doxorubicin, mitoxantrone (Figure 1.1 d) (9–12) are used against 
cancer.  Other fields of application include natural product-derived drugs used as immune suppressants 
and to lower the cholesterol levels (13).  
Although natural products from microorganisms are known as therapeutic agents for the treatment 
and prevention of diseases from late 1920s (14).  The delay of clinical trials was caused by the lack of 
proper procedures to produce enough quantities of the pure products. Starting from this stage, an era 
followed which is characterized by a steady increase in the discovery of novel compounds (15, 16). 
However, natural products as a source for new medicines were largely abandoned by “big pharma” after 
the 1970’s mainly for economic reasons, leading to an “innovation gap”: basically no new structural 
classes of antibiotics were introduced until the 2000’s  (17).  
Enabled by progress in modern techniques such as next-generation sequencing and high-
resolution mass spectrometry, strategies for drug discovery for pharmaceutical applications are currently 
in a revolutionary period (18). With the availability of automated instrument systems, robots and high-
throughput screening (HTS) platforms providing powerful tools for screening large compound libraries in 
a cost-effective manner (15). Over the last two decades, development in HTS and analytical techniques in 
combination with genomics-based methods. This triggered new directions of natural product research, 
including studies of biosynthesis, revealing that genes responsible for biosynthesis of complex secondary 
metabolites are often located adjacent to each other (clustered) in microbial DNA that encode for 
polypeptides or proteins. Altogether, genes responsible for synthesis of secondary metabolite are 
encoded in a large gene cluster producing protein domains with defined functions. These insights into 
the molecular basis of natural product formation have changed the view of natural product research by 
enabling the emendation of known structures and prediction of novel compounds based on the gene 
sequences and generation of unusual compounds by combinatorial biosynthesis. 
These methods facilitate the development of new drugs which are needed to control the 
pathogenic bacteria showing resistance to the effect of antibacterial drugs. These bacteria were reported 
as “ESKAPE” pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter species) (19). There are only a few 
natural products that pass through clinical trials and are approved as drugs. This generates a great 
demand for new compounds to fill the gaps in the pharmaceutical industry. Developing methods as such 
could ensure a steady stream of new drugs to meet the current needs. 
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1.2 Assembly logic of secondary metabolism: modular pathways 
Secondary metabolites in general are chemical entities produced by but not involved in the normal 
growth of an organism. These compounds are often thought to be used as defences against competitors; 
plausible examples are compounds with antibacterial or antifungal activities. Advances in natural 
products biosynthesis research over the last 10-20 years led to an improved understanding of their 
biosynthesis including the organization of biosynthetic genes in so called gene clusters found as genomic 
islands in the chromosome of the producing organism. These gene clusters produce remarkable peptide 
secondary metabolites belonging to the class of nonribosomal peptide synthetase (NRPS) and polyketide 
synthase (PKS). As a result, several biosynthetic pathway which are multi enzymatic and multi domain 
megasyntheses were identified. In addition, several bacterial species have been identified as the source 
of novel natural products using so-called genome mining approaches (20). Since the availability of 
automated tools for genome annotation, bacterial genomes are nowadays routinely investigated for the 
presence of PKS and NRPS clusters, exposing a large number of novel gene clusters with currently 
unknown function. 
Compounds derived from PKS and NRPS biosynthetic machinery represent two large families of 
structurally diverse and complex microbial metabolites that include many potential drug leads. 
Understanding the ‘assembly line’ logic behind the formation of these compounds helps to develop 
strategies for the production improvement and targeted alteration of the metabolites associated with 
PKS and NRPS gene clusters (20). According to textbook biosynthetic logic, biosynthesis by PKSs and 
NRPSs is typically accomplished using acyl-coenzyme A monomers and amino acid building blocks in an 
assembly line fashion. Both of their biosynthesis are assisted by large multimodular proteins in which 
each enzymatic module catalysis one round of elongation and a variable set of modifications on a 
growing polyketide- or polypeptide chain, respectively (21, 22). To some extent, this knowledge allows to 
estimate the structures afforded by PKS and NRPS pathways based on bioinformatic analysis of genome 
information; however the correct prediction of precise molecular structures of products is not routinely 
possible. 
1.2.1 Polyketide synthases – PKS 
Polyketides are a class of secondary metabolites which are structurally complex organic 
compounds exhibiting wide range of biological properties. Biosynthesis of polyketides is usually 
accomplished through the decarboxylative condensation of activated dicraboxyl acid units resembling 
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fatty acid synthesis (FAS) (23, 24). Polyketide synthases (PKSs) are a group of multi-domain enzymes that 
are responsible for the production of polyketides. 
Depending on their molecular architecture and enzymatic properties like the subunit organization 
and mode of synthesis, PKSs are historically subdivided into three groups (25). Type I PKS consist of 
multifunctional mega-enzymes organized into modules in which each active site is involved in the 
enzymatic processing of intermediates along the pathway as exemplified by the 6-deoxyerythromycin B 
synthase (DEBS) for the biosynthesis of reduced polyketides such as erythromycin A (21) where each 
successive incorporation of building block which is further reduced by keto reductase (KS) from ketone 
group to a hydroxyl group (Figure 1.2). They are further divided into iterative PKS and modular PKS. 
Iterative type I PKS are monomodular exhibiting a set of domains used in a cyclic fashion. Modular PKSs 
contain several individual modules and usually do not iterate reactions, although exceptions have been 
reported. Type II PKSs, also work iteratively, featuring each catalytic site on individual mono- or bi- 
functional proteins as exemplified by the biosynthesis of aromatic polyketides such as tetracenomycin C 
(26–28). Type I and type II PKS uses acyl carrier protein (ACP) to activate the acyl CoA substrates to 
transport the polyketide intermediates. Type III PKSs also known as chalcone synthase like PKSs, are 
homodimers where each monomer catalyzes a complex set of reactions including priming, extension, 
and cyclization iteratively to form polyketide products extensively utilizing acyl-coenzyme A instead of 
ACP-bound monomers, as exemplified by the RppA synthase for the biosynthesis of aromatic polyketides 
such as flaviolin (29–32). 
Every PKS module consists of a set of core domains. A loading module generally contains an 
acyltransferase (AT) domain selecting the appropriate starter unit which frequently is an acetyl-CoA. The 
starter group is loaded on to the acyl carrier protein (ACP) domain on the starter module (Figure 1.2). 
The chain is then transferred from the ACP domain of the previous module to the Keto-synthase (KS) 
domain of the current module. The malonyl group is attached to a thiol of the current ACP domain 
catalyzed by the current AT domain. This thioester formed with the terminal thiol of a 
phosphopantetheine moiety that is posttranslationally attached to a serine of the ACP. The 
phosphopantetheine (ppant) has the function of a flexible arm, which carries the growing chain to the 
different catalytic domains that act on the biosynthetic intermediate (33).  
 Furthermore, optional domains such as ketoreductase (KR) which reduces the β-keto group to a 
β-hydroxy group, oxidation (Ox), dehydratase (DH) which chops off H2O resulting in the α-β-unsaturated 
alkene, enoylreductase (ER) which reduces the α-β-double-bond to a single-bond, methyltransferase 
(MT) domains inducing α-methyl branches, modify the growing polyketide molecule. The last module 
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typically possesses a thioesterase (TE) domain to catalyse the hydrolysis of the polyketide chain from the 
final ACP-domain, resulting in the release of the final product from the enzyme (30).  
Some bacterial biosynthetic pathways lack internal AT domains, which are complemented by 
freestanding AT-domain containing enzymes, so called trans-AT pathways (34). The trans-AT PKSs are 
highly diverse often containing previously unseen arrangements of enzymatic domains, thus usually 
resulting in poor biosynthetic assignment of clusters using standard collinearity rules, i.e. the assumption 
that the order of modules encoded in a biosynthetic pathway is reflected by the order of monomer 
incorporation or elongation (35). This can be exemplified by the gene cluster for the antibiotic 
Chlorotonil, but more and more trans-AT pathway examples are now being reported (36, 37). 
Figure 1.2: Schematic representation of modules involved in initiation and chain extension steps. (a) Selection of acyl-
CoA by AT domain for chain building and trasnfer to ACP . (b) Acylation of starter unit by KS domain by first extension 
module. (c) Modification of keto group by DH,ER and KR domains. (d) Extension of reduced chain by sucessive modules 
and the final product is catalized by TE 
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Several novel compounds have been assessed by molecular and biochemical studies including 
experiments such as loading module relocation, point mutations, module deletion, module insertion, 
domain swapping, domain inactivation and more (21, 38). The biosynthetic genes can be to some extent 
transferred between pathways from different organisms has given rise to the thought that horizontal 
gene transfer (HGT) might also play a role in PKS evolution (39–41).  
 
A common graphical representation for multimodular biosynthetic pathways is the “ball scheme” 
derived from annotation or bioinformatic prediction, which can be read like an “enzymatic activity 
string” in order to get an idea of the compound produced (Figure 1.3). 
1.2.2 Nonribosomal peptide synthetases – NRPS 
A conceptual alternative to peptide synthesis on ribosomes was first demonstrated in 1971 with 
the nonribosomal peptide synthetases (NRPS) of gramicidin S and tyrocidin (42). Today, these 
nonribosomal peptide synthetases are accepted as a “factory” for synthesizing many specialized 
peptides. Similar to PKS, NRPS are also multimodular enzyme organizations comprising a series of 
functional units, each responsible for the addition of a specific and often non-natural amino acid. The 
modules of NRPSs contain a minimum of three domains catalyzing a particular set of reactions in the 
incorporation of a monomer (Figure 1.4)(43–45).  
Figure 1.3: Ball scheme representation for biosynthesis of erythromycin from strain NRRL2338 (Saccharopolyspora 
erythraea) along with the growth of polyketide chain by the addition of ketide group in each step. The blue line 
denotes the extension of individual modules. 
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In the loading step, the amino acid is activated by an adenylation (A) domain. A domains catalyze 
the ATP-dependent reaction, transforming the amino acid into an AMP-charged aminoacyl (46). Then, 
the activated monomer is loaded onto the peptidyl carrier protein domain (PCP) binding covalently with 
the thiol of a 4’-phosphopantetheinyl (Ppant) cofactor by forming a thioester, generating an enzyme- 
bound aminoacylthioester intermediate (33, 47, 48). This step enables the transport of the activated 
amino acids between the catalytic centers of the NRPS. In order to attach, transport substrates and 
intermediates, Ppant is post-translationally attached to PCP to a conserved serine residue, thereby 
converting the PCP domain into its holo form. This reaction is catalysed by a specialized external enzyme 
4‘-Ppant transferase (49–51). Elongation stage starts with loading of specific amino acid onto PCP of each 
module. The condensation domain is responsible for forming the amide bond between the amino acids 
of previous module to that of the current module (47). The extended peptide is now tethered to the PCP 
of the downstream module (Figure 1.4).  
Figure 1.4:  Domains and modules involved in the biosynthesis of Tyrocidine, a polypeptide antibiotic.  
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A module, solely containing A and PCP domains, is sometimes observed as the first module of the 
NRPS, while a module with thioester domain(TE) is considered as the terminating module responsible for 
hydrolysis or macrocyclization of the peptide chain from the PCP domain of the previous module, 
releasing peptide chain from synthetase (52, 53). In linear NRPSs, synthesis is initiated with the loading 
module, the sequence of modules acts as the template for adding a specific amino acid that dictates the 
resulting peptide's sequence, finishing it by TE domain releasing the peptide (43). The final-stage 
intermediate can also be released by cyclisation, as in the case of tyrocidine (Figure 1.4). 
Along with these three domains (C, A, PCP), additional optional domains may be present within the 
modules, which are responsible for residue modifications. For example, epimerization (E) domains lead 
to formation of D-amino acids, N-methyltransferase (N-MT) control the methylation state of the peptide 
products, heterocyclization (HC) domains from thiazolines from cysteines, oxidation (Ox) domains are 
responsible for oxidation of thiazolines, reduction (Red) reduces thiazolines or oxazolines to thiazolidines 
or oxazolidines, respectively. Formylation (F) and heterocyclisation (HC) domains induce cyclization into 
thiazoline or oxazolines.  All these additional domains facilitate NRPSs to synthesize varied number of 
biologically active peptides which are distinct from peptides synthesized by the ribosome (22, 54).  
Nonribosomal peptides not only contain proteinogenic amino acids but also frequently contain 
non-proteinogenic amino acids. In addition, A-domains may exhibit some degree of substrate 
promiscuity (exemplified by incorporation of D-Phe or D-Trp in tyrocidines). These traits make it possible 
to obtain great structural diversity of NRPS-derived natural products, yielding wide-ranging biological 
activities and pharmacological properties. Nonribosomal peptides are often the backbone for the 
biosynthesis of antibiotics (e.g. daptomycin, vancomycin) and immunosuppressants (e.g. ciclosporin), of 
which some prominent ones are used commercially (55–57).  
Since the first description of an NRPS assembly line, numerous bioactive molecules synthesized by 
NRPSs have been discovered and their biosynthetic pathways characterized (58). NORINE is a database 
extensively dedicated for collecting NRPS structures and lining them to biosynthetic gene clusters, 
equipped with computational tool for systematic study of these molecules across microorganism species 
(59).  Increase in the number of biosynthetic clusters found in the public databases provides a clear 
advantage to investigate both chemical and enzymatic properties of those pathways. In addition, 
directed evolution and combinatorial approaches also contribute valuable information to a better 
understanding and exploitation of these complex machineries, but also leading to the identification of 
new metabolites. For example, a peptide siderophore from Streptomyces coelicolor named coelichelin 
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was identified from a NRPS gene cluster sequence through prediction of the structure and biochemical 
properties (60). 
1.2.3 NRPS-PKS hybrid pathways 
Although distinct mechanisms of condensation exist in PKS and NRPS from chemical aspects, there 
are significant similarities between them in terms of structure and functionality, including similarity 
between the carrier domains of both types which are post-translationally modified by a 4’-
phosphopantetheine prosthetic group by a family of 4’-Ppant transferases (50, 51). Many secondary 
metabolites such as rapamycin (antifungal/immunosuppressive), epothilone (anticancer), bleomycin 
(antibiotic/antitumor) were found to be synthesized by the fusion of PKS and NRPS synthetases (PKS-
NRPS hybrids) (61–63). For this, new strategies are developed to exploit the potential of microorganisms 
to produce important bioactive compounds. It is the peptide-polyketide metabolites studies that also 
gained spotlight for their potential utility in the field of combinatorial biosynthesis. Therefore, a 
pronounced challenge lies ahead in the studies exposing structure-function association and molecular 
organization features of hybrid pathways so that they may contribute to the production of new peptide-
polyketide metabolites through combinatorial biosynthesis.  
 
Figure 1.5: Ball scheme representation of domains and modules involved in the biosynthesis of Dkxanthene from 
strain DK1622 (Myxococcus xanthus)  
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Based on the domains functions, intermodular linkers and similar modular arrangement of NRPS 
and PKS modules, construction of chimeric PKS-NRPS hybrids is in principle possible (64). An example for 
a natural occurring NRPS-PKS hybrid pathway from myxobacteria is illustrated in Figure 1.5. In fact, the 
Dkxanthene molecule was only identified through a “gene to compound” approach following the 
inactivation of the assembly line in the producing strain Myxococcus xanthus DK1622 (65). 
1.3 Role of genome mining for natural products discovery 
The process of identifying natural products from microbes is usually long and laborious. Isolation of 
a pure bacterial culture is generally followed by cultivation in laboratory conditions and description of its 
secondary metabolites via physical and chemical methods, usually following bioactivity profiling and 
chromatographic purification of active fractions (Figure 1.6).However, some gene clusters from microbes 
may not be expressed at all when grown in vitro using traditional cultivation methods (66–68). An 
estimation of the “silent” part of biosynthetic potential is therefore required for the majority of bacterial 
strains. One of the methods used to evaluate the non-expressing clusters employs initial screening 
through degenerate PCR, however, not all biosynthetic gene types can be identified by this method. As 
such a wide range of natural products that are encoded in microbial genomes are yet to be discovered. 
Much faster and comprehensive is the process of sequencing the whole genome of a given organism, 
which can grant full access to a high volume of genetic information translating into a comprehensive 
view of the potential for biosynthesis of natural products. 
Genome sequencing aims to determine the whole genetic information of an organism, including 
coding and non-coding sequences of nucleic acids (DNA) (69). Genome sequencing has been initiated 
since the seventies with the invention of the Sanger sequencing method (70–72).  
Since then, this has led to the tremendous growth of various disciplines in the field of 
bioinformatics. Enabled with efficient techniques a large number of sequencing projects were finished, 
starting from bacterial genomes to human genomes (73–76). Later, whole genome shotgun sequencing 
was proven to be more cost effective and is now widely accepted (77, 78). Since the last century, many 
new high throughput sequencing methods have emerged such as to 454/Roche, Illumina, PacBio, 
Sequencing by synthesis and Ion semiconductor sequencing etc. (79–82) resulting in the deposition of 
large quantities of sequencing data from various organisms in public databases. Such data can be utilized 
to survey genomic information for enzyme encoding genes. This process of exploiting genomic sequence 
data has intensified rapidly, expanding the knowledge of genetic and biochemical aspects of secondary 
metabolite biosynthesis especially in microorganisms (83). It became clear that many microbial genomes 
  
11 Introduction 
contain genes participating in the synthesis of complex bioactive products which are not associated with 
the known metabolites. In the case of microorganisms, these circumstances were first experienced with 
complete genome sequences of Streptomyces coelicolor A3 and Streptomyces avermitilis MA-4680 (66, 
67, 84). These examples provide evidence that the availability of genomic sequences can empower the 
research of natural product producers with the help of bioinformatics approaches (i.e. genome mining). 
Genome mining is now used as a tool for discovering important and complex secondary metabolites 
such as nonribosomal peptides (NRPSs), polyketides (PKSs) and terpenoids. In other words, the term 
genome mining basically comprises actions to exploit genetically encoded information in the gene 
clusters of microbial genomes for the discovery of new metabolites.  Every family of natural products has 
a characteristic underlying pattern of proteins which is also evident on genomic level. This provides key 
for genome mining where conserved protein motifs and consensus sequences are used to identify loci of 
putative biosynthetic pathways. 
With the increasing availability of genomic data from databases and the use of computational 
comparison tools, enzymes encoding genes that are involved in biosynthesis can be readily identified in 
Figure 1.6: Schematic workflow of identifying natural products. (a) Cultivation and extraction of microbes. (b) 
Chemicals creening using insrtumentation analysis for derplication of known compounds.(c) Biological screening by 
bioactivity assays and discover novel compounds 
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genomes. This information can be used to search for biosynthetic gene loci likely involved in assembly of 
new bioactive compounds. Several routes can be taken to pursue genome-mining. These include ”gene 
to compound” correlation approaches using gene knockout experiments, statistics-based  methods that 
resemble biomarker discovery, or “compound to gene” strategy where putative biosynthetic assembly 
lines are inferred from a molecules structure. The different approaches to discover new natural product 
chemistry by genome mining are briefly explained in the following. Metabolite profiling is a well-used 
approach for identification of new metabolites and their corresponding pathways in the genomes. For 
example, the bioinformatics analysis identified 18 biosynthetic gene clusters from strain DK1622 
belonged to myxobacteria. Until 2012 only five compound classes were known but by coupling principal-
component analysis (PCA) with pre-processed LC-MS datasets resulted in three new secondary 
metabolites c506 (myxoprincomide), c844, and c329 (85). Similarly, compounds such as aurafuron A and 
B from myxobacterium Stigmatella aurantiaca (86, 87), the iron chelator coelichelin from Streptomyces 
coelicolor (60) and several other compounds were isolated by a comparative metabolic profiling genome 
mining approach. These results unarguably demonstrate the importance of genome mining for the 
identification of new secondary metabolites. 
Genome mining is supported by numerous techniques providing hints for the structure prediction 
or at least estimation of compound class, although statements about associated bioactivity cannot 
usually be made (88).   Moreover, precise structure prediction is also hindered by the fact that new 
biosynthetic logic is frequently encountered in the biosynthesis of microbial natural products by PKSs 
and NRPSs machinery (89–91).  
However, advances in the field of predictive bioinformatics tools made it possible to classify 
genes responsible for secondary metabolite production according to their functional specificities. As the 
prime example, several models have emerged that can predict substrate specificity of adenylation (A) 
and acyltransferase (AT) domains responsible (Figure 1.2) for building block selection in each module of 
NRPS and PKS assembly lines. 
Substrate specificity predictions along with the collinear enzymatic logic in modular PKS and 
NRPS pathways (although deviations are possible and notably frequent in myxobacteria) provide 
powerful tools, which in some cases can predict many of the structural features of the products of novel 
modular PKS and NRPS systems from their sequences.  However, the predictions are  not always reliable 
as many non-linear enzymatic assembly logic exist, such as iterative domain or module usage or module 
skipping both present in PKS and NRPS pathways which makes it complex for predicting the structure. 
Furthermore, for pathways where enzymatic action is unknown, prediction of structure is highly error 
prone.  
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Several bioinformatics tools are being developed for the prediction of secondary metabolite gene 
clusters including ClustScan (92), SBSPKS toolbox (93) and CLUSEAN (94) are available. Among all, the 
most user friendly and convenient tool in this field is currently antiSMASH 3.0 (95). It is a widely used 
tool that comes close to a de-facto standard for the automated genome-wide analysis of bacteria, fungi, 
and archaea for biosynthetic gene clusters and offers various modules for analyzing the pertinent 
pathways. This freely available tool enables rapid annotation studies that can be used as preliminary 
basis to prioritize species of interest by their biosynthetic potential, as well as helping with gene cluster 
annotation. However, the antiSMASH (95) could only provide the predicted secondary metabolite 
pathways that the genome is capable of producing. It does not provide any related information of the 
predicted biosynthetic pathways in terms of similarity to that of the existing characterized pathways. 
This leaves the natural product researcher to perform exhaustive search for the identification of known 
genes clusters from the pool of gene clusters reported. Currently the most widely used for the process of 
identifying known gene clusters is through sequence based approaches such as BLAST (96). These 
sequence based tools become complex and probably hard to analyse with increase in amount of 
sequenced data. In cases, where a biosynthetic pathway is hypothesized by researcher upon observing 
the novel compound extracted, it is impossible to use these sequence based tools for the identification 
of similar gene clusters without the availability of sequence information. Hence, new tools are needed 
which can efficiently analyse and generate dereplication library of biosynthetic pathways with or without 
the presence of sequence information. 
1.4 Myxobacteria as producers of natural products 
Natural products are important as leads for drug development, and the traditionally established 
producers of secondary metabolites include many plants, fungi and various bacteria, like, for example, 
the long known actinomycetes. More recently the myxobacteria have been added to this list, and are 
now also considered as an established source for natural products (97, 98). 
Myxobacteria are a group of soil-living bacteria which are classified under the delta-subgroup of 
proteobacteria (99). They were first isolated by Roland Thaxter in 1892 recognizing them as an 
independent group. Since their discovery, this group of bacteria has fascinated scientists over 
generations due to their striking characteristics, mainly their distinct life cycle and social behaviour.  
Additionally, unique is their ability to aggregate into multicellular fruiting bodies when lack of nutrients is 
encountered (Figure 1.7). They move by gliding over the surface and are found to be ubiquitous in nature 
(100). Myxobacteria have relatively large genomes when compared to other bacteria. For example, the 
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circular genome of Sorangium cellulosum strain So ce56 contains 13,033,779 base pairs, which makes it 
one of largest bacterial genomes sequenced to date (99). Myxobacteria produce secondary metabolites 
with structural elements that are not commonly produced by other microbes such as unusual hybrids of 
polyketides and non-ribosomally made peptides (86, 101)  (Figure 1.7). Many of these myxobacterial 
compounds also exhibit structural features which were novel at the time of their discovery (100). 
 
Over the last 30 years, myxobacteria have been shown to produce compounds exhibiting a wide 
range of biological activities. For example, epothilones produced by the myxobacterium Sorangium 
cellulosum strain So ce90, show anti-tumor activity (Figure 1.8 a). Their analogues are used for the 
treatment of cancer, one such analog is the “ixabepilone”, which has recently been approved by FDA 
(U.S. Food and Drug Administration) and is now in use for the treatment of breast cancer (102). Other 
secondary metabolites such as etnangien (Figure 1.8 b), corallopyronin  (Figure 1.8 d) and ripostatin  
(Figure 1.8 c) from myxobacteria strains Corallococcus coralloides Cc c127 and  Sorangium cellulosum 
Figure 1.7: Stereophotomicrographs of myxobacterial fruiting bodies. A) Corallococcus sp. on agar. B) 
Cystobacter sp. aggregates of sporangioles C) Pyxidicoccus sp. golden yellow color sporangioles D) 
Myxococcus sp. on soil crumb and at the edge of filter paper. Photos courtesy:  Ronald Garcia. 
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Soce377 are observed to possess antibacterial activity due to their function as inhibitors of RNA 
polymerases (97, 103). Argyrin (Figure 1.8 g), Cystobactamids (Figure 1.8 i) extracted from the 
Archangium gephyra, Cystobacter sp. Cbv34 is a new myxobacterial metabolite exhibiting activity against 
gram-negative pathogens. Soraphen (Figure 1.8 h) is an immunosuppressive cyclic peptide extracted 
from Sorangium cellulosum Soce26,  exhibiting the ability to inhibit T-cell independent antibody 
formation by murine B cells (104–106), while myxochelin (Figure 1.8 e) and nannochelin (Figure 1.8 f) are 
two similar compounds extracted from the myxobacteria Angiococcus disciformis and Nannocystis 
exedens, respectively, which have iron-chelating activity (107, 108). 
Over 9,000 myxobacterial strains were isolated to date by workgroups at Helmholtz Center for 
Infection Research, Braunschweig and at the Helmholtz Institute for Pharmaceutical Research, 
Saarbruecken.  In-house data indicate that these strains yielded around 900 compounds belonging to 
more than 140 compound families (although numbers cited in the literature are lower). 
Myxobacteria are considered as “metabolite factory” with novel types of chemical structures and 
unique mode of action. However, since these microbes are difficult to isolate and are slow growing (109). 
In addition, the amount of secondary metabolites in cultures is often low which might be because of 
product degradation or end product inhibition (110). This might be one of the reasons that there are 
several unexplored metabolites   from the strains of myxobacteria which are often cultivated in the 
laboratories. With respect to their genome size, it is thought that network is essential to produce 
chemical substances enhancing the survival and competitively of both the individual and the population 
(111). This can be observed at the genetic level of myxobacteria involved in secondary metabolism. 
Exceptionally large genome of the myxobacterium Sorangium cellulosum Soce56  has around 20 
secondary metabolite loci reported, and thus should  have more than the reported compounds to be 
discovered (99). Myxococcus xanthus DK1622 has around 18 secondary metabolite gene clusters 
accounting for around 9% of its genome (112). The high abundance of secondary metabolite 
biosynthesis-related gene clusters in the genomes of these strains indicates their genetic potential for 
the production of secondary metabolites which exceeds far more the number of previously reported 
compound classes from each strain. This finding implies that there is a need for improved analytical 
methods for the detection, identification and characterization of myxobacterial secondary metabolites.   
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Figure 1.8: (a) Epothilon, drug with anti-tumor activity (b, c, d) Etnangien, Ripostatin and Corallopyronin possess 
antibacterial activity. (e, f) Myxochelin and Nannochelin are iron-chelating agents (g, h) Argyrin, and Soraphen 
possess T-cell regulatory abilities, (i) Cystobactamide is a new myxobacterial metabolite exhibiting activity against 
gram-negative pathogens. 
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1.5 Myxobase / Mxbase server:  a comprehensive chemical & biological 
database 
As the increase of the availability of sophisticated technology, multi-disciplinary research in the 
field of biology is quickly transforming it into data-rich science generating enormous amounts of 
information, steadily increasing the need for storing, analyzing and communicating this information. For 
this, a database project named "Myxobase" for collecting and linking chemical and biological information 
about known myxobacterial natural products and the producing strains has been pursued for five years 
at the Institute of Pharmaceutical Biotechnology of Saarland University and the Helmholtz Institute for 
Pharmaceutical Research Saarland (Group of Prof. Dr. Rolf Müller). This is a typical client-server 
application where the authorized user can add or update the information and the system is multi-user 
enabled. Contributing to this framework by improving existing-and adding new functionality was also an 
integral part of the work presented here. 
Mxbase is a system for retrieving, storing and analysing of chemical and biological experimental 
data in a comprehensive multi-part database. Researchers can use the database to expand and improve 
the discovery process of novel microbial natural products. This also provides functions for extracting only 
that information needed to answer a specific biological question. Mxbase is not only a powerful 
approach to collaborative knowledge management in a multi-disciplinary lab. It integrates tightly with 
instruments-based analytical workflows, and the available tool set expands continuously. The Mxbase 
Figure 1.9: Organization and information content of Myxobase 
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concept covers diverse techniques needed e.g. for the characterization of new microorganisms, 
screening and dereplication, chemical structure elucidation, mass spectrometric analysis, bioactivity 
testing, genome- and metabolome mining (contributed by the present work) and many other methods 
(Figure 1.9). 
 The concept behind the Mxbase system (Figure 1.10) is to supply a combined framework for 
knowledge management and analysis workflows centred on the discovery of natural products from large 
numbers of biological sources. Technically, Mxbase can be divided into: 
 the client software - MxbaseExplorer - which most users interact with for data deposition, 
information retrieval and specific data analysis procedures 
 and the Mxbase server, which hosts an extensive database backend and additional analysis 
functions used by the client software, but also accessible to specialized data mining procedures 
using standard tools such as KNIME, Matlab and R. 
 
In the course of this work, important additions to the Mxbase project have been made in the fields of 
genetics data, archiving and presentation of biosynthetic pathways, as well as (most importantly) the 
management and comparison of biosynthetic pathways datasets from myxobacterial strains. 
 
Figure 1.10: Framework of Mxbase demonstrating the workflow of 
various components involved 
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1.6 Aims and scope of this work: a new approach to the (myxobacterial) 
genome mining challenge 
Initial situation and prerequisites 
 In light of the latest advances in whole-genome sequencing technologies, enabling the 
bioinformatic mining of increasing numbers of large myxobacterial genomes for the presence of 
biosynthetic pathways becomes an important issue for successful genomics-based discovery of new 
natural products and biochemical processes..  
Myxobacterial genomes contain a wide variety of secondary metabolic gene clusters encoding 
polyketide synthases (PKSs), non-ribosomal peptide synthetases (NRPSs), or PKS/NRPS hybrids, besides 
other types of pathways. Thus, they offer great potential for the discovery of new bioactive metabolites. 
Different strains of myxobacteria have already been shown to produce compounds which are of 
potential clinical value. The rapid decrease in the cost of genome sequencing now allows the detection 
of hundreds or even thousands of gene clusters encoding the biosynthetic machinery for such 
compounds. However, laboratory research cannot keep pace with the speed of genomics-based 
discovery, as the experimental characterization of each gene cluster is often laborious and time-
consuming.  It is therefore important to prioritize resources for the investigation of pathways. From the 
point of view of natural products discovery, the most interesting gene clusters are those encoding 
pathways which are: i) responsible for the production of a compound with known structure exhibiting 
potent biological activity, or ii) similar to a previously characterized biosynthetic pathway so that an 
assumption about the molecule class likely produced can be made, or iii) uncommon or even unique 
pathways likely to produce novel chemistry. As a consequence, effective in silico identification and 
comparison of known and predicted biosynthetic pathways within genomes is essential for the efficient 
mining of the genomic richness available. Similar to the dereplication of known chemical entities in 
complex natural product-rich extracts, the dereplication of known biosynthetic concepts (also termed 
“models” in the following) and the underlying gene clusters has to be achieved in a genomics-based 
discovery workflow. The methods to be developed for this purpose have to take into consideration that 
there are different sources for- and ways of generating biosynthetic models (see Figure 1.11) 
1. Automated genome analysis, where large numbers of reads obtained from sequencing are 
assembled through assembler algorithms resulting in contigs or scaffolds or closed genomes. These are 
commonly submitted to antiSMASH, a software pipeline to predict and annotate secondary metabolite 
pathways. As it is the quasi-standard in the field, it was one requirement that newly developed tools in 
this project must be able to interface with the output of the antiSMASH analysis engine.     
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2. Experimental characterization of biosynthesis, where a biosynthetic model is created from the 
structure and matched with the in-silico interpretation of a confirmed biosynthetic pathway (genes 
already available). Such verified pathway-compound assignments are at the heart of a biosynthetic 
model database to be developed for the purpose of biosynthetic gene cluster dereplication. 
3. Starting from a newly discovered compounds, where a hypothetical biosynthetic pathway is 
designed manually for the freshly elucidated structure through sequential biochemical considerations, in 
a way that could be termed “retro-biosynthetic analysis” (no genetic information available yet). It is an 
additional requirement, that the toolbox to be developed in this work has to be able to accommodate 
and operate also with such “sequence-free” biosynthetic pathway models. 
 
Challenges and strategy 
Current approaches for the comparison of biosynthetic gene clusters are mostly using sequence-
based methods. Sequence alignment and comparison tools, such as BLAST and HMM, are the commonly-
used, traditional methods to identify homologous genes. These methods assume that sequences 
exhibiting significant similarity share common ancestry i.e. is homologs. However, the complex and to 
date not exhaustively understood mechanisms driving the evolution of multi-modular biosynthetic 
pathways imposes difficulties on sequence-based approaches. Furthermore, the performance of 
Figure 1.11: Methods of generating biosynthetic models 
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sequence-based tools can quickly become a serious bottleneck when it comes to compare high numbers 
of genes/pathways present in elevated numbers of sequenced genomes. For example, if the following 
myxobacterial genome data availability were to become a reality within few years from now (which is 
not far-fetched), it is foreseeable that a “real-time” or “on the fly” analysis of this data volume is hardly 
feasible unless tremendous computational capacity would be spent even for relatively simple analysis 
scenarios: 
 up to 200 myxobacterial whole-genome sequences of 9-18 Mbps 
 where each encodes 10 to 30 secondary metabolite biosynthetic pathways 
 the gene cluster for each pathway has 1 to >20 genes  with up to > 50 domains 
 each domain has multiple biochemical properties / predictions inferred from the primary 
sequence 
In addition, much of the valuable information for pathway comparison in light of the produced 
structures does not lie in the primary sequences and their similarity, but is derived from the “enzymatic 
activity string” that results from bioinformatics analysis of the genomic input. These data include (but are 
not limited to) domain types and module composition, operon organization, domain order and predicted 
substrate specificity of monomer-activating domains. 
Thus, the undertaking described in this work was met with a challenge to relate/compare the 
domain pattern of biosynthetic models with and without connection to genome sequences, linked to 
various layers of meta-information about building blocks, linkage, and enzymatic modifications that are 
expected to occur during the process of biosynthesis. These requirements motivated the development of 
a new approach to the comprehensive biosynthetic concepts-based mining of myxobacterial genomes in 
this study., Thereby, the genomic, chemical and biosynthetic knowledge which has accumulated in the 
workgroup over the past fifteen years (reflected largely in myxobase) plus genomic information from 
publicly accessible sources served as input for tool development and as test dataset for the performance 
evaluation of developed methods. 
Three basic usage scenarios could be envisaged for this bioinformatics framework: 
1. Matching a single pathway, e.g. an experimentally characterized secondary metabolite gene 
cluster or a speculative biosynthetic model from retro-biosynthetic analysis, against the 
multitude of pathways present in the database (which could themselves be pathways found in 
auto-annotated genomes, or discrete curated pathways manually deposited in the database). 
This search aids the identification of potential sources encoding a gene cluster for a newly 
discovered compound, and provides alternative sources for a gene cluster under investigation. 
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2. Assigning to each gene cluster found in a newly sequenced genome a plausibly close relative 
from the database, which helps the dereplication process and basically translates into a 
sequential procedure as in (1). When a compound produced by a reference gene cluster is 
already known, the link between gene cluster and putatively produced structure or compound 
class can be rapidly made. 
3. Creating a comprehensive overview of biosynthetic pathway diversity in the database through a 
“match all against all” approach, where the aim is to construct a comparative map of gene 
cluster similarity. This multiple relation in turn may be used to support large-scale analysis such 
as phylogenetic distributions and the study of pathway evolution across entire microbial taxa. 
The overview obtained also enables the estimation of species richness in terms of biosynthetic 
pathways and may reveal insights into the degree of “pathway uniqueness” within a given clade 
of producers. 
Implementation and deliverables 
The aforementioned concepts and prerequisites served as a guideline for bioinformatic tool 
development throughout the present work and markedly influenced the directions taken during 
implementation. Since “everyday usability” of newly established tools and analysis workflows by 
scientists working in the institute’s research environment was desirable so that the new methods 
provided can unfold their impact on scientific advancement, the project also comprised significant 
software engineering efforts.  The key components of the implementation and deliverables which were 
made available in the course of this work are briefly highlighted in the following (see also Figure 1.12). 
 Direct interfacing to the output of the antiSMASH annotation pipeline, which required the 
integration of a new module into antiSMASH to generate structured results representations. The 
developed functionality has become a standard output module since the release of antiSMASH 
version 3 (95). 
 Development of an xml-based container format named “BiosynML” to shuttle biosynthetic models 
and all their associated meta data, with or without sequence information, between different parts 
of the envisaged analysis workflows. 
 Visualization and editing tools allowing for manual inspection and curation of annotated pathways 
by scientists. This was implemented in the form of a “BiosynML plugin” for the widely used 
Geneious bioinformatics software, allowing making use of an already well-developed and familiar 
graphical frontend as well as re-using certain standard sequence-based functionality from the 
Geneious software package. In addition, the plugin enables direct submission and result retrieval 
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to/from the antiSMASH web service (public or in-house). The BiosynML plugin for Geneious has 
been released to the general public, coordinated with the publication of antiSMASH version 3 (95). 
 Addition of BiosynML import functionality to the in-house research database system Mxbase, 
including the creation of all required data schemes and software components to develop Mxbase 
towards full support for management and analysis of genomic data and biosynthetic pathway 
models. 
 The bioinformatic core of the project: development of algorithms for matching and comparing 
biosynthetic pathways and their implementation within a remote-procedure framework, based on 
the Apache Thrift technology. This approach enables future re-use of the developed BiosynML 
analysis engine for various application scenarios, including the possibility for its integration into 
analysis workflows different from the one established in this study. 
 Parametrization, critical evaluation of analytical performance and optimization of developed 
algorithms using a variety of real-world test cases. 
 Implementation of user interface functionality allowing users of Mxbase to conduct analysis using 
the BiosynML engine, including the formulation and submission of jobs to the analysis queue as well 
as graphical results representation and evaluation. These components were continuously built into 
the MxbaseExplorer software (the graphical frontend to the Mxbase system) since version 3. 
 Evaluation of the BiosynML concept in terms of its inter-operability with the MIBiG (“minimum 
information on biosynthetic gene clusters”) initiative (113), a recent community-supported move 
towards standardizing the basic information needed to describe secondary metabolite biosynthesis 
pathways. This included the tentative implementation of an adaptor to “bridge” between the 
information-rich BiosynML containers and the evolving MIBiG database. 
Following the development and implementation phase, the newly created tools and workflows 
were applied to the analysis of biosynthetic pathways from myxobacterial genomes available at the 
institute, as well as using pathways and genomes from publicly accessible sources. For this purpose a 
collection of 35 manually curated myxobacterial secondary metabolite gene clusters was compiled and 
71 myxobacterial genomes from ongoing sequencing projects were used to populate the test database. 
Several scenarios for conceptual genome mining were subsequently run in order to test-drive the 
BiosynML analysis framework and to evaluate analytical performance of the method. Furthermore, the 
power of the conceptual approach to generate an overview of pathway diversity in the database was 
explored and the method was compared to conventional sequence-based genome mining strategies. 
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Figure 1.12: Schematic overview of the BiosynML framework and interoperation of its components with publicly 
available resources (antiSMASH pipeline, Geneious software suite, MIBiG initiative) and in-house technology 
(Mxbase system, Myxobase). Green boxes highlight contributions from the present work. 
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2 Materials and methods 
2.1 DNA sequencing and assembly 
 Accurate determination of the primary DNA sequence is crucial in the field of natural product 
genome mining and discovery of novel compounds. DNA sequencing of bacterial strains used by us 
included massively parallel next-generation sequencing (NGS) technologies (Solexa/Illumina, Roche/454) 
and recently developed third generation sequencing technology (TGS) by Pacific Biosciences. The third 
generation sequencing technologies differ from NGS mostly by the ability to sequence single, 
Strain Technology Assembly software / algorithm 
Outcome, 
contigs 
Chondromyces crocatus MSr (Cm_c5)   PacBio   SMRT Portal 2.1.1 / HGAP 2  1 
Corallococcus coralloides MCy6431 (Ccc1071)   PacBio   SMRT Portal 2.2.0 / HGAP 3  1 
Pyxidicoccus sp. MCy9557 (SBCy002)   PacBio   SMRT Portal 2.2.0 / HGAP 3  1 
Sorangium cellulosum MSr8242 (Soce26)   PacBio   SMRT Portal 2.2.0 / HGAP 3  1 
Sorangium cellulosum MSr1566 (Soce836)   PacBio   SMRT Portal 2.2.0 / HGAP 3  1 
Sorangium cellulosum MSr8412 (Soce1128)   PacBio   SMRT Portal 2.1.1 / HGAP 2  1 
Sorangium cellulosum MSr7282 (SoceGT47)   PacBio   SMRT Portal 2.1.1 / HGAP 2  1 
Myxococcus virescens ST200611   454 Roche  
 Newbler unspecified version / Overlap 
Layout 
987 
Myxococcus xanthus MCy8278 (Mxx48)   Illumina   Abyss pe 1.3.6 / K mer  393 
 Myxococcus xanthus MCy8986 (DK897)   454 Roche   Newbler 2.6 / Overlap Layout 1081 
Sorangium cellulosum MSr9369 (Soce26Y2)   Illumina    Abyss pe 1.3.6 / K  350 
Sorangium cellulosum MSr1795 (Soce307)   Illumina   Abyss pe 1.3.6 / K mer  320 
Sorangium cellulosum MSr8404 (Soce38)   454 Roche   Newbler 2.6 / Overlap Layout Consensus 888 
Sorangium cellulosum MSr7234 (Soce377)   Unknown   Unknown    1478 
Sorangium cellulosum MSr6597 (Soce1525)   454 Roche   Newbler 2.6 / Overlap Layout Consensus 721 
Table 2.1: Assembly algorithms used based on overlay-layout-consensus, k-mer approaches used for strains 
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unamplified molecules. This fact also significantly reduces skews in data and context-dependence (114).  
Commercially-available Single Molecule Real-time Sequencing (SMRT) from Pacific Biosciences can 
yield read lengths up to several tens of kilobases, a figure outperforming all other available technologies 
by few orders of magnitude. Another issue specifically inherent to biosynthetic gene clusters is their 
modular structure, which contributes to difficulties of assembling them because of increased likelihood 
for repeats (115). Various algorithms were developed which to various extent mitigate the problem of 
assembling highly repetitive sequences in NGS and TGS data. For this work, we used assembly algorithms 
based on overlay-layout-consensus, k-mer approaches (MIRA, abyss-pe, HGAP) (see Table 2.1). For 
genetic sequence annotation, Prokka 1.7 was used. 
2.2 Mxbase infrastructure 
Mxbase explorer is a user interface which is designed to support efficient handling of the 
scientific data. The Mxbase explorer is equipped with several functions or methods through which a 
researcher communicates with a program to achieve desired result. Many of the functions in Mxbase 
explorer perform processing on the client computer but functions that require more computational 
power run on the Mxbase server backend via apache thrift service which provides a binary RPC protocol 
for supporting service invocations, enabling multiple programming language implementations to talk to 
each other. Thrift is a framework designed to be efficient and available across all platforms and 
programming languages. Functions like target analysis report upload and export, metabolome upload 
and mining and search and match functions of biosynML require increased computational power for 
execution; in order to optimize speed and usability of these functions they run on Mxbase server which 
directly process the data and write the information to the appropriate tables in the database. In 
addition, mxbase server has scripts that notifies information to the all users via email and has a file 
system that stores data in the database which can be downloaded through mxbase explorer. It also has 
documents about the different projects that uses mxbase server extensively. With the availability of all 
the technology the researchers can easily and quickly generate reports on various datasets stored in the 
myxobase depending upon their interest. 
A detailed schematic workflow of various components in the Mxbase infrastructure is illustrated 
in Figure 2.1. 
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2.3 Geneious framework 
Geneious (Figure 2.2) is a cross-platform bioinformatics software suite developed by Biomatters 
for search, organize and analyze genomic and protein information via s powerful desktop program.  One 
of the main advantages is its strong focus on user-friendly interface and ease of use in combination with 
established bioinformatics tools which are “wrapped” into the application (Figure 2.2). It features wide 
variety of algorithms for sequence alignment, phylogenetic analysis, contig assembly and primer design. 
In addition, researchers can use this tool to access NCBI and UniProt databases, BLAST, protein structure 
viewing, automated PubMed searching (116). 
In addition, Geneious provides a powerful public API consisting of a set of classes and interfaces 
necessary for the programmers to develop customized plugins and integrate them into the framework. 
Exploiting the concept of plugin development kit, a plugin is developed in this study to improve the 
Figure 2.1: Mxbase infrastructure 
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quality of the biosynthetic pathways predicted. This development became instrumental for building a 
department-wide myxo pathways repository.  
2.4 antiSMASH: antibiotic and Secondary Metabolite Analysis SHell 
antiSMASH is a tool capable of identifying biosynthetic loci covering a wide range of known 
secondary metabolite compound classes (polyketides, non-ribosomal peptides, terpenes, 
aminoglycosides, aminocoumarins, indolocarbazoles, lantibiotics, bacteriocins, nucleosides, beta-
lactams, butyrolactones, siderophores, melanins and others). It aligns the identified regions at the gene 
cluster level to their nearest relatives from a database containing all other known gene clusters, and 
integrates or cross-links all previously available secondary metabolite specific gene analysis methods in 
one interactive view. Genes are extracted or predicted from the input nucleotide sequence, and gene 
clusters are identified with signature gene pHMMs and predicts the biosynthetic pathway. Finally, the 
output is visualized in an interactive XHTML web page (Figure 2.3) (95).  
antiSMASH also provides meta information including substrate specificity of PKS and NRPS which 
are predicted based on the active sites of the domains such as acyltransferase (AT) and adenylation (A) 
using various methods. Ketoreductase (KR) domain-based stereochemistry predictions for PKSs are also 
performed. A final chemical structure of the biosynthetic pathway predicted is generated as a SMILES 
string. 
Figure 2.2: Geneious: tool for search, organize and analyze genomic and protein information 
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2.5 Datasets used in this study 
In this work to perform the evaluation test of newly implemented tools, genomes of Actinomycetes 
(277), Bacillus (77), Cynobacteria (63), Proteobacteria (47) and Serratia(3) genomes and 42 published 
clusters (Table 2.4) from myxobacteria are downloaded from NCBI. These genome datasets and clusters 
are passed through antiSMASH for secondary metabolite cluster prediction which gives biosynml (.xml) 
file as output. The respective output module was added in the course of this work. The biosynML files of 
genomes and published clusters from myxobacteria were curated manually using biosynML plugin in 
Geneious. These datasets (.xml files) were imported into the Myxobase biosynthetic pathway repository 
and are used as input for targeted search query and genome annotation tools. The published and 
unpublished genomes (Table 2.2 and Table 2.3) from ongoing projects in the department were also 
channelled into the analysis. 
 
 
Figure 2.3: antiSMASH output for secondary metabolite gene cluster 
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Organism #Gene clusters 
Chondromyces crocatus Cmc5 28 
Corallococcus coralloides MCy9080 30 
Haliangium ochraceum DSM14365 14 
Myxococcus fulvus HW1 20 
Myxococcus stipitatus MCy9235 26 
Myxococcus xanthus DK1622 19 
Corallococcus coralloides Ccc1071 37 
Pyxidicoccus unclassified MCy9557 22 
Sorangium cellulosum Soce56 19 
Sorangium cellulosum So0157 26 
Sorangium cellulosum SoceGT47 18 
Sorangium cellulosum Soce836 37 
Sorangium cellulosum Soce1128 44 
Stigmatella aurantiaca DW4/3-1 28 
Sorangium cellulosum Soce26 28 
unclassified unclassified MNa9516 6 
Melittangium lichenicola Mel24 22 
unclassified unclassified MCy10635 10 
unclassified unclassified MCy11274 3 
unclassified unclassified MSr10681 14 
unclassified unclassified MSr9506 12 
unclassified unclassified MSr10575 15 
unclassified unclassified MSr9528 15 
Plesiocystis pacifica MNa11107 12 
unclassified unclassified MCy11225 15 
unclassified unclassified MCy10622 16 
Table 2.2: List of complete genomes used in this study 
 
Organism #Scaffolds #Gene clusters 
Aetherobacter fasciculatus MSr9330 6 20 
Aetherobacter fasciculatus MSr9337 3 20 
Aetherobacter rufus MSr9331 11 22 
Aetherobacter unclassified MSr9329   48 20 
Aetherobacter unclassified MSr9335 83 21 
Angiococcus disciformis AngGT8 92 40 
Archangium unclassified MCy9003 4 31 
Byssovorax cruenta Har1=Byc1 14 26 
Chondromyces apiculatus Cma2 182 26 
Chondromyces catenulatus MSr9030 9 21 
Corallococcus coralloides ST201330 26 40 
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Cystobacter ferrugineus Cbfe23 155 24 
Cystobacter fuscus MCy9118 188 29 
Cystobacter fuscus MCy9127 2 30 
Cystobacter unclassified MCy9101 36 39 
Cystobacter unclassified MCy9104 133 31 
Cystobacter velatus Cbv34 20 28 
Hyalangium minutum NOCb10 158 17 
Minicystis unclassified MSr9310 3 26 
Myxococcus fulvus MCy9270 62 30 
Myxococcus fulvus Mxf50 141 41 
Myxococcus fulvus Mxf65 168 24 
Myxococcus unclassified MCy9171 47 24 
Myxococcus virescens ST200611 14 23 
Myxococcus xanthus DK897 42 21 
Myxococcus xanthus MxA47 73 18 
Nannocystis exedens Nae478 3 20 
Polyangium spumosum Plsm9 138 22 
Sorangium cellulosum Soce10 138 13 
Sorangium cellulosum Soce1525 14 26 
Sorangium cellulosum Soce307 51 19 
Sorangium cellulosum Soce377 31 22 
Sorangium cellulosum Soce38 17 19 
Sorangium cellulosum Soce969 101 23 
Stigmatella aurantiaca Sga32 14 28 
Stigmatella erecta Pde77 43 26 
Archangium gephyra Ar3548 57 40 
Corallococcus coralloides Ccc127 3 25 
unclassified unclassified MCy10585 2 42 
unclassified unclassified MCy10597 2 41 
unclassified unclassified MCy10634 2 7 
unclassified unclassified MCy10649 2 33 
unclassified unclassified MCy10653 2 43 
unclassified unclassified MCy9487 2 69 
Table 2.3: List of draft genomes with less than 200 scaffolds used in this study 
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Cluster Characterized from strain 
Ajudazol Cmc5 (Chrondromyces crocatus) 
Althiomycin DK897 (Myxococcus xanthus) 
Ambruticin So ce10 (Sorangium cellulosum) 
Argyrin Ar8082 (Archangium gephyra) 
Aurafuron DW4/3-1 (Stigmatella aurantiaca) 
Carolacton So ce836 (Sorangium cellulosum) 
Chivosazol So ce56 (Sorangium cellulosum) 
Chondrochloren Cmc5 (Chrondromyces crocatus) 
Crocacin Cm c5 (Chondromyces crocactus) 
Dawenol DW4/3-1 (Stigmatella aurantiaca) 
DKxanthene DW4/3-1 (Stigmatella aurantiaca) 
Etnangien So ce56 (Sorangium cellulosum) 
Hyafurone NOCB10 (Hyalangium minutum) 
Leupyrrin So ce690 (Sorangium cellulosum) 
Lipothiazole SoceGT47 (Sorangium cellulosum) 
Melithiazol Me l46 (Melittangium lichenicola) 
Microsclerodermin M MSr9139 (Jahnella unclassified) 
Myxalamid DK1622 (Myxococcus xanthus) 
Myxochromid DK1622 (Myxococcus xanthus) 
Myxoprincomide DK1622 (Myxococcus xanthus) 
Myxothiazol DW4/3-1 (Stigmatella aurantiaca) 
Myxovalargin MCy6431 (Corallococcus coralloides) 
Myxovirescin MCy9151 (Myxococcus xanthus) 
Pellasoren So ce38 (Sorangium cellulosum) 
Phenalamid MCy6431 (Corallococcus coralloides) 
Pyxidienon MCy9557 (Pyxidicoccus sp. SBCy002) 
Rhizopodin Sga 15 (Stigmatella aurantiaca) 
Ripostatin Soce377 (Sorangium cellulosum) 
Sorangicin So ce12 (Sorangium cellulosum) 
Soraphen So ce26 (Sorangium cellulosum) 
Spirangien So ce90 (Sorangium cellulosum) 
Stigmatellin Sga 15 (Stigmatella aurantiaca) 
Thuggacin Cmc5 (Chrondromyces crocatus) 
Vioprolide Cbvi35 (Cystobacter violaceus) 
Nannochelin Nae620 (Nannocystis exedens) 
Table 2.4: List of curated gene clusters used in this study 
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2.6 Programming language 
2.6.1 C# and Microsoft Visual Studio  
Microsoft Visual Studio (VS) is an integrated development environment (IDE) developed by 
Microsoft. It is used to develop console and graphical user interface applications along with so-called 
“Windows Forms” applications, web sites etc. VS can run on all versions of windows and has built-in 
languages such as Visual Basic .NET (VB.NET) and C sharp (C#).  Among these C# is versatile and powerful 
and is used widely to create applications running on the Windows platform. It is well suited to develop 
software which features graphical interfaces extensively. 
Here, the VS 2013 IDE with C# built in was used for the project. The VS 2013 is licensed under 
University of Saarland/ MSDN Academic Alliance conditions.   
2.6.2 Java and NetBeans Platform 
Netbeans is a framework written in java which is programmed for NetBeans Integrated 
Development Environment (IDE), but can support other languages such as PHP, C/C++ and HTML5. The 
modular architecture improves the usability of the application by allowing the functions to be reused. 
We mainly used this application for programming the functions for matching and scoring algorithms as 
well as for development of the BiosynML plugin for Geneious. These functions mainly run on the Apache 
Thrift service through remote procedure call framework (RPC). Because of its advanced window 
management, powerful built-in profiler, excellent integration with Apache Thrift service and easy 
modular design allowing developers to develop and distribute extensions to the modules. 
2.7 Apache Thrift 
Apache Thrift is a software framework (originally developed by Facebook, later handed over to 
the Apache foundation) for creating interoperable scalable cross-language services development. Thrift 
is composed of efficient protocols and services infrastructure which Facebook use for their back-end 
services. It combines a software stack with a code generation engine to build services that work 
efficiently and seamlessly between C++, Java, Python, PHP, Ruby, Erlang, Perl, Haskell, C#, Cocoa, 
JavaScript, Node.js, Smalltalk, OCaml and Delphi and other languages. Although thrift was originally 
developed at Facebook, it is now an open source project in the Apache Software Foundation licensed 
under the Apache 2.0 (117). The main advantage of thrift is the high-performance services that can be 
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called from multiple languages. The design of thrift makes it as the ideal choice where the speed is a 
concern while communication between multiple languages is needed and when clients and servers are 
co-located.  
2.8 Graph Visualization: ZedGraph 
ZedGraph (http://sourceforge.net/projects/zedgraph/) is a set of classes, written in C#, for 
creating 2D line and bar graphs of arbitrary datasets. The classes provide a high degree of flexibility in 
terms of personalization of graphs according to need. At the same time, usage of the classes is kept 
simple by providing default values for all of the graph attributes. The classes include code for choosing 
appropriate scale ranges and step sizes based on the range of data values being plotted.  
ZedGraph also includes a User Control interface, allowing drag and drop editing within the Visual 
Studio forms editor, plus access from other languages such as C++ and VB. ZedGraph is licensed under 
the LGPL. 
2.9 MySQL Database platform 
MySQL is an open source database originally developed by Michael Widenius and now 
developed further by Oracle as a community project. MySQL is the most popular database which is 
widely used in many prominent websites. Key features include efficient storage ability but also high 
performance, high reliability, scalability and ease of use.   
In order to access MySQL the user needs to have an account (username and password) on 
MySQL server. We use a MySQL database (version 5.5.43) as backend for data storage throughout the 
Myxobase project. The server system was kindly hosted by the ITS department of Universität des 
Saarlandes. 
2.10 Extensible Markup Language (XML) 
Extensible Markup Language (XML) is a simple, very flexible text format developed by World 
Wide Web Consortium (W3C). It is a markup language derived from Standard Generalized Markup 
Language (SGML), a format which is both human-readable and machine-readable. The design goals of 
XML are to meet the challenges of large-scale electronic publishing and share structured data across the 
internet. XML is a robust self-describing or self-defining document that can be stored without schemas 
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as they contain meta-data. Any XML tag can possess an unlimited number of attributes, containing 
structured information.  
An XML document contains elements, defined by beginning and an ending tag. XML documents 
must contain a root element under which all elements are contained. XML can also support nested 
elements, or elements within elements. This ability allows XML to support hierarchical structures where 
the terms parent, child, and sibling are used to describe the relationships between elements. Element 
names describe the content of the element, and the structure describes the relationship between the 
elements. An attribute in xml of elements describes the characteristics of the elements in the beginning 
tag. 
The major advantage of using xml is that there is no fixed set of tags; new tags can be created as 
they are needed, creating liberty to define a markup language in terms of specific problem set allowing 
everyone to build their own tag library which suits their needs perfectly. It is not only free style to 
develop, but also free to develop tools that meet needs exactly based on the user defined structure of 
tags. The tree structure of XML documents provides better searching and navigation efficiently element 
by element. XML data is stored in text format making it easier to expand or upgrade without losing data 
by allowing user to add additional tags. 
Altogether, xml is simple, can manage large data by consolidating them in to an xml document in 
an organized way. 
2.11 MUSCLE: alignment software 
MUSCLE (multiple sequence comparison by log-expectation) is a multiple sequence alignment 
program used for protein and nucleotide sequences. The MUSCLE algorithm process an alignment in 
three stages. First, is the draft progressive, the algorithm concentrates on speed over accuracy and 
outputs a draft multiple alignment. The second step called as improved progressive, the algorithm 
reestimates the binary tree used to create the draft alignment using the Kimura distance. In the third 
step called as refinement, the algorithm improvises the generated in the second step. Due to the speed 
and accuracy of the MUSCLE, it is widely used ahead of ClustalW as it also gives more robust results 
depending upon the chosen options. MUSCLE has been made an integral part of several free and 
commercial softwares such as Geneious, MacVector, Sequencher, MEGA and UGENE (118). 
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2.12 Bioinformatics functions 
It was a fundamental requirement of this work to develop algorithms for the rapid comparison of 
(potentially large numbers of) biosynthetic models which can answer simple and complex questions. 
Similarity score is the measure to show how similar two or many sets of pathways are to each other. To 
find the similarity is to find the comparison between the two or more pathways and grade it after a score 
system. 
Cosine similarity 
It is a measure of similarity between two vectors of an inner product space that measures the 
cosine of the angle between them, where the range of the cosine similarity is [0, 1]. 
 ”1” indicates that x and y have the same domains 
 “0” indicates that they share no domains 
To assign a numeric score to a document for a query, the model measures the similarity between 
the query pathway (since query is also just domains and can be converted into a vector) and the 
target pathway. Typically, the angle (similarity) between two pathways is used as a measure of 
divergence between the pathway, and cosine of the angle is used as the numeric similarity (119). 
The cosine similarity between two vectors x (the target pathway) and y (query pathway) is given 
by:  
 
𝑠𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦(𝑥, 𝑦) = cos(𝜃) =  
𝑥 . 𝑦
||𝑥|| ∗ ||𝑦||
 
The cosine similarity provides a nice metaphor. Cosine similarity gives maximum value when θ = 
0 or when the vectors coincide. It gives lowest value when the vectors are independent of each other. 
This can be seen in the Figure 2.4. The main advantage of Cosine similarity index is their ability to 
score partial matches irrespective of the order of the domains in the pathways. 
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Smith–Waterman algorithm 
The Smith-Waterman algorithm is a dynamic programming method for determining similar regions 
between nucleotide or protein sequences. The algorithm was first proposed in 1981 by Smith and 
Waterman and is identifying homologous regions between sequences by searching for optimal local 
alignments. It is a variant to the idea proposed by Needleman and Wunsch (120) for global alignments. 
To find the optimal local alignment, instead of looking at the total sequence, the algorithm compares 
segments of all possible lengths. Based on these calculations, scores or weights are assigned to each 
character-to-character comparison: positive for exact matches/substitutions, negative for 
insertions/deletions (121). For a given strings, let x and y are the alphabets iterated over the string. H(i, j) 
stores the similarity score for the prefixes x[1, i] and y[1, j], W is the gap penalty for insertion or deletions 
of single characters. 
𝐻𝑖𝑗 = max {𝐻𝑖−1,𝑗−1 + 𝑠(𝑥𝑖 , 𝑦𝑗); 𝐻𝑖−𝑘,𝑗 − 𝑊; 𝐻𝑖,𝑗−1 − 𝑊; 0) } 
for all  𝑖, 1 ≤ 𝑖 ≤ |𝑥|,  
      and 𝑗, 1 ≤ 𝑗 ≤ |𝑦| 
The Smith-Waterman algorithm starts with the highest values and walks back to the path of the 
previous high value recursively until it reaches to the least value. Then, the alignment is reconstructed 
where gaps (insertions or deletions) are placed if a diagonal jump is observed. 
 
 
 
Figure 2.4: The projection of the vector A into the vector B. By 
Wikipedia. 
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EstimateS: Statistical estimation of species richness and shared species from 
samples 
EstimateS  (http://viceroy.eeb.uconn.edu/estimates/index.html) is a tool that computes variety of 
biodiversity statistics, estimators, and indices based on biotic sampling data. One such function is the 
estimation of species richness through non-parametric estimators (Chao1 and Chao2) (122).  
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3 Results and Discussion 
The main objectives of the present work, as outlined in chapter 1.6, can be briefly summarized as 
follows: firstly, the development of a framework to facilitate the seamless transfer of biosynthetic gene 
cluster information including extensive meta data between the antiSMASH pipeline and various 
downstream analysis tools; secondly, the development of new algorithms for the conceptual comparison 
of genome-encoded secondary metabolite pathways as opposed to primarily sequence-based analysis; 
and finally the application and critical performance evaluation of newly developed tools for genome-
mining with natural product sources, with special focus on myxobacteria. According to these objectives, 
this chapter reports first the efforts to establish the BiosynML analysis framework including a number of 
technological and implementation issues (chapter 3.1), followed by the description of BiosynML 
algorithm development (chapter 3.2).  
Datasets accumulated inside Myxobase in the course of this work form the basis for the 
development and testing of conceptual genome mining functions. Ultimately, application of the 
complete BiosynML framework to several prototypical analysis scenarios using genomic data from both 
Figure 3.1: Schematic overview summarizing the functions and interoperation of key components forming the 
BiosynML framework 
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in-house and public sources is the subject of chapter 3.3, covering in particular myxcobacterial pathways 
and genomes. The schematic overview below (Figure 3.1) summarizes the functions and interoperation 
of key components forming the BiosynML framework. 
3.1 Bioinformatics Framework for conceptual genome mining 
The routine analysis of secondary metabolite producers from various taxa which are sources for 
secondary metabolite-rich samples in the course of screening for novel compounds, in combination with 
the analysis of biosynthetic gene clusters encoded in the genomes of these producers, generates an 
overwhelming amount of biosynthetic pathway-related data. It was therefore a major aim of this project 
to develop practical tools enabling researchers to take better advantage of the high information content 
of these data. In particular, existing sequence-based analysis approaches for identifying and comparing 
biosynthetic pathways (based largely on the output of antiSMASH) should be complemented by an 
approach which can operate with or without sequence information, allowing anyone to instantly 
annotate a secondary metabolite cluster on the basis of all biosynthetic model information in the 
database available at that very moment. This ability should help to better “bridge” the knowledge from 
chemical, biochemical, biological and genomics research efforts within an integrated and highly 
interdisciplinary natural products discovery setting. Another important requirement was the ability to 
conduct targeted queries across all biosynthetic pathway datasets, to facilitate the identification of 
pathways exhibiting specific domain arrangements along with their properties of interest. It was also a 
crucial pre-requisite that all tools be implemented in conjunction with the Mxbase system, in order to 
enable distributed work across several labs and achieve “near-real time” collaboration of researchers 
concerning the data itself as well as the derived conclusions. 
The framework described in the following, reflecting these ideas, evolved gradually throughout 
this study until it reached the current state. Besides describing this state of art, the following paragraphs 
will shed light on the most important steps that lead to the development of different components in the 
framework, collectively named “BiosynML”. This explains best how the current features emerged and 
the design decisions which have been taken.  
3.1.1 BiosynML Language and container 
The basic needs for this framework start with the definition of a format and a container for storing 
biosynthetic models, including the primary sequence data (optional) and associated annotations for 
secondary metabolite gene cluster(s). A language (syntax) is essential to capture these models and 
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describe all their properties in great detail, in a systematic and extensible way. At the same time a 
container (file format) to store these descriptions and transport them between different tools and 
analysis workflows is required.  
Traditionally, the GenBank format has been widely used, as a computer and human readable flat file 
format used to store sequences and associated annotations where the fields containing different types 
of information are well-labelled. Although, GenBank has an advantage for being the de-facto standard 
used by many tools a major difficulty faced is in updating and extending the information. In addition, the 
GenBank file format was not designed to comprise the potentially verbose output of multiple prediction 
tools applied to sequence motifs (many of which co-exist in typical secondary metabolite modular 
pathways). Moreover, it is generally difficult to represent relationships between various data fields in a 
flat file, which makes it hard to group fields and link information across multiple entries.  The area of 
natural product research is a dynamic field with complex information related to the annotations which is 
hard to handle by flat files. To overcome this difficulty, an XML format, being a portable and accessible 
format, was chosen to store the annotated data where the key feature is to use identifiers to enclose the 
sections of the data.  It is also possible to further define data with appropriate tags and attributes which 
makes it easy for the researcher to identify the nature of the data. 
 
BiosynML: “Biosynthetic Markup Language”  
To overcome the lack of a suitable data format for storing and transporting complete biosynthetic 
pathway models between tools and databases, a new specialized mark-up language, named "BiosynML" 
was devised at the beginning of this study. BiosynML is an xml dialect, annotating a document in a way 
that is syntactically distinguishable from the content (text) itself. Information stored in the BiosynML 
containers can extend significantly beyond the content of GenBank files, where only relatively minimal 
information on genes and domains is included. Typically, information in xml schemes is stored in a 
systematic order in the form of hierarchic nodes. BiosynML has 6 elementary nodes: 
 Header, stores the basic information of the content like the date, author etc. (Figure 3.2a). 
 Model, stores the complete meta information of the pathway like the details of the organism the 
pathway belongs to, compound information that the pathway involved in and the gene cluster 
information. The model also has a chemical and a modules layer where the information of the 
building blocks and the modules containing set of domains which function together are stored, 
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respectively. A BiosynML file can store multiple independent pathways (models) which belong to 
the same organism (Figure 3.2b). 
 Domainslist, stores all information on biosynthetic domains, such as (observed or predicted) 
enzymatic activities and substrates used. It also stores the positions in the genes. (Figure 3.2c).  
 Genelist, stores the information of the coding sequences involved in the pathway(s). It also 
accomodates the qualifiers from antiSMASH and GenBank such as gene prediction scores, 
translated protein sequence etc. (Figure 3.2d). The information for each gene is connected to 
sequences in Sequencelist. 
 Motiflist, stores the information and predictions for signature motifs e.g. as obtained from 
antiSMASH (Figure 3.2e) or any other analysis tool. 
 Sequencelist, optionally stores the primary sequence for a sequence-related biosynthetic model, 
this could vary from single scaffold to multiple scaffolds or even a whole genome (Figure 3.2f).  
Importantly, the BiosynML format is able to capture the full information content 
available from various analysis tools and is flexible and extensible to adapt for future changes 
with regards to this information. It is designed for semantic access to this information, i.e. so 
that specialized analysis modules can easily extract the required information layer. Moreover, 
the format maintains a certain degree of “human readability”, which is an important aspect for 
its use in script language-based analysis workflows. 
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Figure 3.2: BiosynML layers a: header, b: model, c: domains, d: genes, e: motifs, f: sequences 
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3.1.2 Interfacing BiosynML to the “antibiotics & Secondary Metabolite Analysis Shell” 
(antiSMASH) 
The variety of biological activities observed from (microbial) secondary metabolites - including 
antibiotics, immunomodulation agents, receptor antagonists and agonists, enzyme inhibitors and 
antitumor agents – motivates efforts to detect their biosynthetic pathways in the genomes of producers. 
This information in turn facilitates the experimental elucidation of biosynthetic pathways for secondary 
metabolites clusters and may also support the finding of new metabolites by genome mining 
approaches.  
To underpin these endeavours, software tools are required to predict and annotate biosynthetic 
pathways and flexibly link it to the sequence information which is used for more detailed analysis in the 
course of pathway characterization. 
antiSMASH is a tool for the analysis of secondary metabolite gene clusters in bacterial and fungal 
genomes (95). It is a in fact a combination of various secondary metabolite-related prediction tools with 
high accuracy of identifying individual cluster annotations in a genome; in particular, it integrates several 
tools for the analysis of distinct types of NRPS- and PKS-related domains, such as NRPSpredictor for A-
domains (123).  
As part of this work, a new function was appended to the antiSMASH prediction pipeline which 
exports the results generated by antiSMASH into the information-rich BiosynML format. Based on the 
functional information of domains from antiSMASH, BiosynML can add extra meta information of 
domains from an online domain directory (see also 3.1.3) which is at the moment maintained specifically 
for use with BiosynML (but with official integration of BiosynML into antiSMASH could also be continued 
as a community repository in the future).   
The HTML interface of antiSMASH displays the minimum information of substrate predictions for 
domains, whereas, BiosynML files store detailed substrate predictions obtained from various prediction 
modules integrated in antiSMASH. Furthermore, when antiSMASH predicted genes lack domains, 
BiosynML can add specialized domains from the domain directory based on smCOG analysis and later 
researchers may choose to delete or modify these domains (Figure 3.3). 
The code to generate BiosynML output from antiSMASH results has been integrated into the 
publicly available antiSMASH package with the release of version 3.0 (95).  
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3.1.3 The BiosynML Geneious plugin  
In the course of analysis of secondary metabolite biosynthetic gene clusters there is a constant need 
to visualize pathways, as well as to add and edit pathway-related meta information and to create an 
overview of pathways present in one or multiple genome(s). In addition, biosynthetic models need to be 
submitted to bioinformatics tools such as antiSMASH in order to create annotated models, and the 
results must be retrieved to feed them back into in-house databases and downstream analysis 
workflows. These requirements were addressed in the course of this project by the development of a 
BiosynML plugin for the Geneious software. Geneious is a cross-platform bioinformatics software suite 
developed by Biomatters for search, organize and analyse genomic and protein information via a 
desktop program (116).  One of the main advantages is its strong focus on user-friendly interface and 
ease of use along with the seamless integration of a number of published bioinformatics methods. The 
newly devised BiosynML plugin originating from this work facilitates the creation of detailed biosynthetic 
pathway annotations, especially for modular gene clusters responsible for the production of microbial 
secondary metabolites. Typical tasks include refining the automatic predictions obtained by antiSMASH, 
addition of domains and meta-data based on manual analysis and/or experimental results (curation), 
such as grouping of domains into functional modules and assignment of biosynthetic building blocks. This 
information is key to establishing the connection between genes and chemical compounds and also a 
crucial prerequisite for the design of experiments to investigate the molecular basis for secondary 
metabolite formation. The core functionality of the BiosynML plugin for Geneious which has been 
implemented as part of this work is described in the following. 
Figure 3.3: Outline of the pipeline for genomic analysis of secondary 
metabolites (modified from (1)) 
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BiosynML Import: 
  This BiosynML plugin function creates a new sequence object in Geneious using the DNA 
sequence from the BiosynML sequencelist and creates "CDS" features and a "BiosynML" annotation 
track. The latter contains qualifiers generated on the sequence according to genelist, motiflist, 
modulelist, domainlist and nodelist (Figure 3.4). It assigns the information from various tags to the 
appropriate BiosynML annotation tracks as additional "qualifier" values which help to create annotations 
conforming to the BiosynML ontology. By observing to the guidelines for Geneious plugin construction, 
the resulting Geneious object is in principle GenBank-compatible which means, when exported in the 
widely used .gb format, BiosynML qualifiers can be preserved (albeit without the semantic access which 
the BiosynML format offers). The plugin provides an additional BiosynML tab in the Geneious user 
interface where user can add/edit the pathway information. 
BiosynML tab consist of several functions to deal with the information imported into Geneious 
such as an overview table which displays the whole information of the pathway, and a sidebar for the 
detailed information review (Figure 3.4). 
 
 
 
Figure 3.4: BiosynML tab: Ball scheme representation (box outlined in green), sidebar (box outlined in blue) and 
overview table displaying the whole information of the pathway 
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Ball-scheme representation : 
This function uses the BiosynML qualifiers to create a ball-scheme representation of a 
biosynthesis model, like it is commonly created by researchers and is the de-facto standard for 
illustration of biosynthetic models in publications. Each ball, representing a biosynthetic function carries 
its internal node number and displays a functional abbreviation alongside with selected additional data, 
such as substrate specificity for monomer-incorporating domains (e.g. A, AT). This function graphically 
enables users to have a quick overview of the domains in a biosynthetic model. A tool tip is provided to 
view the properties of the each node represented as a ball (Figure 3.4 (green box)) and the details are 
also accessible in the sidebar. 
 
Sidebar for information review and editing: 
The BiosynML plugin sidebar displays the detailed information of a node selected from the 
gridview where the user can review or modify details. The sidebar consists of panels where the 
information is displayed in a pre-organized way, e.g. a panel exists carrying the information of model, 
node, domain, motifs and modules (Figure 3.4 (blue box)). 
 
Creating modules:  
Domains in biosynthetic pathways are commonly grouped into modules based on (bio) chemical 
considerations, in order to declare their joint action to bring about specific substructures of a compound. 
BiosynML models generated from antiSMASH output initially do not contain any information about 
modules. To fill the module information, a function has been added to the BiosynML Geneious plugin for 
the users to create modules by selecting set of nodes in the gridview which the user presumes to 
function as a module. Furthermore, on module creation the ball scheme representation will also be 
updated where ball images are grouped representing their participation in modules.  
 
Automatic BiosynML: 
If the user intends to generate a BiosynML from an previously existing annotation document e.g. 
in GenBank format, then the function “Automatic BiosynML” is helpful which will guide the user to 
generate a BiosynML document. For this, the user has to select the type of annotation in the Geneious 
frontend which presumably contains domain information in GenBank format, e.g. misc_features, and 
then the function will search for the matching domains from the annotated features and generate a list 
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of domains and their properties in the BiosynML tab. If details cannot be auto-assigned by the function, 
the user can later add those details with the help of functions in the BiosynML tab. Thus, this function 
assists with the conversion of existing annotations into BiosynML format.  
 
Cleanup: 
It is a function when user wish to modify some data in the Geneious sequence view window for e.g. 
user wish to change the domain length or extending the module region, then this function will reflect the 
changes in the BiosynML tab and autocorrects the existing data with the changed data. For e.g. if the 
length of the domain is increased then this function will adjust the length of the node automatically.  
 
Add node/domain:  
Biosynthetic pathways predicted from the antiSMASH might have some shortcomings, such as a 
domain might be missing or it may predict a domain which in reality may not be present. In order to 
correct such prediction errors, users can add/delete a node/domain and can even manually assign new 
domain to an existing module (Figure 3.5). This manual refinement of biosynthetic models is commonly 
carried out in the course of experimental characterization of a biosynthetic pathway. 
 
Figure 3.5: Window to add a 
node/domain 
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Extract domains:  
It is a function to extract annotations of interest to a new document. Users are provided with 
multiple options in order to extract the regions of interest, such as “Extract currently selected domains” 
is an option useful when the user likes to extract a subset of domains selected from the grid view in 
BiosynML tab. Additionally, if user wants to extract the derived protein sequence, then the function will 
automatically translate the nucleotide sequence into protein and add annotation on to the translated 
protein sequence. On the other hand, if user wants to extract annotations of interest, for e.g. if one 
wants to extract all the “AT” domains then user can select the option “Extract domains matching these 
criteria” and can chose the extraction option to obtain the required subset of the annotation features. 
The result of the extraction can be done as a sequence list in a single document or can save them as 
individual documents (Figure 3.6). The extraction function is typically used to submit domain sequences 
from selected pathways to downstream analysis, e.g. Alignment, tree-building and visualization as 
phylogenetic trees.  
 
 
 
Add/edit building blocks:  
The output from antiSMASH carries predicted information about building blocks presumably 
incorporated by monomer-activating domains. This information can be manually amended, and in 
addition information about the building blocks which are actually incorporated (based on experimental 
Figure 3.6: Features of the Extract domains 
function 
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evidence) can be added or edited using the “Add/edit building block” function. This could also be helpful 
if the BiosynML is generated by “Automatic BiosynML generation function” or to add missing building 
block information to the nodes (Figure 3.7). 
 
 
 
 
Split model: 
Several gene clusters which represent separate pathways are sometimes “fused together” by 
antiSMASH during cluster predictions. This happens due to the simple rationale used by antiSMASH for 
the definition of independent clusters, which basically uses a 5-20 kb window depending on the type of 
the cluster. Any detected core gene within this window will be assigned to the same cluster. Split model 
function is used to manually separate those fused clusters, making BiosynML plugin recognize them as 
individual clusters. 
 
Pathways overview: 
This function is used to summarize biosynthetic clusters contained in a genome in the form of a 
collection of ball scheme representations. Thus, it creates a visual overview and at the same time 
enables users to access the detailed information on selected models / nodes (Figure 3.8). 
Figure 3.7: Window for building block 
modifications 
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Biosynthetic domains directory:  
A number of recurring enzymatic domains are involved in multi-step biosynthetic pathways, each 
with a specific role in precursor selection and activation, linkage of building blocks, or their modification, 
to name only a few processes. BiosynML uses an online domain directory that supplies the common 
"vocabulary" for biosynthetic pathway annotation, also providing basic information about common 
domains. In addition, new submissions of missing or new domains are actively curated and added to 
domains directory by experts (Figure 3.9). 
This helps to maintain controlled vocabulary used in diverse project parts, which is consistency and 
interoperability especially important for meta information such as name, class, context, function, 
chemistry, substrate and keywords associated with domains. It prevents ambiguities during data markup 
of BiosynML file. Thus, the domain directory approach can also serve in the future as a bridge between 
potentially concurring vocabularies. 
 
 
 
Figure 3.8: Window showing detailed overview of biosynthetic 
pathways within a genome 
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Building blocks registry:  
Assigning biosynthetic building blocks to enzymatic domains that activate small molecules and 
incorporate them into complex products is an important analysis step when dealing with secondary 
metabolite pathways. The BiosynML plugin assists this analysis by providing a list of previously observed 
biosynthetic building blocks, using short codes in agreement with other popular databases from the 
natural products field (such as e.g. Norine (2)). Structures are generated by using Indigo library using 
SMILES format. In addition, new submissions of missing or new building blocks are actively curated and 
added to building blocks repository by experts (Figure 3.10) (59). 
 
Figure 3.9: Overview of domain directory created by BiosynML plugin in Geneious 
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Prepare for MiBIG: 
The MiBIG initiative aims to establish a community repository of annotated natural product 
biosynthetic pathways according to the MiBIG standard ("Minimal information on biosynthetic gene 
clusters"). The BiosynML plugin helps users to prepare their curated pathways for submission into the 
MiBIG database, by pre-filling many fields in the MiBIG form with the relevant details (113). 
 
 
Submission and retrieval to/from antiSMASH:  
BiosynML plugin functions can be used to manually add and edit biosynthetic pathway information 
in Geneious, but information-enhanced documents are usually first created by submitting the sequence 
of a biosynthetic pathway (or an entire genome) online to the antiSMASH annotation engine. The 
BiosynML plugin handles job submission and retrieval of results, using the BiosynML format as a shuttle 
between the analysis server and the Geneious client. This works with both the public antiSMASH web 
Figure 3.10: Building blocks list generated within the BiosynML plugin adapted from 
Norine database 
  
54 [Type the document title] 
service and an in-house server setup using the standalone variant of antiSMASH (Figure 3.11). The 
BiosynML antiSMASH submission function basically reflects the options also available in the web 
interface. The function as become publicly available with the release of antiSMASH v3.0 (95).  
 
 
Export BiosynML:  
Once the BiosynML content is imported, Geneious provides several methods to manipulate the 
"BiosynML" qualifiers, or enables the user to manually add such qualifiers to Geneious documents which 
do not have BiosynML content. After the modification of BiosynML content, the plugin can export the 
complete information from the Geneious sequence object to the BiosynML format. The export is 
basically the reverse function as described for the Import (Figure 3.12). This is important so that 
BiosynML documents edited within Geneious can be transferred into databases, i.e. the Mxbase system 
used in this project, and also facilitates their use in script-language based analysis workflows. 
Figure 3.11: antiSMASH job submission and retrieving 
window 
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In summary, the BiosynML Geneious plugin provides all essential functionality for users to interact 
with biosynthetic models in the course of this project, while interfacing to the antiSMASH analysis 
pipeline ensures that the output of this de-facto standard tool can be seamlessly channelled into 
downstream analysis workflows (see also previous Figure 3.1). 
3.1.4 BiosynML Editor for manual creation of pathway models  
In order to generate hypothetical pathways, in the sense that no sequence is known but a string of 
enzymatic activities (domains) which may produce a metabolite is deduced from the chemical structure 
of a known compound, an editor has been implemented where the user can create a biosynthetic model 
using functions like drag and drop of domains. This editor is typically used by the researcher to create 
pathway models manually for newly discovered and then structurally elucidated compounds. This allows 
researchers to store and compare their “estimated” pathways making use of BiosynML functions. In 
particular, researchers can also submit their pathways directly to the matching function to find the 
similar pathways that are available in the database (Figure 3.13) even in the absence of sequence 
information for the strain producing a novel compound. 
 
Figure 3.12: Export of BiosynML file from Geneious BiosynML plugin 
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3.1.5 Integration of BiosynML with Mxbase 
Import of BiosynML models into Myxobase  
Myxobase is the Helmholtz Institute’s collection of data that is related to research on 
myxobacterial strains and compounds. The technical platform for Myxobase is the Mxbase system (see 
chapter 2.2) which is built on a relational database, making use of the widely popular MySQL technology. 
It helps to organize all accumulating research results, such as bioactivity screening results according to a 
strain or compound, thus facilitating to connect these data. Similar to metabolomic data, the BiosynML 
information on genomes and pathways encoded therein is a large amount that would become 
unmanageable in spreadsheet form or on hard disk with the increasing amount of genomes that are 
sequenced.  To enable better collaboration on results, a frontend function was added to Mxbase to 
transfer the information from the BiosynML files (generated by antiSMASH or Geneious plugin) and store 
all relevant data in the Mxbase database. In order to maintain records for ongoing use, BiosynML 
identifiers are assigned to strains and compound families which makes it easy to search and retrieve the 
information and also to generate reports (Figure 3.14). Furthermore, this biosynthetic model repository 
serves as the basis for more extensive bioinformatics analysis and genome-mining processes, triggered 
automatically or manually by individual users. Throughout this study, the BiosynML pathway repository 
Figure 3.13: BiosynML editor for drawing hypothetical modules of biosynthetic pathway which 
can be submitted for search and match algorithm 
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in Myxobase was updated whenever new genomes became available, or when new or existing pathways 
were characterized. 
All the features from BiosynML pathway datasets are stored in the Mxbase biosynthetic repository 
with a unique biosynthetic pathway key linked to strain and compound key. The interface (Figure 3.15) 
designed for importing has a function that can read the strain and compound information from the .xml 
file supplied via the Geneious BiosynML plugin after curation of the pathway annotation initially 
generated by antiSMASH. This information is then assigned to the biosynthetic pathway while it is 
imported into Myxobase biosynthetic pathway repository. 
Figure 3.15: A schematic representation of integrating BiosynML into Myxobase 
Figure 3.14: BiosynML importer interface for biosynthetic gene clusters (.xml file) 
integrated in Mxbase Explorer 
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Myxobacterial pathways overview 
The Mxbase explorer is an interface that provides access to the various gene clusters in the 
BiosynML repository that are linked to strains. This provides a medium for the researcher to have an 
overview of the clusters that a strain harbours.  The interface “pathway repository” generates a detailed 
report of all the pathways that are available or a detailed report of the pathways with restricted 
taxonomy (class, order, suborder, family, genus and species) (Figure 3.16). The import of pathways and 
assignment to a strain will immediately highlight this respective strain as a potential producer of all 
compounds linked already to gene clusters contained in that report. In addition, a function is 
implemented in the Mxbase explorer which can extract the information form the BiosynML content 
stored and generate a ball scheme representation for the biosynthetic model which is similar to the 
representation created manually by researchers. It enables users to access the detail information on 
models / nodes (Figure 3.17). 
 
 
Figure 3.16: Biosynthetic pathway repository overview window showing the list of pathways 
that is available in the database 
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3.2 The BiosynML analysis engine 
In the previous sections the establishment of peripheral components of the BiosynML 
bioinformatic framework for conceptual genome mining and the technical prerequisites for its operation 
were described. The following part of this work deals with the development of methods and algorithms 
which are at the heart of the analysis framework, i.e. which form the core analysis engine. The main 
objective is to create a set of tools allowing to compare biosynthetic models on the basis of conceptual 
similarity as opposed to primary sequence similarity. Key considerations for these tools include the 
requirement to match single pathways with a library of well-characterized pathways, to search for 
pathways showing architectural similarity and rank these accordingly, and to create an overview of 
biosynthetic model diversity within a potentially extensive database of (predicted and characterized) 
pathways. 
 
 
Figure 3.17: The “pathway overview” window showing ball scheme representation of biosynthetic gene clusters 
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3.2.1 Algorithms developed for conceptual genome mining 
A typical modular secondary metabolite biosynthetic pathway of PKS, NRPS or hybrid type 
(example in Figure 3.18) consists of a set of genes G = {g1, g2, g3,….,gn}, where each gene encodes several 
domains with predefined functions. Each domain has properties such as function (overall biochemical 
role of a domain), substrate (the monomer incorporated or modified by the catalysed reaction) and 
status (whether the domain is active or inactive).  
We consider the problem of finding the similarity of a given pathway of interest, which we call query 
pathway Q, against a database of pathways P = {P1, P2, P3,….,Pn}. Here, we call each database pathway Pi 
as a target pathway. In the course of this project three different methods for comparing and finding the 
similarity between the query and each of the target pathways were developed. Since each pathway is a 
sequence of genes, and the distribution of domains doesn’t follow a fixed pattern, hence matching 
should not be based on a symmetric relation i.e., Sim(Q, Pi) ≠ Sim(Pi, Q). Thus, we match pathways in 
both ways, i.e., we evaluate Sim(Q, Pi), Sim(Pi, Q), which enhances the similarity score between query 
and target pathways by comparing all possible genes and gene combinations in either of the pathways. 
We note that the similarity between two genes essentially depends on the domain compositions of the 
genes compared. 
 
Approach 1: LocalBestGreedy (LBG) 
The first method, termed LocalBestGreedy, performs gene-wise comparison of pathways taking into 
account the domain compositions based on similarity calculations over genes. To find the similarity 
between the query pathway Q against a database of pathways P, the first step is to find a gene (or a 
consecutive sequence of genes of a given window size w) in the target pathway having a similar domain 
composition as the query gene. 
Figure 3.18: Biosynthetic gene cluster for surfactin biosynthesis in Bacillus subtilis strain w168, repeatedly used as 
an example in the following 
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We emphasize here, that we compare a single gene from the query with a consecutive sequence of 
more than one gene from the target pathway; the length of such sequence (or the number of genes 
considered) is limited by a user-defined maximum window size wmax. 
To make it more precise, let us define GwP as a set of gene sequences, where each sequence is 
obtained by concatenating w consecutive genes from the target pathway P. We now describe how we 
measure similarity between query gene gQ and G
w
P. For this, we need a similarity measure between two 
genes gQ and g
w
P, which we denote by Sim(gQ, g
w
P). We define 
𝑆𝑖𝑚(𝑔𝑄 , 𝐺𝑃
𝑤) = max
w ∈ {1,2,…,wmax}
max
{gP
w∈GP
w}
sim(gQ, gP
w) 
The next question is how to measure the similarity between two genes gQ and gP
w. The similarity 
between the domains of two genes is calculated considering the domain properties, namely function, 
substrate and status. We call the similarity based on function, substrate and status as functional 
similarity, substrate similarity and status similarity respectively. 
We denote functional similarity, substrate similarity and status similarity as SF, SSb, SSt respectively 
between domain compositions of two genes, calculated as  
𝑆𝐹(gQ, gP
w) = max(𝑐𝑜𝑠𝑖𝑛𝑒𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦(gQ, gP
w)) 
Figure 3.19: Search for genes with similar domain composition using cosine similarity. (a) query pathway from 
Bacillus subtilis strain w168, (b) target pathway from Bacillus subtilis  strain QB928. The colour of the boxes shows 
the expected matching of the genes respectively 
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𝑆𝑆𝑏(gQ, gP
w) = max(𝑐𝑜𝑠𝑖𝑛𝑒𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦(gQ, gP
w)) 
𝑆𝑆𝑡(gQ, gP
w) = max(𝑐𝑜𝑠𝑖𝑛𝑒𝑆𝑖𝑚𝑖𝑙𝑎𝑟𝑖𝑡𝑦(gQ, gP
w)) 
the final scores for any two genes is given as the weighted mean of SF, SSb and SSt where the 
coefficients are the weight of function (WF),  the weight of substrate (WSb) and the weight of status 
(WSt) 
𝑆 = (𝑊𝐹 ∗ 𝑆𝐹(gQ, gP
w)) + (𝑊𝑆𝑏 ∗ 𝑆𝑆𝑏(gQ, gP
w)) + (𝑊𝑆𝑡 ∗ 𝑆𝑆𝑡(gQ, gP
w) 
𝑆(gQ, gP
w) = 𝑆/3 
 
 
By experimenting with various weight values, we arrived at the following combination: Through 
manual analysis of the results using various weight values, the best results are obtained at WF = 2.9, WSb 
= 0.05 and WSt = 0.05. Note that the weight of the domain function is much higher than the other 
weights. This is because the biosynthetic pathways, predicted through antiSMASH, can have occasionally 
problems with accurate substrate and status prediction whereas the type of domain is in most cases 
assigned with high confidence. Moreover, this setting also simply reflects that the basic biochemical role 
of a domain is its most relevant feature when defining the enzymatic activity string underlying the 
biosynthesis of a PKS/NPS metabolite. 
 In Figure 3.19, using cosine similarity, the query genes are mapped to that of the target gene with 
similar domain composition within a given window size. The bidirectional matching (i.e., matching 
between and query and target both ways) results in a so-called global set where all the genes in the 
query are matched to all the genes in the target. High scoring pairs (HSP) from the global set are 
extracted based on their scores. 
The overall quality between query and target is calculated based on the alignment of domains from 
HSPs found using the Smith–Waterman algorithm (121). More precisely, we count the number of 
matches and mismatches in each HSP by aligning domains of each property across all the hits. This 
contributes to the similarity score between query and target pathways. 
To enhance the similarity score of domain composition between pathways, the weight of the 
matches (m) is chosen as 3 and mismatches (mm) weight is chosen as 2 providing 60% weight to the 
matches and 40% to the mismatches. 
Let us define MF as the number of matched functional property, MMF as the number of 
mismatched functional property, MSt as the number of matched status property and MMSt as the 
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number of mismatched status property. Similarly, MSb is the number of matched substrate property and 
MMSb is the number of mismatched substrate property. 
Then the raw scores are calculated as  
𝑟𝑎𝑤𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑆𝑐𝑜𝑟𝑒 (𝑅𝐹)  = (∑ 𝑀𝐹𝑖
𝑣
𝑖=0
 ) ∗ 𝑚 − (∑ 𝑀𝑀𝐹𝑖
𝑣
𝑖=0
 ) ∗ 𝑚𝑚 
𝑟𝑎𝑤𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒𝑆𝑐𝑜𝑟𝑒 (𝑅𝑆𝑏)  = (∑ 𝑀𝑆𝑏𝑖
𝑣
𝑖=0
 ) ∗ 𝑚 − (∑ 𝑀𝑀𝑆𝑏𝑖
𝑣
𝑖=0
 ) ∗ 𝑚𝑚 
𝑟𝑎𝑤𝑠𝑡𝑎𝑡𝑢𝑠𝑆𝑐𝑜𝑟𝑒 (𝑅𝑆𝑡)  = (∑ 𝑀𝑆𝑡𝑖
𝑣
𝑖=0
 ) ∗ 𝑚 − (∑ 𝑀𝑀𝑆𝑡𝑖
𝑣
𝑖=0
 ) ∗ 𝑚𝑚 
where v = 1, 2, 3, …., R, where R is the number of HSPs. 
Bit-score is a normalized score, expressed in bits, that estimates the magnitude of the search space 
to look through before finding a score as good as or better than other one by chance. Bit-score is 
calculated based on Althshul definition (124), 
𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝐵𝑖𝑡𝑠𝑐𝑜𝑟𝑒 (𝐵𝐹) =  
𝜆 ∗ 𝑅𝐹 − ln (𝑘)
ln2
 
𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒𝐵𝑖𝑡𝑠𝑐𝑜𝑟𝑒 (𝐵𝑆𝑏) =  
𝜆 ∗ 𝑅𝑆𝑏 − ln (𝑘)
ln2
 
  
𝑆𝑡𝑎𝑡𝑢𝑠𝐵𝑖𝑡𝑠𝑐𝑜𝑟𝑒 (𝐵𝑆𝑡) =  
𝜆 ∗ 𝑅𝑆𝑡 − ln (𝑘)
ln2
 
where 𝜆 = 1.39 and k = 0.747 are the constants. 
The overall bit-score (BS, for short) is calculated by taking mean of all the bit-scores obtained from 
properties of domains in the pathways. The weights of the substrate (sb) are defined by user depending 
on the importance of substrate matched and to reduce the influence of status on the overall score, the 
weight of status (st) is set at 0.2, 
𝐵𝑆 = 𝐵𝐹 + (𝐵𝑆𝑏 ∗ 𝑠𝑏) + (𝐵𝑠𝑡 ∗ 𝑠𝑡) 
In the context of database searches, the E-value is the number of distinct matches with a score 
equivalent to or better than BS, that are expected to occur in a database search purely by chance. The 
lower the E value, the more significant the score is, 
𝐸 = 𝑘𝑋𝑌𝑒−𝐵𝑆, 
where X is the length of domains in the query pathway, Y is the size of the database, BS is the 
bitscore calculated and k is the constant from Althshul definition. 
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The advantage of the greedy approach over a window of genes (a combination of domains obtained 
by neighbouring genes with in a given window size provided by the user) is that it requires only a small 
amount of memory and it is much faster to compute. However, since the greedy approach decides the 
next best step by exploiting only the local information (here, the window size) without considering the 
global structure of the problem, one cannot guarantee to find an optimal solution. An example 
illustrating this scenario is shown in Figure 3.20, where target pathway has similar domain composition 
but different operon organization and domain distribution, i.e. the domains from the set of query genes 
are relocated in the target genes, alongside other differences such as predicted substrate specificity. In 
such cases, the algorithm fails to identify the pathways although the two pathways have overall similar 
domain composition and could be plausibly regarded as candidates for the production of related 
molecule classes, based on biochemical considerations. Without providing a proper window size the hit 
might get a low score and hence it is buried in the other hits among the results. It should be pointed out 
here that deviations shown between biosynthetic models in Figure 3.20 are not arbitrary and could 
actually occur to this extent between pathways which are nevertheless similar from a biochemical point 
of view. Modules could be re-arranged, split across several genes or combined on one gene (e.g. m1, m2, 
m3; m4, m5, m6) and still bring about the same molecular substructure in the product. Similarly, single-
standing domains in the vicinity of multimodular genes could be located differently, and additional 
domains (possibly of unassigned type) could be present in the compared pathways. Thus, in the context 
of conceptual genome mining one must demand for increased robustness of the method in order to 
include in the result set also the pathways exhibiting a considerable extent of deviation in terms of 
operon organization and the distribution of domains across genes. 
Figure 3.20: An example highlighting the disadvantage of LBG where the algorithm fails as the domains from the 
query genes are differently located in target genes. Despite the different domain distribution, these pathways 
could be considered potential conceptual relatives and in principle the chance to achieve matching through the 
BiosynML comparison engine would thus be desired. 
  
65 Results and Discussion 
 Approach 2: LocalBestCoalesce (LBC) 
Note that the first method LocalBestGreedy (LBG, for short) has the disadvantage of missing hits 
where sets of domains are distantly located/distributed in a target pathway, albeit overall domain 
composition is similar. To overcome the disadvantage a modified version of LBG, named LBC, was 
developed that matches domain compositions of pathways iteratively (Figure 3.21). 
 If a hit for domain composition of a query gene is obtained, then the hit and query gene are 
removed from the search space. The procedure is repeated with the remaining domains of the genes in 
the pathway. In this way with every iteration, the neighbouring genes will be changed and can lead to 
discovering pathways with high similarity even though the domains composition of genes are distantly 
located. Because of the iterative removal and matching, this method is able to identify domain 
subgroups which are distantly located. However, one main disadvantage is that in order to identify 
distantly located domain composition, the pathways have to be of similar size. Otherwise, the algorithm 
fails to find similar pathways which are only partially predicted and are thus missing a number of 
domains. This may happen especially when working with draft genomes scattered across increased 
numbers of scaffolds, showing a high probability that predicted biosynthetic models are incomplete. The 
problem is illustrated with an example in Figure 3.22.  
 
Figure 3.21: A flow chart describing the iterative process of matching genes between query and target pathway 
where each identical query and hit genes are mapped and removed from the search space 
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Due to the presence of genes (highlighted in blue box) with mismatching domains in between 
potential hit target genes in the pathway, LBC fails to match the domains of query gene srfA1 to the 
target genes BCB4264_A2461 and BCB4264_A2462, if a proper window size is not provided. For e.g. with 
a given window size of 2, the query gene srfA2 and srfA3 will result as a perfect match with domains of 
target gene BCB4264_A2463 in the target pathway.  But domain of query gene srfA1 will not be matched 
to domains of target genes BCB4264_A2461 and BCB4264_A2462 due to the presence of genes with 
unspecific domain between them. This results in having a low similarity score for the hit pathway despite 
of having identical domain composition along with additional domains. 
Approach 3: GlobalBestSubset (GBS) 
Since the methods LBG and LBC depend on the window size that heavily influences the outcome, 
both algorithms have problems to locate a pathway with distantly located domains groups. Thus, a new 
method is needed that is independent of the window size and should be able to identify hits where 
distinct domain arrangements are potentially disconnected or even distantly located. Considering this 
requirement, a new algorithm was developed which we call here as GlobalBestSubset (GBS for short). In 
this approach the concept of set intersection is used (125) which can find pathways that have distantly 
located domain compositions without depending on the window size. 
Let S(Q, Pi) be the similarity between the query pathway Q and one of the pathways Pi, i = {1, 2, 
3, 4,…, R} from the database P containing R pathways, and let Sg(gQ, G) be the similarity between domains 
of a gene in query and a list of genes from pathway where G = {g1, g2, g3,…. ,gn }. 
Figure 3.22: An example highlighting the disadvantage of LBC. Due to the presence of genes unidentified 
domains/genes (highlighted in blue box) in between potential hit target genes in the pathway, LBC cannot 
efficiently match the domains of query gene srfA1 those located on target genes BCB4264_A2461, A2462. 
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As described earlier in LBC ad LBG, the similarity between domains of two genes is calculated 
based on domain properties namely function, substrate and status. 
Let Sjk be the similarity score between gene gj of query pathway and gene gk of target pathway, 
calculated by intersecting the individual domain properties in the genes compared,  
Sjk = S (g
Q
j, g
Pi
k)       where  g
Q
j  ∈ Q, g
Pi
k ∈ Pi 
Again, we refer similarity based on function as functional similarity, substrate as substrate 
similarity and status as status similarity. 
We denote functional similarity, substrate similarity and status similarity as SF, SSb, SSt respectively 
between domain compositions of two genes and MF as the number of matched functional property, 
MMF as the number of mismatched functional property, MSt as the number of matched status property 
and MMSt as the number of mismatched status property. Similarly, MSb is the number of matched 
substrate property and MMSb is the number of mismatched substrate property, calculated as, 
Let M = length of gj, N= length of gk 
𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑀𝑎𝑡𝑐ℎ (𝑀𝐹) = |𝑔𝑗
𝐹 ∩ gk
F |  
𝐹𝑢𝑛𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ (𝑀𝑀𝐹) = (M –  MF)  +  (N –  MF) 
 𝑆𝐹(𝑔𝑗
𝐹 , 𝑔𝑘
𝐹) =  
𝑀𝐹
𝑀
+
𝑀𝐹
𝑁
 
𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 𝑀𝑎𝑡𝑐ℎ (𝑀𝑆𝑏) = |𝑔𝑗
𝑆𝑏 ∩ gk
Sb| 
𝑆𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ (𝑀𝑀𝑆𝑏) = (𝑀𝑆𝑏–  M) + (𝑀𝑆𝑏–  N) 
 𝑆𝑆𝑏(𝑔𝑗
𝑆𝑏, 𝑔𝑘
𝑆𝑏) =  
𝑀𝑆𝑏
𝑀
+
𝑀𝑆𝑏
𝑁
 
𝑆𝑡𝑎𝑡𝑢𝑠  𝑀𝑎𝑡𝑐ℎ (𝑀𝑆𝑡) = |𝑔𝑗
𝑆𝑡 ∩ gk
St| 
𝑆𝑡𝑎𝑡𝑢𝑠  𝑚𝑖𝑠𝑚𝑎𝑡𝑐ℎ (𝑀𝑀𝑆𝑡) = (MSt –  M)  +  (MSt –  N) 
 𝑆𝑆𝑡(𝑔𝑗
𝑆𝑡, 𝑔𝑘
𝑆𝑡) =  
𝑀𝑆𝑡
𝑀
+
𝑀𝑆𝑡
𝑁
 
The final scores for any two genes are given by putting more weight on functional property, 
which is a linear combination of F, Sb and St with weight of function (WF), weight of substrate (WSb) and 
weight of status (WSt) 
𝑆 = (𝑊𝐹 ∗  𝑆𝐹(𝑔𝑗
𝐹 , gk
F )) + (𝑊𝑆𝑏 ∗  𝑆𝑆𝑏(𝑔𝑗
𝑆𝑏, gk
F )) + (𝑊𝑆𝑡 ∗ 𝑆𝑆𝑡(𝑔𝑗
𝑆𝑡, gk
F )) 
𝑆𝑗𝑘 = 𝑆(𝑔𝐽
𝑄 , gk
Pi) = 𝑆/3 
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This calculation is repeated for domains of each and every gene of the query pathway with all 
the genes in the target pathway. If there are no identical matches found, then the algorithm proceeds to 
the next step to find similar composition of domains by combining multiple genes with respect to the 
domain composition of the query gene. 
Let, Gt = {g1, g2 … gm} be the top hit genes from the target pathway Pi to a gene gQ in the query 
pathway and let 𝑆𝑔𝑄𝐼𝑘
𝑘  be the similarity between gQ, let  k be the concatenation of any of the k genes of 
Gt. Here we vary k from 1 to m where m is chosen as 4 in our experiments to limit the combinatorial 
explosion in the computational time. This process is repeated for all the genes in the query pathway to 
find the best hits in the target pathway. Each gene is mapped to the target gene with a similarity score 
Sjk. Finally we take the best of all the scores max {𝑆𝑗𝑘, max
𝐼𝑘
 𝑆𝑔𝑄𝐼𝑘
𝑘 } 
The bidirectional matching (i.e., matching between query and target forward and backwards) 
results in a so-called global set where all the genes in the query are matched to all the genes in the 
target. High scoring pairs (HSP) from the global set are extracted based on their scores. To get the overall 
quality of the pathways matched, the bitscore and E-values are obtained by applying the methods 
described in section 2.2.1. 
Pesudocode: 
Method  SubsetMatchingOfPathways() 
forward = SubsetsMatching(Source, Target) 
reverse = SubsetsMatching(newTarget, newSource) 
globalmap = combine (forward, reverse) 
bestResultMapping = GetBestFromGlobalMap(globalMap); 
  Bitscore = CalculateBitScore(bestResultMapping); 
end 
Method  SubsetsMatching  
Input: Q, T 
Output: score 
for each gj ∈ Q 
     for each gk ∈ T  
  compute S (gj, gk) 
    end 
   Let Gt  = { g1, g2 … gm} be the top hit genes 
   compute Sk (gQ,  k), where  k is concatenation of any of the k genes of Gt 
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 Let  k* be the best match for gQ 
 score(gQ, k*) = S
k (gQ,  k*) 
end 
end 
 
The pathway matching algorithms described earlier in this section showed the results of LBG and 
LBC, which majorly depend on the windows size setting provided by the user. Although these algorithms 
are fast, in cases of complex pathway matching where the genes are distantly located, these algorithms 
fail to identify those particular pathways  as a good hit  that are supposed to appear on the top of the 
output with high similarity scores. GBS uses the concept of set intersection and works independent of 
windows size, which makes it robust compared to other algorithms. Since it considers evaluating all 
combinations of genes and their domain compositions, there is no chance of missing pathways with 
genes having highly similar domain composition even when domain subsets are distantly located. 
3.2.2 Usage scenarios and comparison of BiosynML methods 
The BiosynML methods presented in the previous section 3.2.1 were devised with several 
application scenarios in mind, as has been outlined already in chapter 1.6. Perhaps the most prototypical 
task which occurs repeatedly throughout research with secondary metabolite pathways is the 
comparison of previously characterized (“known”) pathways to predicted genome-encoded biosynthetic 
models stored in a database using a scoring function, where the scores account for the differences 
between the predicted and established pathways like missing modules, extra modules, ambiguity of 
predicted properties, altered positions of the genes and domains and their additional properties (meta 
information like specificity, active or inactive, etc.). Usually this initial comparison is followed by expert 
review and by additional manual analysis which may later extend to the complex genome context. The 
pathways in the database are considered for in depth comparisons based on the genes, domains and 
their arrangements, predicted substrates etc. A similar approach, though ideally with less manual 
supervision, can be basically taken for the automatic tentative identification of predicted biosynthetic 
gene clusters, by comparing each predicted pathway in a newly sequenced genome to the reference 
library of well-characterized pathways. Finally, a “compare all-to-all” approach can be taken to establish 
a similarity matrix based on gene cluster architectures, in order to reveal groups of similar clusters and 
outliers. 
Taking care of all these requirements, a “conceptual genome mining” module was developed and 
integrated into the Mxbase application.  The newly added functionality comprises of three main 
components: a windows-based application interface, additions to the Mxbase back-end (MySQL data 
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structures on the server, being the foundation of Myxobase) and a worker thread, implemented as a 
remote procedure call (RPC) framework that communicates between functions located on the server and 
the graphical user interface. The design and functions of components added to Mxbase in the course of 
this project have been depicted in Figure 3.1 and earlier in Figure 1.12, and their use is described in the 
following section.  
The interface is equipped with numerous options and enables the user to make a query against 
the Myxobase to generate results covering all pathways from the BiosynML pathway repository. The 
pathways which make up the search space are then passed to the algorithms where major 
computational tasks are involved. Myxobase is the database (the knowledge repository for secondary 
metabolite annotation) which contains information about the known gene clusters along with their 
meta-data, as well as genome sequences from different strains of myxobacteria.  
After the retrieval of pathways from the database the worker thread starts computing the 2nd pass 
calculations such as functional deviations, substrate deviations, domain status deviations and scores 
them, to finally return compiled results to the user.  
 Genome mining using the BiosynML engine 3.2.2.1
Predicted pathways from genomes enter the BiosynML repository via a route briefly consisting of 
these steps: The raw data from sequencing is passed through the genome assembly pipeline. The 
assembled data is passed through antiSMASH to extract biosynthetic meaningful information from 
complex datasets and then inventorize the full complement of putative gene clusters in the form of 
representative domains and their properties (the pathway models). The dataset obtained after 
processing through antiSMASH is deposited in the BiosynML repository inside Myxobase and consists of 
domains found and their function and meta-information attached. The “Conceptual genome mining” tool 
has the function to identify the known models from a genome using any of the algorithms developed 
such as LocalBestGreedy (LBG), LocalBestCoalesce (LBC) or GlobalBestSubset (GBS). Thereby, known 
biosynthetic clusters are highlighted and the obtained report can in principle provide the information 
regarding similar pathways that are present in various strains. Thereby, users can also take advantage of 
extended and up-to-date information from the BiosynML collection which is supplied by other users. 
Most importantly, the BiosynML workflow decouples the pathway analysis from the need to access the 
raw sequences or GenBank files. This application is used to answer common questions like, 
 which of the predicted pathways in a new genome is similar to any of the known models 
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 is there a pathway which matches the hypothetical biosynthesis for a newly elucidated 
compound 
 The user’s expectation for the algorithm is to reliably report similar pathways (“primary hits”), 
when using a biosynthetic model as input, without sequence-based comparison (=”conceptual”) and in 
presence of typical sequencing- or prediction-derived errors and uncertainties. Furthermore, the 
identification of putatively related pathways must work robustly also in a background of many pathways 
per genome, containing a multitude of modules when some of them would just by chance have a domain 
composition similar to a small portion of the query model (distinguishing them as “secondary hits”). 
The Pathway query module is implemented with input categories, the available search settings 
provided are: 
1. Input of a pathway(s) (one specific pathway or a complete set of pathways from a genome, or  
model for a hypothetical pathway designed by researcher using BiosynML Editor, see 3.1.5) 
2. Choice of available search and match algorithms (LBG, LBC, GBS)  
3. Search space (entire database or restricted to selected genus or species) 
4. Search parameters (window size, substrate specificity, additional domain penalty, collinearity 
and pathway completeness) 
 
Input  
The input for a pathway query is information relating to biosynthetic pathway(s). Based on the 
types of available information and specific interests of the user, three kinds of input are implemented 
and available, which might be biosynthetic pathway(s) from repository linked to a strain or compound  
 pathway from external source 
 pathway model designed through the BiosynML editor 
For the pathways which are given as input, the interface is able to handle a single pathway or a set 
of pathways that are obtained from a genome linked to strain. Characterized pathways typically originate 
from the Geneious plugin; hypothetical pathways are created by users in the BiosynML editor. 
Search and match algorithms 
See section 3.2.1 for detailed explanation of algorithms implemented for matching and scoring 
of biosynthetic pathways. 
 
  
72 [Type the document title] 
 
Search space 
Myxobase contains an organized collection of biosynthetic clusters that are linked to strain and 
compound information. The researcher can limit the search space to a particular genus or species prior 
to searching for pathways similar to the query pathway. While the researcher aims to find the best 
similar pathway among the all pathways across all strains, each pathway in search space represent one 
feasible solution marked by its value or fitness for the query. 
 
Search parameters 
The scoring reflects not only the overall similarity, but allows the investigator also to evaluate 
the differences regarding domain composition of modules, their distribution across genes, pathway 
organization, and match of substrate specificity (“meta information”) for domains in corresponding 
positions. The scores also accounts the differences between the predicted and established pathways like 
the missing modules, extra modules, ambiguity, positions of the genes and domains and their additional 
properties (meta information like specificity, active or inactive, etc.). The possibility to parametrize the 
search was developed which is exemplified by adding options for intuitive parameters:  
Window size: the algorithms GBG and GBC requires user to define window size to select various 
aspects of limitations for the search in order to yield more confident results. 
Substrate specificity: it defines the importance of the substrate that has to be matched during the 
search influencing the overall score of the hits. The range of the substrate specificity is [0, 1] where 
0 – no importance 
1 – very important 
Pathway completeness: it defines the importance of finding complete set of domains irrespective 
of additional domains present. This will boost the overall score of the hits which has all domains with 
respect to the query. 
Collinearity:  this is the parameter is to search efficiently for a subsequence of domains or generally 
a pattern in large sequences of domains arranged in the same order in various pathways preserving 
collinearity. This will boost the score of the hits which have highly similar arrangements of the domains 
spanning an extended range. The importance can range between 0 and 1 
0 – no importance 
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1 – very important 
Additional domain penalty: it defines how strongly extra domains present or missing domains in 
the genes that are not predicted by the tool are penalized. Values ranges between 0 and 1. 
0 – no importance 
1 – very important 
These parameters influence the scoring function of the algorithm used for search and compare, 
reflecting the positioning of pathways in the result list.  
To reduce the burden of the processing on the user’s machine, the search and match functions are 
located on Mxbase server which performs the operations based on user input and stores the results in 
the database which are subsequently retrieved by the client. Access to BiosynML functions on Mxbase 
server is through a dedicated interface integrated into the Mxbase Explorer application (Figure 3.23). 
This interface covers all the aspects with default values of the parameters. Typical use can be exemplified 
using the Chondramid gene cluster from strain Cmc5 (Chondromyces crocatus) where the query pathway 
(known and characterized for the production of Chondramides (126)) is submitted to the search and 
match class, using GBS algorithm and setting substrate specificity to 0.3 and additional domain penalty to 
0.1. The results can be accessed through the results window designed with a datagridview, giving an 
overview of the matching results (Figure 3.25), a bit score plot and also a ball scheme representation for 
visualization (Figure 3.24 and 3.26).   
Figure 3.23: BiosynML interface for submitting query pathway to the search and match class with parameters, 
integrated in the Mxbase Explorer application. 
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 The bit score plot generated reveals a confidence interval where the hits above the confidence 
interval (the “jump” in the plot) have domain architecture highly similar to that of the query pathway 
(Figure 3.24).  
We here emphasize that the first hit is always a “self-hit” which sets the theoretical maximum score 
based on which the confidence interval is generated. The second hit in this example is from the auto-
annotated Cmc5 genome and the third hit is from MSr9030 (Chondromyces catenulatus) (ball scheme 
representation of query and target pathway are displayed in Figure 3.25. The latter pathway is highly 
similar to the Chondramid (query) pathway; however it lacks the genes for a tailoring halogenase and the 
Tyr precursor-generating aminomutase. This finding might be explained by missing prediction during 
auto-annotation, or the genes are located elsewhere in the genome (in theory the pathway might also 
produce only non-halogenated derivatives; however the strain has been shown before to produce the 
chlorinated chondramides, too (127)). Distribution of PKS domains across genes is also slightly different, 
a possible consequence of operon re-arrangement during evolution, or as an artefact during sequencing 
since the split occurs in an unusual way between genes that together harbours the complement of 
domains from cmdA. Despite these deviations, the detection of a high-scoring candidate cmd gene 
Figure 3.24: Bit score plot generated for Chondramid pathway from C. crocatus Cmc5 used as query. The grey box 
represents the confidence “interval” (in the sense of a gap separating high-confidence and low-confidence hits). 
The pathways above the grey box are highly similar to the query pathway. The high affinity hits above the 
confidence interval are from auto-annotated genomes of strains Cmc5 (Chondromyces crocatus) and MSr9030 
(Chondromyces catenulatus) genomes. Note, the first hit is always the “self-hit” which sets the theoretical 
maximum score. Due to differences resulting from manual curation, the auto-annotated version of the same 
pathway from a genome might not reach the same score. 
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cluster in C. catenulatus by the BiosynML approach in this example is plausible and anticipated as the 
strain is known as a chondramide producer (128). 
Furthermore, analysing the first hit below the confidence interval, a NRPS/PKS hybrid pathway from the 
strain MSr9331 (Aetherobacter rufus) is found (Figure 3.26).  
The target gene (ctg6_orf00410) has NRPS domain modules of same functionality but different 
substrate specificity as that of the query gene (cmdD), and overall number of NPRS modules is 2 versus 3 
in chondramide biosynthesis. In addition, there are differences regarding domain composition and 
operon organization compared to that of the query, such as additional MT domains (internal as in 
Figure 3.26: Example of the first hit (MSr9331 (Aetherobacter rufus)) below the confidence interval from 
where the similarity deteriorates 
Figure 3.25: Results window with summary table and ball scheme representation of the query and hit. 
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ctg6_orf00410 and single-standing) Although still rudimentary similar to the cmd pathway, it appears 
justified that in this search the A. rufus candidate pathway is significantly down-ranked compared to the 
original pathway from C. crocatus and the model detected from C. catenulatus. 
By chosing different algorithms and varying setting of parameters the result set may change 
depending on the complexcity of the matching, as examplained earlier in section 3.2.1. Thus, in the 
following sections the limitations of the algorithms developed for search and match approach and their 
response to varying parameters will be exemplarily demonstrated. 
 Comparison of BiosynML methods 3.2.2.2
The architectural comparison of biosynthetic pathways is a crucial part for several steps of the workflows 
established here as part of the biosynthetic pathway mining tools. The characteristics of functions tried 
out in the course of this project are described and discussed in the following. 
Figure 3.27: Bitscore plot generated for Surfactin pathway from Bacillus subtilis strain w168by using LBG algorithm. 
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 As an example, applying all the three basic algorithms for comparing the Surfactin pathway against 
predicted models from biosynthetic pathways of published genomes (downloaded from NCBI and 
biosynthetic pathways predicted through antiSMASH), the results of LBG (Figure 3.27), LBC (Figure 3.28) 
and GBS (Figure 3.29) are plotted taking bitscore on y-axis and strain identifiers on x-axis. The query is 
executed with substrate weighting value of 0.3 and additional domain penalty of 0.3. 
 
Since the scoring methods are applied on the datasets, it will also be more interesting to see the 
efficiency of scoring function for pathways which has overall similar domain composition but doesn’t 
have the same domain architecture.  A careful consideration of the hits in the output reveals differences 
in the results generated by the three algorithms. 
The initial hits (Table 3.1) in the result set, identified by all three algorithms shows similar set of 
pathways from organisms since these pathways exhibit a highly similar domain architecture to that of 
the query (Figure 3.30). However, the interesting aspect is to observe the fate of the pathways which has 
similar domain composition and dissimilar domain architecture.  The LBG and LBC failed to identify 
biosynthetic pathways which deviate from the query domain architecture (in the sense of placing these 
hits above the confidence interval) and as the algorithms assign lower scores to such pathways, they are 
misplaced in the output result set, which might be considered as unspecific result by a chemist. These 
Figure 3.28: Bitscore plot generated for Surfactin pathway from Bacillus subtilis strain w168by using LBC 
algorithm 
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two algorithms (LBG and LBC) thus generate results with different levels of false negative rates, reflecting 
the lost opportunities of numerous interesting results that a natural product researcher would like to 
know or expect 
However, GBS tends to reduce the false negative results by matching the domains composition at a 
global level. Due to the concept of subset intersection, GBS has identified the pathways (Table 3.2) which 
does not follow exactly the query’s domain architecture (Figure 3.31) but having similar composition and 
are scored accordingly. Thus, GBS generates a result set which is highly relevant and is devoid of false 
negative results. The bitscore plot for LBG and LBC may be deceiving as some pathways are misplaced 
because of the limitations in both the algorithms, but the plot generated by GBS shows a set of results 
that is more accurate from the point of view of the natural products chemist. In fact, the score plot hints 
at the presence of two groups of similar pathways (two plateaus in Figure 3.29), one representing the 
Surfactin pathway family with relatively little deviations, and the other group being “Surfactin-like”, 
showing overall similar domain composition but some degree of deviation in architecture and substrate 
specificity. These two groups are well discriminated against the backdrop of many NRPS pathways in the 
test dataset using the GBS algorithm, while the second group was not revealed by the LBG and LBC 
algorithms. 
Figure 3.29: Bitscore plot generated for Surfactin pathway from Bacillus subtilis strain w168 by using GBS algorithm 
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 It has to be considered that the values of the parameters used for the processing the results affect 
the shape and confidence levels of the bitscore plot generated as these parameters influence on the 
scoring function used to measure the similarity between pathways.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BSRC ID BSYN ID Strain Key Organism  
BSRC471 BSYN3817 11687 w168 (Bacillus subtilis)  
BSRC329 BSYN3126 11682 QB928 (Bacillus subtilis)  
BSRC334 BSYN3163 11687 w168 (Bacillus subtilis)  
BSRC326 BSYN3103 11679 JS (Bacillus sp)  
BSRC328 BSYN3119 11681 PY79 (Bacillus subtilis)  
BSRC331 BSYN3141 11684 W23 (Bacillus subtilis)  
BSRC333 BSYN3155 11686 6051-HGW (Bacillus subtilis)  
BSRC337 BSYN3185 11690 RO-NN-1 (Bacillus subtilis)  
BSRC282 BSYN2855 11635 CAU_B946 (Bacillus amyloliquefaciens)  
BSRC276 BSYN2804 11629 CC178 (Bacillus amyloliquefaciens)  
BSRC281 BSYN2846 11634 AS43_3 (Bacillus amyloliquefaciens)  
BSRC284 BSYN2873 11637 FZB42 (Bacillus amyloliquefaciens)  
BSRC285 BSYN2883 11638 UCMB5033 (Bacillus amyloliquefaciens)  
BSRC286 BSYN2891 11639 UCMB5036 (Bacillus amyloliquefaciens)  
BSRC287 BSYN2900 11640 UCMB5113 (Bacillus amyloliquefaciens)  
BSRC280 BSYN2839 11633 LL3 (Bacillus amyloliquefaciens)  
BSRC277 BSYN2813 11630 DSM_7 (Bacillus amyloliquefaciens)  
BSRC290 BSYN2929 11643 XH7 (Bacillus amyloliquefaciens)  
BSRC289 BSYN2922 11642 TA208 (Bacillus amyloliquefaciens)  
BSRC297 BSYN2977 11650 1942 (Bacillus atrophaeus)  
BSRC319 BSYN3077 11672 DSM13 (Bacillus licheniformis)  
BSRC318 BSYN3068 11671 9945A (Bacillus licheniformis)  
BSRC324 BSYN3098 11677 SAFR-032 (Bacillus pumilus)  
Table 3.1:  Hits identified by algorithms (LBG, LBC and GBS) with Surfactin as a query 
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BSRC ID BSYN ID Strain Key Organism 
BSRC304 BSYN3010 11657 B4264 (Bacillus cereus) 
BSRC350 BSYN3280 11703 YBT-1518 (Bacillus thuringiensis) 
BSRC348 BSYN3269 11701 IS5056 (Bacillus thuringiensis) 
BSRC344 BSYN3241 11697 CT-43 (Bacillus thuringiensis) 
BSRC339 BSYN3202 11692 BMB171 (Bacillus thuringiensis) 
BSRC340 BSYN3209 11693 Bt407 (Bacillus thuringiensis) 
BSRC347 BSYN3260 11700 HD73 (Bacillus thuringiensis) 
BSRC309 BSYN3036 11662 G9842 (Bacillus cereus) 
BSRC342 BSYN3224 11695 HD-789 (Bacillus thuringiensis) 
BSRC423 BSYN3592 11776 NCGM2_S1 (Pseudomonas aeruginosa) 
BSRC422 BSYN3587 11775 MTB-1 (Pseudomonas aeruginosa) 
BSRC421 BSYN3580 11774 M18 (Pseudomonas aeruginosa) 
BSRC418 BSYN3556 11771 DK2 (Pseudomonas aeruginosa) 
BSRC426 BSYN3615 11779 PA7 (Pseudomonas aeruginosa) 
BSRC231 BSYN1999 11584 RHA1 (Rhodococcus jostii) 
BSRC431 BSYN3651 11784 NFM421 (Pseudomonas brassicacearum) 
BSRC232 BSYN2030 11585 B4 (Rhodococcus opacus) 
BSRC228 BSYN1960 11581 103S (Rhodococcus equi) 
BSRC230 BSYN1991 11583 PR4 (Rhodococcus erythropolis) 
BSRC424 BSYN3598 11777 PA1 (Pseudomonas aeruginosa) 
BSRC425 BSYN3605 11778 PA1R (Pseudomonas aeruginosa) 
BSRC436 BSYN3682 11789 Pf0-1 (Pseudomonas fluorescens) 
BSRC435 BSYN3676 11788 F113 (Pseudomonas fluorescens) 
BSRC437 BSYN3689 11790 SBW25 (Pseudomonas fluorescens) 
BSRC443 BSYN3705 11796 RE1-1-14 (Pseudomonas poae) 
BSRC116 BSYN570 11469 ACN14a (Frankia alni) 
BSRC116 BSYN570 11469 ACN14a (Frankia alni) 
BSRC447 BSYN3722 11800 GB-1 (Pseudomonas putida) 
Table 3.2: Additional results displayed by GBS for Surfactin pathways which are not 
available from LBG and LBC 
Figure 3.30: Target pathways from strain QB928 (Bacillus cereus) (b) having similar domain composition, substrate 
specificities and domain architecture to that of the query pathway from strain w168 (Bacillus subtilis)(a) 
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 From the experiments mentioned in this section choosing a right algorithm is important to obtain 
comprehensive results, where throughout this project the most relevant results were stringently 
obtained by using GBS. But it is also important to evaluate the influence of the parameter settings on the 
results generated by search and match engine. 
3.2.3 Influence of parameter settings on the outcome of the pathway comparison 
A matching and scoring algorithm ideally should have parameters whose effect is intuitively clear 
and predictable. In the course of this study, we found that parameters such as substrate specificity 
match, extra domains penalty, collinearity and pathway completeness are important to feed the 
BiosynML matching algorithms in order to downgrade the appearance of irrelevant data from the 
possible outcome. These parameters influence to a great extent in the accuracy and performance of the 
algorithm. 
Influence of substrate specificity  
Intuitively, the substrate specificity parameter defines the influences of missing or wrongly assigned 
substrate specificity on the scoring function. This is currently relevant mostly for monomer-incorporating 
domains such as A- and AT domains (although it should be noted that there is no inherent limitation to 
certain domain types). The value ranges from 0 to 1 where low values meaning ‘liberal scoring of 
mismatched substrates’ and high values meaning ‘strict comparison and scoring of substrates’. To 
demonstrate the influence of this parameter, a query was executed in the BiosynML repository using 
Figure 3.31: Target pathway from strain B4264 (Bacillus subtilis) (b) which has similar domain composition but with 
varied domain architecture to that of the query pathway from strain w168 (Bacillus subtilis) (a), and also different 
predicted substrate specificities. 
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GBS algorithm with a substrate specificity weighting of 0.8 and 0.3, all other parameters are kept 
constant. As a test case, Myxoprincomide pathway from strain DK1622 (Myxococcus xanthus) (Figure 
3.32) was used to investigate the influence of different substrate specificity parameters on the outcome. 
From Figure 3.33 (query using weighting factor 0.8), it can be observed that only one pathway is 
found which shows above the confidence interval. This pathway is itself a curated pathway where 
substrate specificities have been manually corrected by the researcher. All the pathways which have the 
same domain functionality but different substrate specificities, possibly due to the prediction tool 
uncertainty are found below the confidence interval. By decreasing the influence of substrate specificity 
to 0.3, the results changed, as it can be observed that there two more pathways moved above the 
confidence interval as the specificity scoring is relaxed (Figure 3.34).  This means, giving a high value to 
Figure 3.32: Myxoprincomide pathway from strain DK1622 (Myxococcus xanthus) used to evaluate the influence of 
substrate specificity parameters on the results set. The grey-colored A-domain in module 11 was marked as 
“inactive” during manual curation (1), and substrate specificities were inferred from the elucidated structure 
myxcoprincomide-C506. 
Figure 3.33: Distribution of scores for Myxoprincomide pathway using GBS algorithm with substrate specificity 
emphasized by a weighting of 0.8 
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this parameter will decrease the score of the hit pathways whose substrate specificities deviate with that 
of the query. 
It has to be noted that there is no change in the order of the hits resulted by the algorithm (some of 
these shown in Figure 3.35) with the change in substrate specificity but this parameter has a great 
influence in deciding the range of confidence interval. It is a parameter of interest for the researcher 
during automated mining of the pathways from a newly annotated genome, to decide the extent of 
having the same postulated monomeric substrate for query and hit pathways. Note that the utility of a 
stringent parameter setting also depends critically on the overall state of the pathway repository: 
queries using a high substrate specificity weighting can make sense when searching in a library of well-
curated pathways, whereas a collection of auto-annotated genomes might make it necessary to accept a 
higher degree of mis-assigned substrates due to imperfection of preditive tools. 
 
  
Figure 3.34: Distribution of scores for Myxoprincomide pathway using GBS algorithm with a more relaxed substrate 
specificity weighting of 0.3. 
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Influence of penalty imposed on additional domains  
Another important factor of the comparison process between two pathways is the additional 
domain penalties i.e., how strongly are additional domains not present in the query pathway penalized. 
The value ranges from 0 to 1 where low values meaning ‘weak penalty’ and high values meaning ‘strong 
penalty’.  This parameter does not take into account the domains which are missing in the middle of 
multimodular genes but penalize domains from additional or missing genes from the query and target 
pathways. As an example Myxochelin from strains Sga15 (Stigmatella aurantiaca) was used to evaluate 
the influence of penalty on additional domains. The query is executed with additional domain penalty of 
0.1 and 0.8, keeping the rest of the parameters constant. 
 
 
Figure 3.35: Hits reported by GBS algorithm for Myxoprincomide gene cluster from strain DK1622 (Myxococcus 
xanthus). Query is represented in black box. Blue circle represents the domains which deviate in substrate specificity. 
Red box represents the pathways with translocated modules and orange box represents the pathways with an extra 
(C-A-PCP) module. The pathway in green box has identical domain architecture with deviations in substrate 
specificities. 
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Form the Figure 3.36, it can be observed that there is no distinction of hit pathways which have only 
the “myxochelin” domain set and pathways exhibiting additional domains. This is due to the low value 
(0.1) used for additional domain penalty.  
 
Figure 3.37: Distribution of scores for Myxochelin pathway using GBS algorithm with increased additional domain 
penalty of 0.8. There is now a noticeable distinction of scores for the pathways with additional domains as 
exemplified by the pathways outlined in green, black and blue colors. 
Figure 3.36: Distribution of scores for Myxochelin pathway using GBS algorithm with low additional domain penalty 
of 0.1. The pathway represented in green and black outline has similar domain architecture to myxochelin pathway. 
Though the black outlined pathway has additional domains there is no significant distinction of scores. 
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Therefore, the result set contains unsorted list of pathways which has exact matching domains with 
respect to query as well as pathways with (varying numbers of) additional domains. With increase in the 
penalty of the additional domains to 0.8, the result set is sorted and pathways with additional domains 
are well distinguished (Figure 3.37). This parameter is useful to prioritize the hits showing sets of 
matching domains which a chemist might be interested in. 
 
Impact of Collinearity weighting on the outcome  
Collinearity weighting refers to the relationship where there is a high correlation on both 
composition and order of domains between two pathways. As an example, a surfactin like pathway from 
strain CT-43 (Bacillus thuringiensis) (Figure 3.40) was used to evaluate the impact of collinearity 
parameter. The tests were done with collinearity values for 0.1 and 0.8, all the other parameters are set 
to zero. 
With a value of 0.8, the algorithm reported hits which are above the level of confidence interval. 
These hits have very high domain composition similarities as well as the order of the domains is 
preserved (Figure 3.38).  On reducing the value of collinearity to 0.1 there is a significant change in the 
range of confidence interval (Figure 3.39) where the hits with well-matching domain composition but has 
lower similarity in the sequence order of the domains are also considered.  
Figure 3.38: Results displayed using collinearity weighting value of 0.8. Only eight hits are reported above the 
confidence interval 
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 This parameter is very useful when a search claims to have hits with highly similar domain 
composition and preserving also the order of domains.  A manual observation also confirmed that, with a 
value of 0.8, the resulted top hits have similar domain arrangements (Figure 3.40). With a decrease in 
the collinearity value to 0.1, there is a change in the range of confidence interval, thus the pathway with 
high similar domain composition but with dissimilar arrangement (Figure 3.41) were also seen above the 
confidence interval.     
 
  
Figure 3.39: Results displayed using low collinearity weighting value of 0.1. Several additional hits are 
reported above the confidence interval 
Figure 3.40: High scoring hit pathways with similar domain arrangement. (a) Query pathway from strain CT-43 
(Bacillus thuringiensis) (b) hit pathway from G9842 (Bacillus cereus). 
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Influence of Pathway completeness 
 Pathways completeness is an absolute weighting parameter where the researcher requires the 
query pathway to be completely found in the hit. It imposes a strong restriction, where there is an 
inherent risk that pathways with missing modules due to sequencing errors or errors in secondary 
metabolite prediction algorithm will be prevented to appear in the top of the list, even though there is a 
significant degree of domain composition similarity. As a test case, the Althiomycin gene cluster from 
strain DK897 (Myxococcus xanthus) was used with and without pathway completeness parameter. 
Figure 3.41: Lower-scoring hit pathways with similar domain arrangement. (a) Query pathway from strain CT-43 
(Bacillus thuringiensis) (b) hit pathway from w168 (Bacillus subtilis). 
Figure 3.42: Distribution of scores for Althiomycin with Pathway completeness parameter activated 
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 There are domains which are missing in the hit pathways compared to the query pathway (blue box 
in Figure 3.43), due to which the hits are below the range of confidence interval upon activating the 
Pathway completeness parameter (Figure 3.42). Deactivating the parameter modified the confidence 
interval range, showing the hits which have very similar domain composition with that of the query 
(Figure 3.44) although preceding domain detection was apparently incomplete for some of the auto-
annotated pathways. 
 
  
Figure 3.43: Ball scheme representation of query pathway Althiomycin (pathway shown with thin border) from 
strain DK897 (Myxococcus xanthus) and hits pathways from various producers. The blue box represents the 
domains that are missing in the hits 
  
90 [Type the document title] 
 
3.2.4 Pathway query based on signature domains 
An additional mode of using the BiosynML database system should be briefly mentioned here, 
although it is not a strictly “concepts-based” approach for genome-mining.  
The BiosynML record representing a gene cluster contains meta data of domains that are involved 
in the biosynthesis of a product. Meta data contains description of properties such as building blocks, 
functions, status, position of the domains in the genes and many more that are linked to domains. Thus, 
availability of these data enables researchers to simply search and identify the pathways that possess 
specific information across the database. To search by metadata, researcher needs to specify 
information about a domain or a group of domains. The respective research scenario would be to 
retrieve pathways (or connected information, e.g. domain sequences) stored in the database based on 
the query provided by the user. An example would be of query of the database to find pathways from 
any strain which use a tyrosine-derived building block: It retrieves all the pathways with tyrosine-derived 
building block and outputs the detailed information of the pathway. Similarly, one might want to extract 
the protein sequences of all TE domains from hybrid NRPS/PKS pathways: it extracts the protein 
sequence from all domains of annotated type “TE” from all the pathways (Figure 3.45). 
 
 
Figure 3.44: Distribution of scores for Althiomycin with Pathway completeness parameter deactivated 
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A query can contain multiple domains and their properties linked by connector to control the 
output of the pathways from the biosynthetic pathway repository. Each operand in the connectors is 
considered as a condition that contains either true or false value. This determines the overall results of 
the query that is provided by the user. 
Connectors  
Connectors are words used to connect two or more domains and their metadata in a valid way to 
retrieve pathways of researcher’s interest from the database.  
AND (logical and): the query returns all the pathways which contain all of the specified information 
provided by the user.  
OR (logical or): the query returns all the pathways which contains contain at least one of the 
specified information provided by the user.  
NOT (logical not): Finds content items that contain the information that precedes the operator (if 
any), and ignores content items that contain the information that follows it. 
An interface has been implemented for the researchers to retrieve pathways from the database 
based on a given query. This interface provides multiple options for the researcher to search pathways 
containing a specific set of domains and their metadata information based on the keywords provided by 
the user (Figure 3.46). 
For this type of query, the search engine routinely performs a basic SQL search based on 
domains types and their properties that are considered appropriate. In the second step, the interface 
(Figure 3.46) starts with initiating a search against the database where the function performs the domain 
Figure 3.45: Querying database for pathways with specific information such as domains and its meta information 
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matching tasks and outputs the results. The results consist of the information about hits which are 
estimated to have domains and their properties to that of the query given. As mentioned earlier in the 
framework section, the parameters for the search are domain type, properties that the domains possess 
(building block, parent of the building block, subtype and status) and conditions which fits according to 
the researcher needs (AND, OR and NOT ). The output is delivered by the result window depends on the 
pathways that are considered as hits, and generally comprises the BSRC key, BSYN key, Strain identifier 
key, compound identifier as well as compound name and strain name.  
A part from the simple display of the results, a graphical output of the result pathways is 
generated, highlighting the hit domains in the pathways. In addition, to the search and visualization 
function of the interface also allows researcher to extract the protein sequences of the domains such as 
AT, A or KS which would be further helpful to perform sequence related analysis of the pathways. 
As a simple test case, a “domain query” was conducted to reveal candidate pathways which are 
indicative for presence of two activating domains “A” whose building blocks information contains 
“Serine” and “Alanine”. The domain “A” is selected from the dropdown, the building block is selected 
from the property list, the information of the building block is given in the input filed keyword and an 
appropriate condition has to be chosen which in our test case is “AND”. The aim of this query is to verify 
the functions using domains and their properties, aiming to retrieve all candidate pathways exhibiting 
similar information in the database. After the execution of the query, the results can be seen in 
Figure 3.46: Interface for querying pathways with specific domain set. Red box 
shows the query builder, blue box indicates the basic result set generated by 
the query and green box shows the options for extracting protein sequences 
for the selected domains from the results set. 
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datagridview and the graphical output can be generated in the graphical output tab as shown in Figure 
3.47. 
From the Figure 3.47, it can be seen that the best possible hits among all the pathways available in 
the database. The output in the datagridview shows minimal information such as pathway key, strain 
information and compound information (if the information is available for the hits). Along with this basic 
information the graphical interface provides the ball scheme representation of the hit pathways where 
the hit domains are highlighted (Figure 3.47). In addition, the interface also shows the details associated 
with the pathways such as internal Ids, strain details and compound details. This search provides useful 
information for the researchers to find similar pathway with signature domains and their properties of 
interest. 
In addition to the resulting pathway information, researchers can extract protein or DNA sequences 
of the domains from the pathways set for further use. The interface also has a function which can 
generate a graphical output of ball scheme representation of the resulted pathways which can explicitly 
show clusters in terms of individually identified domains and their properties highlighted. 
 
 
 
Figure 3.47: Graphical interface displaying ball scheme representation of pathways with highlighted hit 
domains in blue circle 
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Addition of sequence-based analysis functions 
Traditionally sequence analysis tools play a major role in identifying regions of similarity in DNA, 
RNA and protein through which functional, structural, or evolutionary relationships between the 
sequences are constructed. For several reasons it may be desirable to conduct sequence alignments 
between query and hit pathways following their retrieval from the pathway repository as the result of a 
conceptual query. One motivation could be to increase the confidence of the high affinity hits resulted 
from conceptual matching. In order to amend the BiosynML analysis engine with the capacity to perform 
analysis also at sequence level, MUSCLE, a program for multiple protein sequence alignment was fully 
integrated into the BiosynML framework. The researcher can chose to submit the desired hit to the 
sequence analysis tool through BiosynML interface in Mxbase Explorer to find the similarity of pathways 
at sequence level. As an example the gene clusters of Myxoprincomide from strain DK1622 (Myxococcus 
xanthus) and Althiomycin from strain DK897 (Myxococcus xacnthus) were used to evaluate the similarity 
of the top hits from conceptual matching at the protein sequence level (Figure 3.48 and Figure 3.49). 
From Figure 3.48 and Figure 3.49, it is clear that the Myxoprincomide pathway has hits from the 
strains MxBonn171 (Myxococcus unclassified) and Ccc1071 (Corallococcus coralloides). These hits have 
convincing architectural similarity. However, upon investigating the hit pathways at sequence level the 
hit from strain MxBonn171 (Myxococcus unclassified) showed overall only 68.28% similarity and the hit 
from Ccc1071 (Corallococcus coralloides) showed 66.36% similarity.  The obvious reason is the deviating 
arrangement of NRPS modules up- and downstream of the small PKS part in the center, possibly as a 
common result of pathway evolution. This intuitive example essentially underlines the fact that 
sequence alignments (including methods like blastP on that matter) are not an adequate means for 
genome mining (especially unsupervised) with long multimodular pathways. 
Figure 3.48: Sequence similarity (Similarity/Identity) of (b) hit from Strain MxBonn171 (Myxococcus unclassified) and (a) 
Myxoprincomide pathway from DK1622 (Myxococcus xanthus) used as a query. 
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 To introduce a different example: Using Althiomycin gene cluster as the query pathway against a 
database filled with public genomes, the GBS algorithm resulted in a single hit from strain Db11 (Serratia 
marcescens (129)). Investigating the protein sequence similarity, the query gene almA has 60.62% 
similarity with target gene SMDB11_RS11325, query gene almB has 58.57% similarity with target gene 
SMDB11_RS11320 and query gene almC has 54% similarity with target gene SMDB11_RS11330 (single 
standing MT domain) (Figure 3.51). Simultaneously on the contrary, comparing protein sequence of 
Althiomycin from DK897 (Myxococcus xanthus) with a top hit which is from myxobacterial strain Pde77 
(Stigmatella erecta) showed, the target gene ctg29_orf00028 has a similarity of 81.48% with query gene 
almA and target gene ctg29_orf00029 has a similarity of 85.38% with query gene almB (Figure 3.50). 
Thus, the althiomycin example shows that a conclusion about the suitable sequence similarity threshold - 
especially when thinking of any automated and largely unsupervised analysis workflow covering a wide 
taxonomic range - is not easily made.   
This results suggest that the current sequence based tool that are widely used to identify known 
biosynthetic pathways using protein sequence similarity, have anticipated difficulties in matching protein 
sequences of genes with translocated modules as in the myxoprincomide example (Figure 3.48 b and 
Figure 3.49b). Such pathways results in lower sequence similarity score because of the gaps generated by 
translocated module (Figure 3.52), although the hit pathways have similar domain compositions and 
plausibly similar architecture. In case of larger genes, partial sequences are used to identify the pathways 
which produce similar compounds; hence success critically depends on first identifying the correct part 
of the gene cluster that is to be used to find the matching pathways. Moreover, a definite confidence 
level of similarity which could determine that the query and target gene clusters encode pathways for 
Figure 3.49: Sequence similarity (Similarity/Identity) of (b) hit from Strain Ccc1071 (Corallococcus coralloides) and (a) 
Myxoprincomide pathway from DK1622 (Myxococcus xanthus) used as a query. 
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structurally similar products is not easily defined. Similar domain architecture on the contrary are likely 
to produce similar compounds even if sequence similarity is weak, commonly observed as a result of 
taxonomic distance. This could lead to unspecific results where the researcher has to invest time in 
manually filtering the result set to identify the appropriate result. This limitation highlights the necessity 
of having an automated approach which can efficiently match the biosynthetic pathways based on 
architectural similarity (with or without presence of the sequence information) and outputs the results in 
a way which is understandable to the researcher. 
Figure 3.51: Lower sequence similarity of Althiomycin pathway between (a) query strain and DK897 (Myxococcus 
xanthus) and (b) Db11 (Serratia marcescens) 
Figure 3.50: High sequence similarity of Althiomycin pathway between (a) query strain and DK897 (Myxococcus 
xanthus) and (b) Pde77 (Stigmatella erecta) 
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3.3 Conceptual genome mining with natural products sources  
In the previous sections, the establishment of the framework and the concepts of the BioynML 
analysis engine were discussed along with the preliminary results. The following part mainly focuses on 
applying the new tools on real world data. The key consideration are 1) to conduct targeted queries 
across a BiosynML repository to facilitate the identification of alternative producers of a biosynthetic 
gene cluster of interest, 2) evaluating the automated process of identifying the known pathways from a 
genome based on the architectural similarity and finally, 3) creating an overview of biosynthetic model 
diversity within a potentially extensive database of (predicted and characterized) pathways. 
3.3.1 Overview of datasets used in this study 
Two different datasets were used in this study to evaluate the performance of the BiosynML 
conceptual genome mining toolbox. The first one is the myxobacteria set, comprising 42 characterized 
biosynthetic gene clusters (see Table 2.4) as well as 71 myxobacterial genomes from various sequencing 
projects (few of them already published, many available only in-house).  
 
Figure 3.52: Result of protein alignment of the single-gene Myxoprincomide pathway from DK1622 (Myxococcus 
xanthus) and hit pathway from MxBonn171 (Myxococcus unclassified) with an overall similarity score of 68.2% 
Figure 3.53: Distribution of scaffolds across genomes used in this study 
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These include complete (27) and draft genomes with up to 200 scaffolds (44) as shown in Figure 
3.53. Including the draft genomes is important as the antiSMASH predictions of gene clusters from draft 
genomes necessarily produce annotated pathways which are partial or have some missing domains or 
even missing genes. Their inclusion in the test dataset thus could be of use to check the dependency of 
the conceptual genome mining method in matching and identifying biosynthetic pathways with 
incomplete information.  
In addition, genomes of Actinomycetes (277), Bacilli (77), Cynobacteria (63), Proteobacteria (47) 
and Serratia (3) were downloaded from NCBI and used as second dataset for the analysis. Focus was on 
covering a taxonomically diverse set of known and potential natural product sources. 
Further, the gene clusters were classified into PKS, NRPS, PKS-NRPS, TansAT-PKS and others based 
on the presence of core domains. For the myxobacteria dataset the majority of the gene clusters 
belonged to hybrid PKS-NRPS (490), NRPS (373), PKS (176), TransAT-PKS (52)  and rest of the gene cluster 
types predicted from antiSMASH are counted as others (254) (Figure 3.55). Similarly, analysing the 
distribution of gene clusters from the public collection resulted in more PKS (746), NRPS (884), hybrid 
PKS-NRPS (402), TransAT-PKS (31) and others (2036) (Figure 3.54). This observation suggests that the 
myxobacterial genomes produce a higher number of hybrid gene clusters (PKS-NRPS) compared to 
autonomous PKS and NRPS gene clusters. Since hybrid gene clusters contain both PKS and NRPS 
Figure 3.54: Distribution of gene clusters from public genome dataset according to their types. 
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modules, they support the production of even more structurally diverse products as opposed to pure 
PKS and NRPS compounds, which might be seen as a hint at myxobacteria following an evolutionary 
strategy to produce a large variety of natural products using multimodular NRPS, PKS and hybrid 
pathways. Notably, the genomes from the public collection have significantly more of the “other” cluster 
types than the core PKS and NRPS clusters compared to myxobacteria. 
3.3.2 Targeted genome mining:  identification of similar gene clusters 
In the context of conceptual genome mining with secondary metabolite gene clusters, a “targeted 
query” refers to the procedure of identifying all gene clusters inside Myxobase which contain pathways 
giving rise to matching functional, substrate and status properties. The functionality, substrate and 
status patterns of candidate pathways are compared to the query pathway.  
When the user creates a new “targeted query” job, the interface starts with initiating a search 
against complete database or restricted by genus and species which have been selected by the user and 
then the working thread performs the pathway matching tasks and outputs the results. The results 
consist of the information about hits which are scored to be similar or identical to that of the target 
query. As mentioned earlier in the methods section, the parameters for hit evaluation are overall 
combined into bitscore and e-value. The additional information delivered by the result interface depends 
Figure 3.55: Distribution of gene clusters from myxobacterial genome dataset according to their types. 
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on the database part which is the source of a hit, and generally comprises biosynthetic pathway dataset 
key/strain collection key/compound collection key as well as the name of the organism and compounds 
of both the query input and the hits, if previously assigned. 
As a simple test case, a “targeted query” was conducted to reveal biosynthetic pathways which are 
indicative for presence of the secondary metabolite cluster for Surfactin biosynthetic pathway (Figure 
3.56) from the Bacillus subtilis strain W168, which already served as a basic example in section 3.2.2.2. 
First this analysis the search parameters are chosen, setting substrate specificity weighting to 0.3, and 
using GBS as the method for pathway evaluation and additional domain penalty weighting of 0.3. The 
collinearity restriction is set to 0 (“off”) in order to avoid the chance of losing pathways which might be 
variants of the query pathway (similar domain composition but varied domain arrangements with 
different substrate specificity).  
Figure 3.56: Ball scheme representation of surfactin pathway from Bacillus subtilis strain W168, used in the 
following as an example for targeted genome mining with the BiosynML toolbox 
Figure 3.57: Results for surfactin biosynthetic pathway from Bacillus subtilis strain W168 queried against public 
genome dataset. The result highlighted in yellow is the “selflhit”. 
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The aim of this query is to verify the functions using a known and curated “textbook” pathway, aiming to 
retrieve all candidate pathways exhibiting similar architecture in the database. After the execution of the 
query, the results can be seen in hit summary tab as shown in Figure 3.57.  
According to Figure 3.58, several known pathways are identified which are expected as a result 
because of prior knowledge on the genome dataset from the biosynthetic repository. More specifically, 
the genome annotation in this case reveals the surfactin pathway leads to identical pathways used by 
various strains of Bacillus subtilis (Table 3.3) and different species of Bacillus (Table 3.4). The change in 
score is because of additional predicted domains that are present in the pathway and minor changes in 
the substrate specificity predicted by antiSMASH. There are also hits from Bacillus genus (Table 3.3) 
showing identical domain composition but with varied substrate specificity, which reduced the similarity 
score of the hits as we chose to give high priority to the substrate specificity. We emphasize here, that 
the pathways whose absolute domain arrangement and operon organization differs (Figure 3.59) from 
that of the query pathway (Table 3.5) but has similar composition and relative domain arrangement 
(Figure 3.59) are identified and have a decent similarity score, which are noticeable to a chemist for 
Figure 3.58: Biosynthetic pathway with near-identical domain composition and architecture (besides additional “?” 
domains). The box around the pathway represents query surfactin pathway from Bacillus subtilis strain W168 
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investigation. These pathways and could produce compound derivatives, some of which in practice may 
exhibit reduced toxicity and improved pharmaceutical properties. 
 
BSYN ID Strain key Organism Score 
BSYN5107 11739 W168 (Bacillus subtilis) 329.956 
BSYN5107 11734 QB928 (Bacillus subtilis) 329.756 
BSYN5144 11739 w168 (Bacillus subtilis) 329.756 
BSYN5084 11731 JS (Bacillus sp) 329.755 
BSYN5100 11733 PY79 (Bacillus subtilis) 329.755 
BSYN5166 11742 RO-NN-1 (Bacillus subtilis) 329.755 
BSYN5136 11738 6051-HGW (Bacillus subtilis) 329.755 
BSYN5122 11736 W23 (Bacillus subtilis) 329.755 
Table 3.3: Identical hits for Surfactin pathway from various strains 
BSYN ID Strain key Organism Score 
BSYN4836 11687 CAU_B946 (Bacillus amyloliquefaciens) 329.355 
BSYN4864 11690 UCMB5033 (Bacillus amyloliquefaciens) 329.154 
BSYN4854 11689 FZB42 (Bacillus amyloliquefaciens) 329.154 
BSYN4881 11692 UCMB5113 (Bacillus amyloliquefaciens) 329.154 
BSYN4872 11691 UCMB5036 (Bacillus amyloliquefaciens) 329.154 
BSYN4785 11681 CC178 (Bacillus amyloliquefaciens) 329.154 
BSYN4827 11686 AS43_3 (Bacillus amyloliquefaciens) 329.154 
BSYN4820 11685 LL3 (Bacillus amyloliquefaciens) 319.529 
Figure 3.59: Hit pathway with near-identical domain composition but apparently different operon organization 
and substrate specificities compared to the query surfactin pathway from Bacillus subtilis strain W168 
(represented in box) 
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BSYN ID Strain key Organism Score 
BSYN5183 11744 BMB171 (Bacillus thuringiensis) 269.595 
BSYN5190 11745 Bt407 (Bacillus thuringiensis) 269.595 
BSYN5222 11749 CT-43 (Bacillus thuringiensis) 269.595 
BSYN5261 11755 YBT-1518 (Bacillus thuringiensis) 269.595 
BSYN5250 11753 IS5056 (Bacillus thuringiensis) 269.595 
BSYN4991 11709 B4264 (Bacillus cereus) 269.595 
BSYN5241 11752 HD73 (Bacillus thuringiensis) 269.395 
BSYN5017 11714 G9842 (Bacillus cereus) 268.793 
BSYN5205 11747 HD-789 (Bacillus thuringiensis) 268.793 
    
Table 3.5: Hits for Surfactin pathway with similar domain composition but varied substrate specificity 
In fact this output compares well to the results typically obtained from sequence analysis, a finding 
which will be elaborated in more detail during performance evaluation. In contrast to the sequence 
analysis procedure, however, no access to the sequence data was necessary, and the user did not have 
to supply the protein sequence knowledge of representative domains as the starting point for analysis. 
Annotation is based instead on the pathway knowledge by applying it to the domain feature-predicted 
clusters deposited in the BiosynML biosynthetic pathway repository. For that, the raw data needs to be 
processed only once through antiSMASH, and the pathway content is then available inside the BiosynML 
repository (here: Myxobase) for multiple analyses independently done by researches. The interface is 
equipped with a function to visualize the ball scheme representation of the biosynthetic pathways where 
the researcher can analyse the disturbances in the similarity scores (Figure 3.58). 
Additionally, the interface can also plot distribution of similarity scores against all pathways from 
the database (Figure 3.60). The plot shows a sudden decline in the scores, which indicates the ability of 
the algorithm to distinguish pathways which have high confidence. A low confidence is assigned to 
pathways that disagree with modularity of domain composition and high confidence to those that 
comply with it. This provides the researcher an opportunity to identify the pathways that need more 
attention. However, the selection of the parameter values also affects the outcome of the result. So, 
researcher should follow-up analysing the results until the second jump in the plot, as some pathways 
are scored less because of various factors such as sequencing errors where the antiSMASH pipeline 
missed prediction of possible domains and errors in the prediction of substrate leads to lower score of 
BSYN4958 11702 1942 (Bacillus atrophaeus) 319.328 
BSYN4903 11694 TA208 (Bacillus amyloliquefaciens) 319.328 
BSYN4910 11695 XH7 (Bacillus amyloliquefaciens) 319.328 
BSYN4794 11682 DSM_7 (Bacillus amyloliquefaciens) 319.328 
BSYN5079 11729 SAFR-032 (Bacillus pumilus) 316.328 
BSYN5058 11724 DSM_13_=_ATCC_14580 (Bacillus licheniformis) 309.301 
BSYN5049 11723 9945A (Bacillus licheniformis) 309.301 
Table 3.4: Near-identical hits for Surfactin pathway from various species 
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the pathways even though the pathway is highly similar to that of the query pathway used for matching. 
A detailed result from the targeted results for Surfactin is presented in Appendix 6.1-Tab 
 
 
3.3.3 Architectural matching vs. sequence-based comparison  
Using Surfactin pathway as a query, the architectural matching succeeded to reveal pathways 
which are highly similar to that of the query pathway. It is of interest to check the similarity of the hits at 
sequence level, too – because this has potentially severe implications for the ability or inability of 
genome-mining approaches to reveal pathway similarity at high or low levels of taxonomic relatedness.  
To study this aspect further, the protein sequences of the high scoring gene pairs (query and target) are 
extracted from the BiosynML files that are stored in the BiosynML repository of Myxobase. These protein 
sequences from the query and hit are passed through MUSCLE aligner for multiple sequence alignment.  
Here, the query is Surfactin cluster obtained from W168 strain of Bacillus subtilis, the top hit 
reported by architectural matching was from the strain CAUB946 belonging to Bacillus amyloliquefaciens 
Figure 3.60: Distribution of bit scores for Surfactin pathway across all the pathways in the database. The grey box 
denotes confidence interval of the scores where the domain composition of the pathways starts varying 
significantly. 
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was chosen. The best hits that have better scores than pathway from CAUB946 are from different strains 
of Bacllius subtilis, so, we chose a pathway from a different species but of the same genus Bacillus.  
The query Surfactin cluster has 4 genes that are matched against 7 genes of CAUB946, out of 
which 4 are reported as hits. The protein sequences of the high scoring pairs are aligned and the results 
are as shown in Table 3.6. 
Query W168 (Bacllius subtilis) Hit CAUB946 (Bacllius 
amyloliquefaciens) 
Similarity 
(%) 
Identity 
(%) 
  
83.54 72.09 
  
83.41 73.84 
  88.89 83.72 
sfrA4 
 
BACAU_0308 
 
83.95 75.31 
Table 3.6: Protein sequence similarity of genes between query pathways from W168 (Bacllius subtilis) and hit 
pathway from CAUB946 (Bacllius amyloliquefaciens)  
As the pathway from CAUB946 shows similar domain compositions with exact substrate 
specificities, the sequence analysis also resulted in high similarity.  
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Query W168 (Bacllius 
subtilis) 
Hit B4264 (Bacillus cereus) Similarity (%) Identity (%) 
  
54.7 35.4 
 
 
55.5 34.2 
 
 52.3 32.5 
 
 55.9 34.9 
sfrA4 
 
 
 
 
55.3 30.5 
Table 3.7:  Protein sequence similarity of genes between query pathway from W168 (Bacllius subtilis) and hit 
pathway from B4264 (Bacillus cereus). The red boxes represent the modules that are distributed differently across 
genes, still the full complement of domains could in principle bring about a Surfactin-like molecule. 
Another hit which can be a potential variant of Surfactin was chosen to check the sequence 
similarity between genes. A hit from strain B4264 from Bacillus cereus was chosen to show that the 
specificities of the pathway vary with that of the query (Table 3.7).  The sequence similarity between the 
query and hit shows very low score while the overall domain composition of the pathway looks to be 
similar, albeit with altered distribution of modules across genes and varying substrate specificity. 
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Hits of such type are very easy to be missed by chemist using sequence based analysis as the 
sequence similarity results in very low scores for genes in query pathways. The query gene srfA1 has a 
similarity of 54.7% with BCB4264_A2463. The target gene BCB4264_A2463 partially is also a hit for query 
gene srfA3 has a similarity of 55.5%,  srfA2 has two hit genes BCB4264_A2461 and BCB4264_A2462 
having a similarity of 52.3% and 55.9% respectively and query gene srfA4 has a hit to gene 
BCB4264_A2461 of similarity 55.3% (Figure 3.61). 
We furthermore constructed a cladogram for the hits based on the similarity scores obtained 
through architectural matching. Each leaf of the cladogram displays the label that provides a unique 
biosynthetic pathway identification key (BSYN ID) as well as the strain, genus and species. Considering 
the pathways which are reported as hits compared to the best possible score (score of self-hit), yields 
five distinct groups of “Surfactin-like” candidate gene clusters.  
A clade is a set of closely related pathways which is represented as a subtree as shown in Figure 
3.62. The hit pathways which resembles to Surfactin pathway in terms of both domain functionality and 
specificity are grouped together as a clade (Figure 3.62 a), the hit pathways which have high similarity in 
domain functionality but changes in predicted substrate specificity are grouped as another clade (Figure 
3.62 b) where e.g. the leucine-activating A-domain  was  replaced with isoleucine-specific A-domain. This 
variant of surfactin with isoleucine substitution was in fact already characterized and is found in Norine 
database (130). The pathways which have high similarity in the functionality but have more different 
substrate specificities are also roughly grouped together (Figure 3.62 c, Figure 3.62 d). These clades form 
Figure 3.61: Ball scheme representation of (a) Surfactin pathway from W168 (Bacllius subtilis) (b) hit pathway 
from B4264 (Bacillus cereus). The target gene BCB4264_A2463 has hits with both query genes srfA1 and srfA3, 
query gene srfA2 has two hit target genes BCB4264_A2461 and BCB4264_A2462 and query gene srfA4 has a hit 
with target gene BCB4264_A2461 
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subclades to the difference in the scores obtained because of presence of additional domains in the 
pathways which are penalised. Clade from Figure 3.62 (e) is an example for heterogeneous clade as the 
domain composition disintegrates with respect to the query domain composition. 
 Finally, to analyse the behaviour of the conceptual method with small gene clusters, the 
Myxochelin pathway from strain Sga15 (Stigmatella aurantiaca) was used (131). This pathway represents 
a challenging test case since it has merely a handful of distinct domains, as opposed to the large set of 
domains comprised in the pathway models used in previous examples. In that respect, myxochelin 
represents the “borderline” case for using the conceptual genome mining approach in this study. 
The method reported nine hit pathways from the public genome dataset which resembles 
myxochelin pathway. Among these, there are five hits which have identical domain composition as well 
as substrate specificity (Figure 3.63 a) and four pathways with deviating domain composition and 
Figure 3.62: A cladogram of the pathway established based on the scores obtained from architectural matching of 
Surfactin pathway.  a) Pathways with similar domain functionality and substrate specificity. b) Pathways with 
similar domain functionality and minor deviation in the substrate specificities. c, d) Pathways with similar domain 
functionality with deviations in the substrate specificities. e) Pathways with disintegrating similarity between 
domain functionality as well as substrate specificities. 
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deviations in the substrate specificities (Figure 3.63 b) along with missing KR domain (which is 
supposedly inactive and has no assigned role in the myxochelin biosynthesis ). The pathways which are 
below the confidence interval have overall similar domain composition (small NRPS cluster with terminal 
Red domain) but deviates with substrate specificities (Figure 3.63 c) along with missing and additional 
domains.  
  
 
 
 
 
 
On analysing the protein sequence similarity of best hit from strain DSM44728 (Stackebrandtia 
nassauensis) for Myxochelin pathway gave notable results (Table 3.8). The query gene mxcG has only a 
similarity of 47.4 % with the target gene Snas_4519, the query gene mxcE has similarity of 47.4 % with 
the target gene Snas_4516 and the query gene mxcC has 64.1% similarity with target gene Snas_4514. 
 
 
 
 
 
Figure 3.63: Bitscore plot for Myxochelin genecluster. (a) A plausible myxochelin pathway from strain DSM44728 
(Stackebrandtia nassauensis) which is a near identical hit. (b) A pathway from strain UCBPP-PA14 (Pseudomonas 
aeruginosa) showing deviations in the substrate specificity, but retaining the “C-A-PCP-Red” arrangement as in 
the myxochelin pathway and also harbouring a dhb-activating A-domain. (c) A representative pathway from 
strain EAI5 (Mycobacterium tuberculosis) that has deviations in the substrate specificities, additional and 
missing domains and not preserving the myxochelin-typical four domain NRPS gene. 
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Considering another top hit from strain Soce56 (Sorangium cellulosum) for analysing protein 
sequence similarity showed convincing agreement with the query myxochelin pathway (Table 3.9). The 
query gene mxcG has similarity of 91.6% with the target gene ctg1_orf09037, the query gene mxcE has 
similarity of 78.9 % with the target gene ctg1_orf09020 and the query gene mxcC has 79.8% similarity 
with target gene ctg1_orf09024.  
 
 
 
 
 
 
 
 
 
 
 
Query  Sga15 (Stigmatella 
aurantiaca) 
Hit DSM44728 
(Stackebrandtia nassauensis) 
Similarity (%) Identity (%) 
 
 
47.4 36.1 
 
 
67.8 56.4 
 
 
64.1 51.6 
Table 3.8: Protein sequence similarity of genes between query pathways Sga15 (Stigmatella aurantiaca) and hit 
pathway from DSM44728 (Stackebrandtia nassauensis) 
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Analysing the similarity at protein level with a hit from strain UCBPP-PA14 (Pseudomonas 
aeruginosa) which has partially similar domain composition but deviations in predicted substrate 
specificities (Table 3.10), the query gene mxcG has 41.4% similarity with target gene PA14_54920. But 
the query gene mxcE which has a single standing, dhb-activating “A” domain showing 68.6% similarity 
with hit gene PA14_54940. The mxcC gene coding for (inactive/unnecessary) KR domain is not found in 
the hit pathway. 
 
 
 
 
 
 
 
 
 
 
Query Sga15 (Stigmatella 
aurantiaca) 
Hit Soce56 (Sorangium 
cellulosum) 
Similarity (%) dentity (%) 
 
 
91.6 87.1 
 
 
78.9 67.9 
 
 
79.8 68.2 
Table 3.9: Protein sequence similarity of genes between query pathways Sga15 (Stigmatella aurantiaca) and hit 
pathway from Soce56 (Sorangium cellulosum)  
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Query Sga15 (Stigmatella 
aurantiaca) 
Hit CBPP-PA14 (Pseudomonas 
aeruginosa) 
Similarity (%) Identity (%) 
 
 
40.91 25.3 
  
68.6 52.2 
Table 3.10: Protein sequence similarity of genes between query pathways Sga15 (Stigmatella aurantiaca) and hit 
pathway from CBPP-PA14 (Pseudomonas aeruginosa) 
On the basis of examples provided in this section, the targeted query module within the BiosynML 
conceptual genome mining framework is able to annotate identical, near-identical and similar to remote-
similar pathways from the database of candidate pathways on the basis of architectural similarity in 
terms of domain compositions, domain arrangement and associated meta data. Some of the reported 
hits might have been achieved also on the basis of sequence similarity (e.g. using blast), however with 
the inherent difficulty of choosing an appropriate sequence stretch and determining the similarity 
threshold, a problematic decision especially in light of similar gene clusters appearing in phylogenetically 
distant taxa. This difficulty is illustrated by the above examples of althiomycin, surfactin and myxochelin. 
In the case of myxochelin, a top hit pathway from strain DSM44728 (Stackebrandtia nassauensis) 
was detected which has discouraging low protein similarity compared to the myxobacterial pathway, but 
has the identical domain composition as well as substrate specificities. It is not known whether this 
species is able to produce myxochelin, but the conceptual genome mining result strongly suggest it could 
be a producer of a structurally very similar molecule. On the contrary, observing the protein similarity of 
the top hit pathway from myxbacterial strain Soce56 (Sorangium cellulosum) showed high similarity with 
the genes in the Stigmatella myochelin pathway and thus would have been easily identified by sequence 
analysis, too. Since targeted query performs search on architectural level, these myxochelin candidates 
from different taxa were detected and reported; decreasing the allowed “substrate specificity” and 
“additional domain penalty” tolerance could possibly also report more hits above the confidence interval 
generated, but at the cost of expecting an increased false discovery rate in terms of deviations in 
substrate specificities and  functionality. These incidents were investigated in-detail by manual 
inspection of ball scheme represented clusters generated in the descending order of bit-score, and it 
depends on the specific application whether it is desired to include less specific hits in the result set. 
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Using a biosynthetic pathway as an input, the targeted genome mining module reports on the 
occurrence of high-scoring pathways with highly similar domain compositions and arrangements, 
regardless whether these belong to a known compound or to an unidentified feature. Output is a set of 
pathways that have highly similar domains architecture ordered in the decreasing order of bit scores 
obtained and thus can be used to rapidly identify alternative producers for the similar pathway from a 
large collection of genomic datasets. The special importance of this analysis is due to the fact that the 
genomics-guided biosynthetic pathway discovery strategies may reveal some novel pathways for 
compounds which are initially only known from the respective discovery strain. When an instant 
overview of potential alternative sources, based on the presence of the underlying pathway, is easily 
available using the targeted query, then chances to purify and structurally elucidate the novel compound 
using an alternative producer are much increased. In a different scenario, the targeted query result may 
highlight a genome-sequenced strain as a producer of the novel compound, using a hypothetical 
assembly line as query input; in that case the result paves the way to the new assignment of a previously 
“orphan” biosynthesis gene cluster to the metabolite it produces. 
Overall, the comparison of biosynthetic pathways across the BiosynML pathways repository, 
facilitated here by the targeted conceptual query tool in Myxobase, should provide a powerful method 
for the natural product researcher for the discovery and identification d of biosynthetic gene clusters. 
 
3.3.4 Genome annotation and dereplication analysis of biosynthetic gene clusters 
Genome annotation refers to the following procedure: using domain properties in a genome 
dataset stored in Myxobase, for each of the biosynthetic pathway in a given genome a query is executed 
against all the pathways in the database. A matching is performed of the candidates and hits are 
evaluated using function, substrate specificity and status deviation as criteria.  
The framework significantly enhances the search of conceptual information stored in the 
database by integrating meta information such as function, specificity and status of the domains in the 
searches. A genome sequence submitted to the procedure is pathway-wise evaluated for high scoring 
hits in the known pathways library and gene clusters are auto-assigned to pathways showing plausible 
architectural similarity. This meta information is used by search and match algorithms which outputs the 
result both in the form of a table showing scores and hits and bitscore plot showing the graphical 
representation of distribution of hits with reference to each pathway from genome queried. The bitscore 
plot generates a confidence interval based on the self-hit score, the best possible score for the query 
pathway; the hits above the confidence interval can be recognised as the clusters which are identical or 
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highly similar to that of the query cluster. When these hit clusters above the confidence interval are 
linked to the compound information of the characterized pathway in the library, any new genome-
encoded pathway used as a query could be tentatively assigned to that metabolite, too.  
As a test case for the genome annotation module, we used datasets from the myxobacterial 
strains DK1622, Cmc5 and Soce56.  A function was added to the Myxobase interface, which imports the 
data from the .xml file delivered by the antiSMASH annotation pipeline into the database. All the 
annotations from the dataset are stored in the Myxobase biosynthetic pathway repository with a unique 
pathway key. For dataset from DK1622 some of the pathways namely Myxochromid, Myxoprincomide 
and Myxovirescin are manually curated using BiosynML plugin for Geneious such that the reference 
library contained both, curated and non-curated pathways.  
The conceptual genome auto-annotation for the following example is triggered with these query 
settings: selection of genome set to be annotated, substrate specificity penalty (0.3), additional domain 
penalty (0.3), and search against all the pathways in the database. The information content is in principle 
similar to that of the targeted query results. 
Observing the results of conceptual genome annotation for strain DK 1622 (Table 3.11), six known 
pathways which are Myxovirescin, Myxochelin, Myxochromid, DKxanthen, Myxalamid and 
Myxoprincomide are identified which are expected as a result because of prior knowledge on the 
pathways from the M. xanthus genome (85, 132), which was used to create the dataset. These known 
pathways from the DK 1622 genome were reliably assigned by the algorithm. 
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Query ID Hits above 
confidence 
interval 
Bitscore  (best hit 
score/ self-hit 
score) 
Assignment to 
pathway (number of 
domains) 
Hits in suborders (frequency) 
BSYN109 0    
BSYN110 
 
 
23 49.9/49.9 (100%) Uncharacterized Short 
NRPS-PKS (6) 
Cystobacterineae (20), 
Sorangiineae (2) and 
Nannocystineae (2) 
BSYN111 
 
2 176.2/176.2 (100%) Uncharacterized NRPS 
(21) 
Cystobacterineae (3)  
BSYN112 
10 66.8/66.8 (100%) Uncharacterized Short 
NRPS (8) 
Cystobacterineae (8) and 
Sorangiineae (3) 
BSYN114 
4 201.2/201.6 (99.8%) Uncharacterized 
NRPS-PKS (24) 
Cystobacterineae (5) 
BSYN115 
 
1 541.4/572.1 (94.6%) Uncharacterized long 
NRPS-PKS  (68) 
Cystobacterineae (2)  
 
BSYN116 
 
42 56.9/58.4 (97.4%) Myxochelin (7) Cystobacterineae (35) and 
Sorangiineae (7) 
BSYN117 2 313.8/319.5 (98.2%) Myxoprincomide (38) Cystobacterineae (2) 
BSYN118 2 622.8/639.5 (97.4%) Myxovirescin (76) Cystobacterineae (2) 
BSYN119 
1 239.1/243.7 (98.1%) Uncharacterized 
NRPS-PKS  (29) 
Cystobacterineae (2) 
BSYN120 10 226.8/226.8 (100%) Myxochromid (27) Cystobacterineae (10) 
BSYN121 10 285.8/285.8 (100%) DKxanthene (34) Cystobacterineae (10) 
BSYN122 
1 403.7/403.7 (100%) Uncharacterized long 
NRPS-PKS  (48) 
Cystobacterineae (2) 
BSYN123 9 386.8/386.8 (100%) Myxalamid (46) Cystobacterineae (9) 
BSYN124 
1 252.1/252.1 (100%) Uncharacterized NRPS  
(30) 
Cystobacterineae (3) 
BSYN125 
15 49.7/49.9 (99.5%) Uncharacterized short 
PKS  (6) 
Cystobacterineae (15) 
Table 3.11: Results of genome annotation for DK 1622 using architectural matching of domains functionality, 
substrate specificity and status.  
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According to the outcome of this analysis, strain Myxococcus xanthus DK1622 has no unique 
secondary metabolite pathways, as each biosynthetic gene cluster is found in at least two other 
myxobacterial strains. This picture may however at least in part because of a fair number of additional 
Myxococcus genomes in the test database, implicitly increasing the chance/risk to encounter 
evolutionary “close” genomic content. 
 
Genome wide detection and identification of known pathways 
The availability of the BiosynML matching method made it possible to construct a dereplicated 
library for biosynthetic pathways, allowing to highlight known pathways from newly sequenced 
genomes, thereby revealing the unknown pathways which might be of interest to the chemist. The 
BiosynML framework efficiently compares the predicted pathways from a genome and assigns 
compound information to the highly similar characterized pathways identified as a hit which are in 
general found indicated above the confidence interval. This automated analysis requires very little 
human interaction to identify the known pathways from the newly annotated genome dataset.  As an 
example DK1622 (Myxococcus xanthus), Cm c5 (Chondromyces crocatus) and So ce56 (Sorangium 
cellulosum) genomes were used to test the functionality and ability of the algorithm to identify the 
known pathways by comparing them to the characterized pathways stored in the database. The queries 
are executes using GBS algorithm, Substrate specificity of 0.3 and domain penalty of 0.3. 
The algorithm identified the known clusters of Myxovirescin, Myxochelin, Myxochromid, 
DKxanthen-534 and Myxalamid clusters from DK1622 genome, Crocacin, Chondramid, Thuggacin and 
Ajudazol, Chondrochloren clusters from Cmc5 genome and Etnangien, Chivosazol and Myxochelin 
clusters from Soce56 genome as expected (Table 3.12). For example, querying myxochelin pathway from 
strain DK1622 identified the similar pathway from Soce56 with high confidence (Figure 3.64). Bitscore 
plots for the respective pathways from the three genomes can be seen in Appendix 6.2.   
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This auto recognition process facilitates the rapid identification of strains that has great potential to 
produce novel secondary metabolites as well as the strains that produce known compounds which has 
the potential for improving the process of natural product pathway characterization to a great extent. 
For example, querying myxochelin pathway from strain DK1622 identified the similar pathway from 
Soce56 with high confidence, together with a high number of additional myxochelin pathways from 
other strains (Figure 3.64). 
With development in the sequencing technologies, the secondary metabolite gene cluster 
information is increasing rapidly, and there is a great demand for a medium which can store the derived 
information efficiently, such that this can be accessible and used by researchers in a collaborative 
manner. A database system is the logical medium for this purpose, but few such specialized systems exist 
for research in the field of natural products. In that respect the Mxbase system represents a novelty, by 
integrating both chemical compound and biological data management and additionally providing the 
tools for analytical workflows in one database-driven environment for natural products research. 
Genome Cluster acknowledged 
DK1622 Myxovirescin 
Myxochelin  
Myxochromid 
DKxanthen-534 
Myxalamid  
Myxoprincomide 
Cmc5 Crocacin 
Chondramid 
Thuggacin 
Ajudazol  
Chondrochloren  
Soce56 Etnangien 
Chivosazol 
Myxochelin  
Table 3.12: Overview of known pathways recognized by BiosynML framework algorithm from genomes DK1622, 
Cmc5 and Soce56. Here, true negatives are the known pathways which are not identified by the algorithm and false 
positives are the hits reported by the algorithm as known pathways which in reality it is not. No such mis-
assignments occurred.   
  
118 [Type the document title] 
It should also be highlighted that the research questions which the tools developed here are able to 
answer, are in fact quite significant for the novel biosynthetic gene clusters discovery.  
The genome wide annotation is used to classify all known and unknown clusters from a genome 
which are stored in the database. In this case, the input is the full complement of pathways in a genome 
dataset. Each pathway features contained therein is compared to clusters stored in the database using 
the annotation properties, and matching is done using the chosen algorithm in order to confirm a 
plausible hit. Thus, this function can highlight pathways, which are to date unidentified and are actually 
likely to make the containing strain a producer of novel compounds.  
The results obtained using the newly developed tools are promising and routine operation of the 
analysis framework is feasible. For reasons of computational performance matching and scoring 
algorithms are placed on the Mxbase server that performs the calculations through a job submission 
system which leaves the interface useable for the user.  
Figure 3.64: Myxochelin pathway from strain DK1622 query resulted in the identification of a hit pathway 
from Soce56 (blue circle) with high confidence. The plot also reveals that the myxochelin pathway is 
ubiquitious in genomes of the suborders Cystobacterinaea and Sorangineae but not in the Nannocystineae 
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 Although the tools for matching are server-side functions, with the increase in the size of 
biosynthetic pathway repository, the tools require relatively high computational power for performing 
the matching functions which make the users wait for long time to obtain results.  In order to reduce the 
waiting time a future version could perform parallelized processing of the pathway comparison. 
Implementing the parallelized version of mining tools on a server-side application would surely increase 
the effective usage of the tools. The generalized workflow of the BiosynML-enhanced genome-mining 
framework is illustrated in the Figure 3.65. 
 
3.3.5 Exposing the diversity of secondary metabolite pathways in myxobacterial genomes 
The present understanding of the diversity of secondary metabolic pathways in myxobacterial 
strains are mostly based on the studies concentrated on the biosynthesis of compounds linked to PKS 
and NRPS pathways. In this study, we performed a large-scale analysis of myxobacterial biosynthetic 
pathways by combining the conceptual information of pathways obtained from the biosynthesis of 
compounds screened from myxobacterial strains as well as the genomic data of myxobacterial strains 
available in the Myxobase biosynthetic pathway repository. This suborder-level investigation allowed 
identification of biosynthetic pathways which are restricted to suborder(s) and the pathways which are 
distributed across all the suborder genomes. 
Figure 3.65: An overview of BiosynML enhanced genome-mining framework 
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The gene clusters from the genomes along with the characterized pathways were analysed using 
GBS methods and results later sorted based on the originating suborder. Due to the differences in the 
quality of the genomes used in this study, analysis in the following is carried out with relaxed 
parameters. This analysis should be repeated at a later timepoint using more stringent parameters with 
genomes of good quality. 
Analysing the distribution of characterized clusters (Figure 3.66) among the suborders, 34 pathways 
are observed to be suborder specific among which 15 pathways exclusively belong to Cystobacterineae 
(40 genomes) encoding gene clusters for NRPS (2), PKS (4), NRPS-PKS (8) and trans-AT PKS (1), 19 
pathways belonging exclusively to Sorangiineae (27 genomes) encoding gene clusters for NRPS (1), PKS 
(3), NRPS-PKS (10) and trans-AT PKS (5) and a single pathway (NRPS-PKS) was found to be suborder 
specific in Nannocystineae (4 genomes). The latter is the biosynthetic pathway for Nannochelin, the gene 
cluster characterized from a member of Nannocystineae. There are two pathways shared between 
Cystobacterineae and Sorangiineae suborders, these are the pathways for myxochelin and tubulysin. 
Myxochelin is known as an iron chelator produced by all species of Cystobacterineae and Sorangiineae 
analysed to date, albeit mass spectrometry data indicate that production titers generally depend largely 
on iron supply in the respective cultivation. Tubulysin production, however, has so far only been 
attributed to strains from Cystobacterineae suborder (133), and Myxobase contains no mass 
spectrometric evidence that strain So ce836 - which is suggested by the analysis here (see Figure 3.67) to 
contain a tubulyin gene cluster – actually produces the compound. Close inspection of the candidate 
Figure 3.66: A Venn diagram showing the distribution of previously 
characterized gene clusters with known products, from suborders 
Cystobacterineae (red), Sorangiineae (green and Nannocystineae 
(blue)). The number of genomes in each suborder was shown in 
brackets. 
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cluster from that strain, however, reveals an unusual domain arrangement where an A-domain seems to 
have been duplicated (Figure 3.67 c). Thus, it could be conceived that the gene cluster might have 
become non-functional as consequence of this mutation, which might explain non-production of 
tubulysins despite the fact that the candidate gene cluster must be clearly classified as a tubulysin 
pathway based on overwhelming architectural similarity. Another explanation may be the production of 
a tubulysin analogue which is not detected in our target screening for MS data. In fact the tubulysin 
pathway has been shown before to produce a large diversity of tubulysin congeners (134). 
 
 
 
 
 
 
 
 
Figure 3.67: Ball scheme representation of tubulysin pathway from And48 (Pyxidicoccus fallax) and hits reported. 
(a) Tubulysin (query) pathway from And48 (Pyxidicoccus fallax) (b) hit pathway from Cbv34 (Cystobacter velatus) (c) 
hit pathway from Soce836 (Sorangium cellulosum) (d) hit pathway from MCy9101 (Cystobacter unclassified) 
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An overview of the pathways found in the available myxobacterial genomes which are plausibly 
similar to characterized myxobacterial pathways can be seen in Tables 3.13 and 3.14. 
  
 Genomes Total 
pathways 
Average 
pathways 
per 
genome 
#Characterized 
pathways 
NRPS PKS Hybrid 
NRPS 
PKS 
Trans 
AT-
PKS 
Myxobacteria 71 1347 18.9 42 6  7  18  6  
Cystobacterineae 40 889 (66%) 22.2 15 (1.7%) 2  4 8 1 
Sorangiineae 27 419 
(31.1%) 
15.5 19 (4.5%) 1  3 10 5 
Nannocystineae 4 39 (2.9%) 9.75 1 (4%) 1     
Shared between 
Cystobacterineae 
and Sorangiineae 
67   2 2    
Table 3.13:Overview table for characterized pathways types distribution 
 
Among the characterized pathways, suborder specific secondary metabolite pathways  occurred in 
40 cystobacterinae at following frequency such as Myxochromide  (in 10 genomes) (Figure 3.68), 
DKxanthene (in 10 genomes),  Myxalamid (in 9 genomes), Myxothiazol (in 7 genomes),  Althiomycin (in 4 
genomes), Aurafuron (in 3 genomes), Rhizopodin (in 3 genomes), Cystobactamide (in 3 genomes), 
Myxovirescin (in 2 genomes), Myxoprincomide (in 2 genomes), Pyxidienon (in 1 genome), Phenalamid (in 
1 genome), Stigmatellin (in 1 genome), Melithiazol (in 1 genome) and Myxovalargin (in 1 genome).  
Other characterized pathways, suborder specific secondary metabolites occurred in 27 sorangiineae at 
following frequency such as  Lipothiazole (in 3 genomes) (Figure 3.70), Epothilon (in 2 genomes), 
Microsclerodermin (in 1 genome), Disorazol (in 1 genome), Etnangien (in 1 genome), Chondrochloren (in 
1 genome), Carolacton(in 1 genome), Chivosazol (in 2 genomes),  Chondramide (in 2 genome), Ajudazol 
(in 1 genome), Ripostatin (in 1 genome), Ambruticin (in 1 genome), Thuggacin (in 1 genomes),  Leupyrrin 
(in 1 genome), Pellasoren (in 1 genome), Crocacin (in 1 genome), Crocapeptin (in 1 genome) and 
Sorangicin (in 1 genome) are observed in suborder Sorangiineae. Nannochelin (in 1 genome) (Figure 
3.69) was only observed in Nannocystineae suborder. 
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The pathways appearing in multiple suborders Cystobacterineae and Sorangiineae are Myxochelin 
(42) (Figure 3.71) and Tubulysin (3) (Figure 3.67); regarding the latter see comment above 
 
 
 
 
 
 
Figure 3.68: Ball scheme representation of Myxochromide, a suborder specific gene cluster found in 10 
Cystobacterineae genomes 
Figure 3.69: Ball scheme representation of Nannochelin, a suborder specific gene cluster found exclusively in 
Nannocystineae genome 
Figure 3.70: Ball scheme representation of Lipothiazole A, a suborder specific gene cluster found in 3 Sorangiineae 
genomes. 
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 Due to the bad prediction of pathway from DW4/3 genome, the hit pathway expected for Dawenol 
was not found in the results set (Figure 3.72). Note that the characterized pathways (marked with * in 
Table 3.14) that are not found by the algorithm are missing simply because of the current unavailability 
of genome sequences with sufficient quality to be included in the analysis.  
As a special case, the Soraphen gene cluster produced three more unspecific hits along with the 
specific hit. This is due to high similarity in domain composition by combining domains from genes 
(Figure 3.73). These pathways actually lack precise domain architecture compared to the query Soraphen 
pathway. Since, the algorithm performs matching based on the set intersection, the unspecific hits were 
scored high with the parameter settings used (substrate specificity (0.3), additional domain penality (0.1) 
and collinearity (0)). The latter was chosen because of the presence of many draft genomes in the test 
dataset where the information is scattered across up to 200 scaffolds. However, with the increase in the 
Figure 3.72: Dawenol pathways from DW4/3 genome. (a) Curated pathway (b) predicted pathway from 
antiSMASH 
Figure 3.71: Ball scheme representation of Myxochelin, the most common characterized pathway appeared in 48 42 
myxo genomes, both in Cystobacterineae (35) and Sorangiineae(7) but not on Nannocystineae. 
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parameter values (substrate specificity (0.5), additional domain penality (0.6) and collinearity (0.7)) 
resulted in a single hit for soraphen which has similar domain architecture. 
 
 
Gene cluster Number of 
Occurrences 
Suborders Type 
Argyrin  (*) 0 Cystobacterineae nrps 
Vioprolide (*)  0 Cystobacterineae nrps 
Dawenol (**) 0 Cystobacterineae t1pks 
Spirangien (*) 0 Sorangiineae t1pks 
Hyafurone (*) 0 Cystobacterineae t1pks-nrps hybrid 
Melithiazol 1 Cystobacterineae t1pks-nrps 
Myxovalargin 1 Cystobacterineae nrps 
Phenalamid  1 Cystobacterineae t1pks-nrps 
Pyxidienon 1 Cystobacterineae transatpks-otherks-nrps 
Nannochelin 1 Nannocystineae nrps 
Stigmatellin 1 Cystobacterineae t1pks 
Ajudazol 1 Sorangiineae t1pks-nrps 
Ambruticin 1 Sorangiineae t1pks 
Carolacton  1 Sorangiineae transatpks-nrps-t1pks 
Chondrochloren A 1 Sorangiineae t1pks-nrps 
Crocacin 1 Sorangiineae nrps-t1pks 
Crocapeptin 1 Sorangiineae nrps 
Disorazol 1 Sorangiineae transatpks-nrps 
Figure 3.73: Unspecific hit (b) from strain which has similar domain composition to that of the query soraphen 
pathway (a), albeit different domain arrangement on closer inspection. 
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Etnangien 1 Sorangiineae trans-AT PKS 
Leupyrrin 1 Sorangiineae nrps-t1pks 
Pellasoren 1 Sorangiineae nrps-t1pks 
Ripostatin 1 Sorangiineae t1pks-t2pks 
Sorangicin 1 Sorangiineae transatpks 
Thuggacin 1 Sorangiineae t1pks-nrps 
Microsclerodermin 1 Sorangiineae t1pks-nrps 
Soraphen A(***) 1 Sorangiineae t1pks 
Myxoprincomide  2 Cystobacterineae NRPS-PKS 
Myxovirescin  2 Cystobacterineae PKS-NRPS 
Chivosazol  2 Sorangiineae nrps-t1pks 
Chondramide 2 Sorangiineae t1pks-nrps 
Epothilon 2 Sorangiineae t2pks-transatpks 
Tubulysin 3 Cystobacterineae 
and Sorangiineae 
nrps-t1pks 
Cystobactamide 3 Cystobacterineae nrps 
Rhizopodin  3 Cystobacterineae transatpks-nrps 
Aurafuron 3 Cystobacterineae t1pks 
Lipothiazole 3 Sorangiineae nrps-t1pks 
Althiomycin 4 Cystobacterineae t1pks-nrps 
Myxothiazol 7 Cystobacterineae t1pks 
Myxalamid 9 Cystobacterineae nrps-t1pks 
Myxochromide 10 Cystobacterineae NRPS-PKS 
DKxanthene  10 Cystobacterineae PKS-NRPS 
Myxochelin 42 Cystobacterineae 
and Sorangiineae 
nrps 
Table 3.14: Distribution of characterized pathways between suborders. (*) these pathways belong to metabolites 
produced by strains for which genome data was not present in the database, (**) the hit pathway expected for 
Dawenol has missing several domains and mispredicted domains due to which the pathway could not be found. 
(***) increase in parameter values removed unspecific hits from Soraphen which appeared because of their high 
similarity in domain composition but lack similarity in domain architecture. 
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For most of the genome-sequenced myxobacterial strains the Myxobase contains mass 
spectrometric evidence from which production of the metabolites connected to the gene clusters in its 
genome can be confirmed (or disproved). As an example, strains revealed to contain a Rhizopodin gene 
cluster based on the present analysis (Table 3.14) could be shown subsequently to produce this 
metabolite based on high-resolution LC-MS measurements. Similarly, existing LC-MS data (not shown 
here; information from Myxobase and personal communication, Daniel Krug) underpin the production of 
suborder-specific compounds by at least one representative of the respective suborder, so that we can 
regard the above analysis of non-overlapping pathways as a realistic picture.  
However, specific gene clusters were also found in strains which have not been known as producers 
of the respective candidate compound to date. In such cases the absence of compounds in LC-MS results 
could be because of the strain not expressed the genes for the pathway under laboratory conditions or 
because of degradation in the cultivating media. The cluster may also be defective, such as in the case of 
tubulysin (see above), the only other overlap seen between Sorangiineae and Cystobacterineae in this 
study besides myxochelin. This low overlap regarding known characterized pathways should be seen in 
light of only 70 currently available myxobacterial genomes.   
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On analysing the distribution of uncharacterized biosynthetic gene clusters from all the available 
genomes (Figure 3.74), resulted in suborder specific gene clusters belonging to Cystobacterineae (698) 
encoding gene clusters for NRPS (217), PKS (63), NRPS-PKS (295), Trans-AT-PKS (32), Trans-AT-PKS- NRPS 
(7) and Others (95) pathways. Similarly, Sorangiineae (304) contains gene clusters encoding for NRPS 
(80), PKS (59), NRPS-PKS (96), Trans-AT-PKS (8), NRPS-Trans-AT-PKS (8) and others (53) pathways. 
Nannocystineae (16) contains very few clusters encoding gene clusters for NRPS (4), PKS (3), NRPS-PKS 
(8) and Trans-AT-PKS (1) pathways (Table 3.15). 
Several of these uncharacterized gene clusters are shared between suborders. There are 184 
clusters belonging to both Cystobacterineae and Sorangiineae encoding gene clusters for NRPS (60), PKS 
(37), NRPS-PKS (34), Trans-AT-PKS (1) and others (52). There are fourteen gene clusters that belong to 
Cystobacterineae and Nannocystineae encoding gene clusters for NRPS-PKS (13), PKS (9) and others (1). 
There are four gene clusters belonged to Nannocystineae and Sorangiineae, all encoding gene clusters 
for NRPS-PKS (5), PKS (1) and others (6) pathways. Among all, there are only seventy four pathways 
observed in all the three suborders which potentially comprise the gene clusters for the “myxobacterial 
core secondary metabolome”, encoding gene clusters for NRPS (4), PKS (5), NRPS-PKS (19), and Others 
(46). 
Figure 3.74: A Venn diagram showing the distribution of 
uncharacterized gene clusters from suborder Cystobacterineae (red), 
Sorangiineae (green) and Nannocystineae (blue). 
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 Genome
s 
Total 
pathway
s 
Average 
pathway
s per 
genome 
Number of 
Uncharacteriz
ed pathways 
Average 
uncharacteriz
ed clusters per 
genome 
NRP
S 
PK
S 
Hybri
d 
NRPS 
PKS 
Tran
s AT-
PKS 
Myxobacteria 71 1347 18.9 1305 18.3     
Cystobacterinea
e 
40 889 
(66%) 
22.2 698 17.45 217  63 295 28 
Sorangiineae 27 419 
(31.1%) 
15.5 304 11.25 80  59 96 8 
Nannocystinea 4 39 
(2.9%) 
9.75 16 4 4  3 8 3 
Shared between 
Cystobacterinea
e and 
Sorangiineae 
67 1317  184 2.7 60 37 34 1 
Cystobacterinea
e and 
Nannocystineae 
44 912  17 0.38 3  13  
Nannocystineae 
and 
Sorangiineae 
31 449  12 0.39  5 6  
Cystobacterinea
e, Sorangiineae 
and 
Nannocystineae 
71 1347  74 1 4 19 48  
Table 3.15: Overview table for uncharacterized pathways types distribution 
 
An overview distribution of combined characterized and uncharacterized pathways across all 
genomes is summarized in a venn diagram shown in Figure 3.75. The picture is essentially similar to the 
diagram drawn for uncharacterized pathways due to the overwhelming prevalence of the latter. 
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Myxobacterial strains are well known for producing compounds with structural complexity and with 
diverse biological activities. However, there are plenty of natural products which are unexplored, which 
might be because of genes that are not expressed under laboratory conditions or simply because the 
metabolites have evaded their analytical detection to date. More attention should be put on previously 
unrecognised secondary metabolite pathways in the genomes and in extracting the end products that 
the unknown metabolic gene clusters could offer. In this analysis, using conceptual genome mining tool 
we were able to get a preliminary results on the pathways which are not yet characterized. Moreover, 
this approach allows to classify the uncharacterized pathway models which are rare (unique), common (2 
to 5 occurences) and rather frequent (>5 occurences), as listed in (Table 3.16). 
 
 
 
 
 
 
 
Figure 3.75: A Venn diagram showing the distribution of 
characterized and uncharacterized gene clusters from suborder 
Cystobacterineae (red), Sorangiineae (green) and Nannocystineae 
(blue). 
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An example of one such rare uncharacterized pathway from the suborder Cystobacterineae is 
shown in Figure 3.76 which is from strain Ccc1071 (Corallococcus coralloides) consisting of 64 domains. It 
is a PKS-NRPS hybrid pathway with a single NRPS module which could possibly produce a PKS-NRPS 
product with glycine incorporated (Figure 3.76). 
An example of rare pathway from the suborder Sorangiineae was shown in Figure 3.77 which is 
from strain MSr9329 (Aetherobacter sp.) consisting of 68 domains. It is a large PKS pathway which might 
produce a complex compound. 
Finally, an example of rare pathway from the suborder Nannocystinea is shown in Figure 3.78 which 
is from strain MNa11107 (Plesiocystis pacifica) consisting of 69 domains. It is also a PKS-NRPS pathway 
with only two NRPS modules which could possibly produce a PKS-NRPS product with glycine and cysteine 
incorporated. 
Figure 3.76: An example of the rare pathways among Cystobacterineae was from Ccc1071 (Corallococcus coralloides) 
with 64 domains. 
Figure 3.77: An example of the rare pathways among Sorangiineae was from MSr9329  (Aetherobacter sp.) with 
68 domains 
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An example of common occurring pathway from strain MCy9151 (Myxococcus xanthus) with 24 
domains belonged to suborder Cystobacterineae (Figure 3.79) appeared for five times. 
 
A pathway from strain MSr9337 (Aetherobacter fasciculatus) with 65 domains belonged to 
Sorangiineae (Figure 3.80) appeared for four times. Given the current knowledge these pathways 
reported were uncharacterized. 
Figure 3.78: An example of the rare pathways among Nannocystinea was from MNa11107 (Plesiocystis pacifica) 
with 69 domains. 
Figure 3.79: An example of the commonly occurring pathway among Cystobacterineae was from MCy9151 
(Myxococcus xanthus) with 24 domains was found 5 genomes 
Figure 3.80: An example of the common pathways among Sorangiineae was from MSr9337 (Aetherobacter 
fasciculatus) with 65 domains was found 4 genomes 
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The most frequent occurring pathways reported among the suborders among Cystobacterineae was 
from strain AngGT8 (Angiococcus disciformis) with 32 domains (Figure 3.82), among Sorangiineae was 
from strain SoceGT47 (Sorangium cellulosum) with 32 domains (Figure 3.83). Due to the limited 
abundancy of genomes, there was no frequent pathway which is exclusively specific to Nannocystineae 
reported. 
 
This analysis suggests that there are unexplored pathways abundant in myxobacterial strains. Prospects 
to identify the expected novel metabolites and to assign them to their corresponding biosynthetic 
pathways are best for those pathways where monomer cooperation can be reliably predicted, i.e. 
especially for NRPS systems with presumed incorporation of specific amino acids. To name only some 
approaches, feeding studies could be conducted to identify the new compounds as stably isotope-
labelled products using mass spectrometry (135), and recently developed strategies like 
peptidogenomics could be applied (136). Where genetic manipulation of strains is feasible, targeted 
gene inactivation (“knockout”) studies with subsequent statistical evaluation of production profiles can 
be performed (85) in order to identify novel natural products. Obstacles for identification may arise – 
among other possibilities - from the production of these metabolites being dependent on certain 
cultivation conditions and media ingredients or being subject to regulation, making their detection under 
laboratory conditions a challenge. In that case heterologous expression in alternative host strains or 
synthetic biology approaches may offer a solution, although this comes with its own specific challenges 
including possibly non-recognized promoters, complicated operon structures, precursor supply 
bottlenecks or problems with codon adaption (137). 
Figure 3.81: An example of the frequently occurring pathway among Cystobacterineae was from AngGT8 
(Angiococcus disciformis) with 32 domains, it was found in 16 genomes. 
Figure 3.82: An example of the frequent occurring most common pathway among Sorangiineae was from SoceGT47 
(Sorangium cellulosum) with 32 domains, it was found in 9 genomes. 
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Towards the estimation of myxobacterial biosynthetic pathway richness 
  Estimating the pathways richness is a persistent challenge which is interesting to the natural 
product research field in general. In the following, an approach to pathway richness estimation for 
myxobacteria is evaluated with the results obtained from conceptual genome mining. For estimating the 
richness of distinct pathways, 71 genomes of Cystobacterineae (40) and Sorangiineae (27) and 
Nannocystinae (4) were used in this study, containing a total of 1347 pathways of which 783 pathways 
are regarded as distinct models (complete distribution matrix shown in fold-out Appendix NN). Among 
the 1347 pathways, 419 pathways belonged to Sorangiineae of which 264 distinct pathways are reported 
by this analysis. Similarly, there are 889 pathways belonging to strains of suborder Cystobacterineae of 
which 492 distinct pathways are reported (Table 3.16). The software EstimateS was used to analyze 
these data with an subsequent extrapolation of rarefaction curves; classic formula of Chao1 and Chao2 
was chosen to compute the data (122). The rarefaction curves were visualized using R based on the 
results obtained from EstimateS tool (Figure 3.83). The pathway Richness estimation (y-axis) is plotted 
versus the number of genome samples (x-axis).This allows to compare rarefaction curves from suborders 
Cystobacterineae, Sorangiineae and combination of suborders Cystobacterineae and Sorangiineae (C+S). 
The rarefaction curve for the distinct pathways by suborders can be seen in Figure 3.83 and separate 
rarefaction curves for the (currently prevalent) genera Sorangium and Myxococcus are shown in Figure 
3.84.  Each of the rarefaction curves represents the rate of discovering new pathways as sampling size 
increases. The steep slope of rarefaction curve for Sorangiineae, Cystobacterineae and C+S indicates that 
the census is far from complete, when considering the currently sequenced genomes. Extrapolating each 
of the suborder populations individually, and calculating in addition also the combined suborders, 
reveals that slopes remain significantly positive when sampling was projected forward to the sequencing 
of 142 genomes, twice the amount currently available (Figure 3.83). The extrapolated rarefaction curve 
shows that, a total of 1050 distinct pathways could be estimated from those 142 myxobacterial 
genomes. Considering that only around 150 structurally distinct classes of secondary metabolites have 
been characterized from myxobacteria so far (according to Myxobase; internal statistics from Institute), 
these numbers support the notion of myxobacteria as a still underexploited resource for the discovery of 
novel natural products. 
Here, it should be emphasized that the genome samples for Sorangiineae are currently majorly 
contributed from genus Sorangium (13 out of 27) with a total of 151 distinct pathways.  Similarly, the 
suborder Cystobacterineae is dominated by Myxococcus species (16 out of 40) with a total of 309 distinct 
pathways (Figure 3.84). Several available genomes of suborder Cystobacterineae were not yet classified 
at genus level but belong to family Myxococcaceae. Since Myxococcus is a well-represented member of 
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family Myxococcaceae, we assumed in the following that the genomes which were unclassified under 
this family could be hypothetically Myxococcus species, too. Therefore, rarefaction curves were 
calculated separately for genera Sorangium and Myxococcus (including the alleged Myxococcaceae 
members), and it can be contended from the flattening-out of plots in Figure 3.84 that the discovery rate 
of new pathways in the two genera Sorangium and Myxococcus is limited. Importantly, addition of 
genomes from other genera is apparently able to increase the slope of the rarefaction curve significantly 
(compare Figure 3.83). Future isolation and sequencing efforts should be soon able to make sufficient 
genomes available to assay this anticipated effect quantitatively. Altogether, despite the currently still 
restricted sample size of myxobacterial genomes, this analysis aided to obtain a richness estimation of 
the pathways within and across suborders.   It should be noted that the present analysis is more likely to 
under- than to over-estimate pathway richness, because the heterogeneous quality of genomes involved 
in the study required to compromise during concepts-based pathway comparison. Search parameters 
such as pathway collinearity and matching substrate specificity were set to rather relaxed values to 
compensate for possible prediction gaps in pathways retrieved from multi-scaffold genomes. Thus, in 
this analysis pathways may have been grouped together to form one distinct model although they might 
actually represent individual models. Since the overall sample size (71 genomes) is not extraordinarily 
large, such effects could have noticeable impact. Nevertheless, the approach taken here can be further 
developed into a blueprint workflow for estimating multimodular pathway richness, to be executed 
again as fresh and improved whole-genome sequence information becomes available from diverse 
myxobacterial taxa. 
 
 Geno
mes 
Total count 
of pathways 
Distinct 
pathway 
models 
Avg. 
number of 
distinct 
models per 
genome 
Uncharacterized 
distinct models 
(may appear 
once or several 
times) 
Unique 
models 
(singletons, 
appear only 
once) 
Myxobacteria 71 1347 783 (58%) 11   
Cystobacterineae 40 889 (66%) 492 (55.3%) 12.3 475 (53.4 %) 261 (29.3%) 
Sorangiineae 27 419 (31.1%) 264 (63.3%) 9.8 245 (58.4%) 162 (38.6%) 
Nannocystineae 4 39 (2.9%) 27 (69%) 6.7 26 (66%) 17 (43.5%) 
Table 3.16: An overview of pathway analysis among the suborders of Cystobacterineae, Sorangiineae and 
Nannocystineae reported using BiosynML algorithm 
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Figure 3.83: Estimation of distinct pathway richness among suborders Cystobacterineae (red), Sorangiineae 
(blue) and combination of both (C+S) (green). The gap in each rarefaction curve is separation between 
experimental (left) and extrapolated curves (to the right) 
 
Figure 3.84: Estimation of distinct pathway richness among suborders Myxococcus (olivegreen) and 
Sorangium (cyan). The gap in each rarefaction curve is separation between experimental (left) and 
extrapolated curves (to the right) 
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4 Conclusion and outlook 
In this work a bioinformatic analysis framework summarized as “BiosynML toolkit” was developed, 
where the most important component is a searching and matching engine for the identification and 
conceptual comparison of multimodular biosynthetic pathways in microbial genomes. Contrary to 
existing genome-mining approaches, the methods devised here rely on previously annotated sequences 
and pathways are matched on the basis of architectural similarity, thereby taking into account overall 
domain composition of pathways, the available functional annotations for domains, their relative 
arrangement, alignment between subsets of domains and operon organization. The underlying rationale 
is that these “enzymatic collectives” together constitute the crucial determinants for the small-molecule 
structure produced by a given pathway, and thus it was anticipated that it should be possible to 
specifically recognize and compare pathways by their evolutionarily established domain pattern (or 
“concept”).  Different algorithms were tested and the “global best subset” (GBS) approach was 
empirically validated to provide best analytical power and robustness for this purpose. 
On the one hand the conceptual mining approach can achieve similar results like conventional 
sequence-base genome mining, a congruence that is understandable because the traditional procedures 
working with sequence data usually employ aligning biosynthetic signature domains, as the protein 
sequences of those domains are conserved. On the other hand, the BiosynML approach is less 
dependent on which part of a pathway is used as input for comparison, and can even accept hypothetical 
assembly lines (“sequence-free”, i.e. manually constructed by natural product chemists on the basis of 
retro-biosynthetic considerations) as input. The possibility to set several parameters for the scoring of 
results allows fine-tuning the BiosynML comparison tool for a range of applications. Examples in this 
study show that selectivity can be achieved even when using very short biosynthetic assembly lines (such 
as the myxochelin pathway) with a small number of domains as input, but also with larger pathways 
showing little diversified domain composition (such as the myxoprincomide pathway, a giant NRPS 
assembly line). Suitable parameters for running the analysis are in practice readily found for varying 
research interests, i.e. depending on whether only high-ranking near-exact matches are desired or 
remotely similar gene cluster architectures should also be reported. As a consequence of increased 
parameter tolerance hits will be included showing significant deviations to the query pathway which 
could be meaningful in a biosynthetic sense, but at the cost of expecting an increased false discovery 
rate.  It is especially encouraging that the false discovery rate using the conceptual genome mining 
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approach was very low in this study when it was applied to the recognition of known biosynthetic 
pathways in myxobacterial whole-genome sequences. 
It is clear that biosynthetic gene cluster prediction, a prerequisite for using the BiosynML approach, sets 
a limit for sensitivity, because certain domains or even entire genes could be missed by the upstream 
gene-finding and annotation pipeline. Moreover, the whole-genome assembly process may not always 
yield closed genomes, whereas every gap comes with the risk of partially losing information for a 
biosynthetic gene cluster.  However, in both fields – whole-genome sequencing and assembly as well as 
bioinformatics prediction of pathways – advancements have been recently made (and are continuously 
being made) which underpin the expectation that genome sequence quality and pathway prediction 
quality will be less and less of an obstacle for using the BiosynML genome mining approach in the future. 
The sequencing and characterization of novel myxobacterial strains and biosynthetic pathways is an 
on-going process. Updates on pathway identification and their assignment to compounds need to be 
carried out as soon as new knowledge becomes available and will contribute in turn to make the picture 
for newly annotated genomes more complete.  Therefore, the BiosynML module developed in this work 
has been tightly integrated into the in-house database system Myxobase to support everyday efforts of 
scientists working on the discovery of new myxobacterial natural products. Usage of the tool is facilitated 
by the implementation of BiosynML import and annotation functions within the Geneious plugin and 
through the addition of BiosynML export functionality to the antiSMASH system. The stringent client-
server design of the BiosynML core engine (implemented as remote procedure framework) allows for its 
re-use in other projects, whereas the perhaps most foreseeable application could be its interfacing with 
the MIBiG pathway repository which is currently being built through a community initiative. Future work 
on the BiosynML engine could incorporate more options for the matching function which could help to 
further fine-tune the search, e.g. by introducing a fundamental differentiation between scaffold—
generating and tailoring domains as it is done by the MIBiG standard. Also the algorithm GBS is regarded 
as computationally expensive; implementing it with multi thread capability should speed up the running 
time. 
The BiosynML methods were ultimately used in this study to generate for the first time an overview 
of myxobacterial biosynthetic pathway diversity, covering NRPS, PKS and hybrid pathways from all 
myxobacterial genomes currently available at the institute (with sufficient quality in terms of 
contig/scaffold numbers). In light of 71 genomes used for the study - with an uneven distribution across 
the three myxobacterial suborders and vastly unbalanced coverage of the 23 known genera (many 
genomes belonged to Myxococcus and Sorangium) - results must be regarded as preliminary. Altogether 
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1347 biosynthetic gene clusters from all genomes were involved in the analysis of which 783 were 
classified by the BiosynML comparison to represent distinct pathway architectures. Rarefaction curves 
were calculated and project significant potential for the discovery of novel pathways in the upcoming 
genomes to be sequenced. However, a more complete appreciation of myxobacterial pathway richness 
will have to await the availability of more genome sequences from more diverse species. It should be 
particularly interesting to see how isolates from hitherto underexploited habitats, belonging to novel 
genera and families and thus likely to constitute sources of additional (bio) chemical diversity, are able to 
contribute to myxobacterial pathway richness. 
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